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ABSTRACT
Prostate cancer (PC) is a major health problem in the Western world. 
Current diagnostic tests such as serum prostate specific antigen (PSA), 
digital rectal examination (DRE) and prostate biopsies each have 
limitations. PSA may be elevated in non-malignant conditions such as 
urinary tract infection, prostatitis and benign prostatic hyperplasia. PC 
screening, risk stratification and monitoring after treatment requires 
cancer biomarkers with higher sensitivity and specificity for prostate 
cancer. Cancer biomarkers that could distinguish between clinically 
significant PC and clinically insignificant disease would help clinicians 
and patients to avoid over-treatment and under-treatment of localised 
PC.
Engrailed-2 (EN2) is a promising novel biomarker for PC. The HV2gene 
is a member of the HOX gene family, which are expressed in the 
embryonic human brain during development. Several human 
malignancies, including PC, have demonstrated re-expression of HOX 
gene products. Human EN2 is protein that is secreted into the urine and 
may be conveniently assayed using ELISA. Urinary EN2 remains stable 
at room temperature for up to four days, and there is no requirement for 
prior DRE.
Prostate Histoscanning™ (PHS) is a novel trans-rectal ultrasound-based 
imaging technique. The manufacturers claim that it has the ability to 
detect and localise PC.
The aim of the studies described in this thesis was to evaluate the roles 
of EN2 and PHS in the diagnosis of PC, risk stratification of patients 
diagnosed with localised PC, and the follow up of patients after radical 
PC treatment.
Urinary EN2 was assayed in healthy volunteers and various groups of 
PC patients. An assay of seminal EN2 was developed, and applied to 
specimens from healthy volunteers and PC patients.
PHS was performed in patients immediately prior to undergoing radical 
prostatectomy.
Urinary EN2 levels were significantly lower among healthy volunteers 
compared to patients with localised PC (either on active surveillance or 
before undergoing radical prostatectomy). There was no significant 
difference between urinary EN2 levels among healthy volunteers and 
patients who were disease-free five years after radical treatment for PC. 
There was a strong correlation between urinary EN2 levels and prostate 
tumour volume among patients undergoing radical prostatectomy. There 
was no significant difference between urinary EN2 levels before and 
after neoadjuvant hormone therapy, or before and after prostate 
brachytherapy. Urinary EN2 levels in the PC relapse group following 
radical prostatectomy and prostate brachytherapy were significantly 
higher than among the cured group. Among PC patients, seminal EN2 
levels were significantly higher than urinary EN2 levels. We found no 
correlation between tumour volume and pathological stage measured by 
PHS versus whole mount RP histology.
PHS failed to detect and localise PC in routine clinical practice. 
However, urinary and seminal EN2 show promise as a PC biomarker.
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1. Introduction
1.1 Incidence of prostate cancer
Prostate cancer (PC) is the second most common cause of cancer, and 
the sixth leading cause of cancer death among men worldwide, with an 
estimated 258,000 deaths in 2008 (1). There were an estimated 543,000 
new cases in 2000 (2) and 899,000 new cases in 2008 (1). Hence, the 
incidence of PC is increasing worldwide.
The incidence of PC is highest in Australia/New Zealand, Western 
Europe and North America (104, 93 and 86 per 100,000 in 2008, 
respectively), where PC screening is common. It is lowest in South- 
Central Asia (4 per 100,000) (3). Bray e/ a/ estimated the worldwide 
prevalence of PC in 2008 to be 3.2 million (4). PC ranks as the most 
prevalent cancer in men in 111 countries worldwide, including the 
Americas, most of Europe and 31 of 46 Sub-Saharan African countries 
(4).
PC accounts for approximately 12% of all cancers and 9% of all cancer- 
related deaths in adult men in the European Union (3). The incidence of 
PC is increasing across Europe, but the greatest increase has been in 
Northern and Western Europe. An annual rise of 28% in its incidence 
among the 35-64 year age group in Lithuania has been reported (5). 
This increase in PC incidence is due mainly to the introduction of 
prostate-specific antigen (PSA) testing and consequent biopsy in these 
men.
The Office for National Statistics reported 29,406 new cases of PC in 
England in 2004 (6). In the UK in 2010, 40,975 men were diagnosed 
with PC, and 10,721 men died from the disease (7).
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1.2 Risk factors for prostate cancer
The major risk factors for PC are increasing age, positive family history 
and ethnicity (8). The risk of developing PC is high in black Caribbean 
and black African men and low in Asian populations (9).
Obesity is associated with increased incidence of aggressive PC, 
increased risk of biochemical failure following radical prostatectomy (RP) 
or external-beam radiotherapy (EBRT), and increased frequency of the 
complications of long-term androgen deprivation therapy (10). These 
associations may be due partly to the difficulties in diagnosing and 
managing PC in obese patients. Obese men have lower PSA values, 
resulting in reduced PSA-driven biopsies (11). It has been hypothesized 
that this reduction is due to increased blood volume in obese individuals, 
leading to PSA haemodilution (12). DRE can be challenging in an obese 
patient, leading to yet more missed cancers (13). Obese men tend to 
have larger prostates, which reduces the chance of detecting cancer at 
biopsy (14).
Dietary factors may also play a role (15; 16). Dietary fat, red processed 
meat, vitamin E, dairy products and calcium may increase the risk of 
developing PC (17). However, selenium, tomatoes, green tea and 
cruciferous vegetables are believed to lower the risk of developing the 
disease (18). Some studies have shown a negative association between 
the risk of developing PC and dietary intake of soya bean products and 
isoflavones (19).
Alcohol consumption may increase PC risk. Alcohol alters the hormonal 
environment, and contains chemical substances such as flavonoids 
which may alter PC cell growth (20).
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Insulin is known to increase cancer risk through its effect on cell 
proliferation, differentiation and apoptosis. Studies have suggested that 
insulin may be involved in tumour formation and neoplastic growth of the 
prostate (21). Insulin resistance and obesity have also been associated 
with an increased risk of progression to castrate-resistant PC, and 
ultimately to increased PC-specific mortality (22).
There is emerging evidence that chronic inflammation triggered by 
infection may precede the development of prostatic intraepithélial 
neoplasia and early carcinoma (23).
In 1941, Huggins and Hodges reported that testosterone may trigger PC, 
or cause a flare of occult PC (24). Their work, on only two patients, 
suggested that giving exogenous testosterone resulted in PC 
progression, whereas reducing serum testosterone caused regression of 
the disease. However, in 2004, a large prospective study reported that 
higher levels of circulating testosterone were related to decreased risk of 
developing PC (25). It was reported that patients who tend to present 
with more aggressive PC had decreased serum levels of testosterone 
(26;27). Low serum testosterone level was an independent predictor of 
treatment failure in PC patients following radical prostatectomy (28). 
Based on these data, Atan reported that low testosterone level is a 
risk factor in the development, diagnosis and treatment of PC (24).
1.3 Various approaches to the diagnosis and treatment of 
prostate cancer
PC is most often symptomless, but may present in different ways. More 
patients are now being diagnosed after routine screening for PSA, and 
are asymptomatic on presentation. Patients may also present with lower
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urinary tract symptoms initially, or the symptoms of advanced PC, such 
as bone pain and peripheral neuropathy.
The use of PSA testing as a means of screening for PC is controversial 
(29;30). Although it can be beneficial in the early detection of PC, it may 
result in over-diagnosis and over-treatment of indolent disease that 
would be life-threatening in only a minority of patients. This may subject 
patients unnecessarily to the complications of radical treatments such as 
erectile dysfunction and urinary incontinence.
Nevertheless, serum PSA testing is used routinely in the Western World. 
Digital Rectal Examination (DRE), trans-rectal ultrasound (TRUS) and 
trans-perineal template-guided biopsies of the prostate are the tests 
commonly used to diagnose PC. Each of these tests has significant 
limitations (31-33). The PSA and DRE may be falsely positive, leading to 
further, unnecessary, invasive investigations. False-positive results can 
lead to sustained anxiety about PC risk. Abnormal PSA or DRE findings 
may lead to prostate biopsies being taken. That can result in 
complications such as infection or bleeding. Also, TRUS biopsies can 
miss up to 35% cancers in the anterior region of the gland (31).
Using a cut-off of 4.0 ng/ml, PSA was reported to yield a sensitivity and 
specificity of 20% and 94%, respectively, for detecting PC. However a 
cut-off of 2.6 ng/ml increased the sensitivity to 40% and reduced 
specificity to 81% (34).
Various modifications to the PSA test have been made to improve the 
accuracy of detection of PC.
• Free to total PSA ratio: PSA in serum exists in free form or bound 
to alpha-1-antichymotrypsin. Total PSA is the combination of free 
and bound PSA. Free to total PSA is the percentage of free PSA
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compared with total PSA. The lower the value of free to total PSA, 
the greater is the likelihood that an elevated PSA represents 
cancer and not BPH. A cut-off value of greater than 20% suggests 
benign prostatic hyperplasia which is defined as a non-cancerous 
increase in the size of the prostate gland, due to an increase in the 
number of cells.
• PSA density: This is the serum PSA divided by prostate volume in 
ml. PSA density values greater than 0.15 ng/ml/ml are suggestive 
of PC, whereas lower values are suggestive of benign hypertrophy 
(35).
• PSA velocity: This is the rise in PSA per year. It is expressed as 
ng/ml/year. PSA velocity less than 0.6 and 0.75 is considered 
normal (36). PSA velocity above 0.75 is associated with increased 
risk of PC (37).
• PSA doubling time: This is the length of time that PSA takes to 
double. Patients with PSA doubling time of less than 3 years may 
be at a greater risk for disease progression (38).
The ability of these PSA modifications to improve the predictive value of 
PSA has been evaluated. None was found to have significant clinical 
impact (39-41).
Advantages of the PSA test
1. PSA may detect PC at an earlier and more curable stage.
2. PSA is useful in monitoring disease progression following radical 
PC treatment.
3. Men at higher risk of developing PC may benefit from regular PSA 
tests for detection of the disease.
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Disadvantages of the PSA test
1. PSA can be raised in benign conditions of the prostate including 
urinary tract infection, prostatitis and benign prostatic hyperplasia. 
That may lead to false positive results, thus exposing patients to 
unnecessary biopsies.
2. A normal PSA test may not reliably exclude PC.
3. Men with raised PSA often undergo TRUS or template biopsies of 
the prostate, which may lead to complications such as sepsis or 
urinary retention (42;43).
4. Detection of insignificant PC may lead to patient anxiety, and 
unnecessary treatments that have significant side effects that are 
detrimental to the patient’s quality of life.
5. PSA correlates poorly with tumour volume.
6. PSA fails to detect cancer aggressiveness.
Patients diagnosed with PC following TRUS or template biopsies, and 
with a Gleason score of >7, are offered further staging with pelvic MRI 
and an isotope bone scan (44). The standard practice is now changing, 
and clinicians are increasingly undertaking multiparametric magnetic 
resonance imaging (mpMRI) prior to taking prostatic biopsies (45;46). 
The advantages of pre-biopsy mpMRI include avoiding a lasting 
haemorrhage artefact, and identifying lesions for targeting with template 
biopsies, thereby reducing the number of biopsies and their side effects. 
Also, an mpMRI scan allows radiological staging of PC.
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1.4 Management of localised prostate cancer
As specified in the NICE guidelines 2014 (38), a multidisciplinary 
approach involving review of each patient by a team of pathologists, 
radiologists, urologists, oncologists, and cancer specialist nurses is the 
standard of care in the UK. The conclusions reached by these teams 
inform management decisions.
PC staging can be divided into: localised, locally advanced and 
metastatic disease. The NICE guidelines (38) recommend stratifying 
localised PC into low, intermediate and high risk (Table 1).
Localised PC can be managed with active surveillance (AS) in men who 
have low risk and low volume PC, thereby minimising unnecessary 
treatments and their side effects. The following are the Royal Marsden 
criteria for AS patients (47), which are consistent with the NICE 
guidelines (38):
• Age 50-80 years
• Fitness for radical treatment
• PSA <15 ng/ml
• Stage T1-2
• Gleason score < 3+4
• < 50% positive cores and/or < 50% of each core involved
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Table 1 Risk stratification for localised prostate cancer as described 
by the NICE guidelines 2014
Risk PSA
Concentration
Gleason
Score
Clinical Stage
Low <10 ng/ml and ^ 6 and T1-T2a
Intermediate 10-20 ng/ml or 7 or T2b
High > 20 ng/ml or 8-10 or ^T2c
The NICE-approved radical treatment (therapy with curative intent) 
options for PC include RP (open, laparoscopic or robotic assisted), 
brachytherapy (BXT) and EBRT. Neo-adjuvant hormone therapy may be 
used in conjunction with BXT or EBRT.
All these treatment options should be discussed with the patient, 
according to the grade and stage of the disease, when appropriate. The 
patient's co-morbidities including lower urinary tract symptoms, previous 
surgery or radiotherapy, and patient preference are taken into account 
before embarking upon any particular treatment option.
The various pathological aspects of prostate cancer, including Gleason 
score, TNM classification, positive surgical margins and peri-neural 
invasion, are summarised as follows.
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In 1974, Donald Gleason described the Gleason scoring system for 
prostate cancer (48). He used this scoring system to compare tumour 
architecture (Table 2) with clinical outcomes. The Gleason score is the 
sum of the primary Gleason score (the most common histological 
pattern) and the secondary Gleason score (the second most common 
pattern in the tumour specimen; Figure 1).
Table 2 Gleason scoring system for prostate cancer.
Grade 1 Small and uniform prostatic glands
Grade 2 Irregular spacing between the glands and irregular outline
Grade 3 Variable shapes and spaces with the glands
Grade 4 Irregular cells between fused glands
Grade 5 Diffuse solid sheets of cells
Figure 1 Gleason 3+3=6 prostate cancer
M X i
Variable shapes of intra­
prostatic glands with 
variable spacing within 
these glands.
(Courtesy of Dr B Haagsma, Consultant Pathologist, Royal Surrey 
County Hospital, Guildford.)
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However, TNM classification (2002) is used to assess the tumour, nodal 
and metastatic status of prostate cancer (Table 3). The prefix ‘c’ is used 
for clinical staging based on digital rectal examination findings. The 
prefix ‘p’ is used for pathological staging on histological analysis.
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Table 3 TNM classification of prostate cancer
T Primary tumour
Tx Primary tumour cannot be assessed
TO No evidence of primary tumour
T1 Tumour present but not detectable clinically or with imaging
Tla Incidental histological finding of tumour in 5% or less of tissue resected
Tib Incidental histological finding of tumour in more than 5% of tissue resected
Tic Tumour identified by needle biopsy following elevated PSA
T2 Tumour confined within the prostate
T2a Tumour involves one half of one lobe or less
T2b Tumour involves more than half of one lobe but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the prostatic capsule
T3a Extra-capsular extension
T3b Tumour invades seminal vesicles
T4 Tumour invades adjacent structures (bladder, rectum, pelvic wall)
N Regional lymph nodes
Nx Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Regional lymph node metastasis
M Distant metastasis
Mx Distant metastasis cannot be assessed
MO No distant metastasis
M l Distant metastasis present
M ia Non-regional lymph nodes
M lb Bone metastasis
M lc Other metastatic sites (lung, liver, brain)
Positive surgical margin is a histological finding on a whole-mount 
radical prostatectomy specimen. It is present if the surgeon performing 
the procedure cuts through the prostate gland containing cancerous 
tissue near the neurovascular bundles. This means the entire tumour 
has not been removed, which may result in future PC recurrence. 
Patients who have positive surgical margins are closely monitored with
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serum PSA. If there is any evidence of PSA >0.2 ng/ml, these patients 
are referred to oncology for consideration of radiotherapy.
Peri-neural invasion (PNI) is another histological finding, which is 
defined as the presence of prostate cancer tracking along or around a 
nerve within the peri-neural space (49). Initially it was considered that 
PNI at prostate biopsy may help in predicting preoperative extra­
prostatic extension and PC recurrence after treatment. Although PNI on 
histological analysis of radical prostatectomy specimen has no 
significance, the importance of PNI found on prostate needle biopsy for 
treatment planning has been previously debated. The predictive value of 
PNI for extra-capsular extension has decreased over time because of a 
downward stage migration due to early detection for PC. As the majority 
of the patients who undergo definitive therapy now present with low risk 
and volume PC, the significance of PNI on prostate needle biopsy 
specimens has decreased.
The zonal anatomy of the prostate is described in Figure 2 (reproduced 
with permission from the publisher: Elsevier Limited, License number 
3433700456554). Prostate cancer is a multifocal disease. Flowever, 
approximately 70% of the prostate tumours occur in the peripheral zone, 
24% arise in the transitional zone, and 8% arise in the central zone (50).
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Figure 2 Zonal anatomy of the prostate gland including the anterior 
zone, transition zone, central zone and peripheral zone
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1.5 The need for new biomarkers of prostate cancer
Serum PSA is prostate-specific but not PC-specific, because it may be 
elevated in some benign conditions of the prostate gland. Thus, there is 
a need for PC-specific biomarkers to overcome the limitations of PSA 
test (51), as described in Section 1.3.
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1.5.1 Definition of a biomarker
According to the World Health Organisation (52), a biomarker is any 
substance, structure, or process that has the ability to measure the 
following:
• Normal physiological processes
• Pathological processes
• Responses to treatment
The characteristics of an ideal biomarker include:
• High sensitivity and specificity
• Can be used as a research or specialist tool to help understand 
the underlying pathology
• Cost effectiveness
• Feasible for routine use
There are several biomarkers that are currently being evaluated for their 
utility in the early diagnosis and monitoring of PC. Novel biomarkers 
could improve screening by avoiding the need for invasive investigations 
and their subsequent complications.
Biomarkers that could distinguish reliably between clinically significant 
and non-significant cancers would avoid overtreatment. They would also 
inform management decisions, such as choosing between active 
surveillance and active radical treatment options.
Pepe eta/m  2001 proposed a phased model of biomarker development 
for early cancer detection (53). To date, the only biomarker to have 
reached prospective screening trials (phase 4) is PSA. (Figure 3, 
reproduced with permission from Oxford University Press, License 
Number: 3185320092258).
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Figure 3 Phases of Biomarker Deveiopment
Preclinical
Exploratory PHASE 1 Promising directions identified
Clinical Assay 
and Validation PHASE 2  Clinical assay detects established disease
Retrospective
Longitudinal
PH A 9 Biomarker detects disease early before it becomes
clinical and a “screen positive” rule is defined
Prospective
Screening
PHASE 4 and characteristics of disease detected by the
test and the false referral rate are identified
Cancer Control PH A S F R Impact of screening on reducing the burden of diseaseon the population is quantified
Pepe M S et al. JNCI J Natl Cancer Inst 2001 ;93:1054-1061
1.6 Novel blomarkers for prostate cancer currently In 
development
1.6.1 Serum biomarkers
Alpha-methylacyl-CoA racemase (AMACR) has been reported to have 
high sensitivity and specificity for detecting PC using polymerase chain 
reaction (PGR) in blood (54). These studies were performed on small 
groups of patients. Very low levels of AMACR protein were detected in 
serum. Anti-AMACR auto-antibodies were therefore tested, and were 
found to have sensitivity and specificity of 61.6 and 71.8%, respectively 
(55). These results were not reproduced in a similar study, which
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showed anti-AMACR antibodies to have sensitivity of 31%, and 
specificity of 82.3% (56).
Other serum biomarkers that have been studied include prostate-specific 
membrane antigen (PSMA) and Early Prostate Cancer antigen (EPCA) 
(57). A study by Paul et al reported sensitivity and specificity of the 
EPCA assay of 92 and 94% respectively (58). This study included 12 PC 
patients and 16 healthy volunteers. Another study reported sensitivity 
and specificity of PSMA of 94 and 65.9%, respectively for PC detection 
(59).
Advantages of Serum Biomarkers
• May be used as diagnostic and prognostic biomarkers
• Minimally invasive
• Low cost
Disadvantages of Serum Biomarkers
• Studies on serum biomarkers have been performed on small 
cohorts of patients
• Results of these studies have not been reproducible
• Results may be influenced by a patient’s health status
1.6.2 Tissue blomarkers
Ki67, Budding Uninhibited by Benzimidazole-Related 1( BUBR1) and E- 
cadherin have been proposed as biomarkers of PC in prostate tissue. 
Staining for these potential tissue biomarkers in prostate biopsy cores 
has shown significant correlation with the Gleason score (60). This study 
reported that sensitivity and specificity for Ki67, BUBR1 and E-cadherin 
staining in discriminating clinically insignificant PC were 75 and 87.5%,
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66.7 and 100%, and 50 and 100%, respectively. The positive predictive 
values (PPV) for Ki67, BUBR1 and E-cadherin were 75, 100 and 100%, 
respectively.
Identification of tissue biomarkers has led to the development of multiple 
commercially available tests to diagnose and/or predict PC 
aggressiveness. Recent studies described the prognostic value of a 
scoring system that used the expression of 31 genes in PC tissue. This 
scoring system was shown to have significant prognostic accuracy pre 
and post prostatectomy, and was subsequently developed into a 
commercially-available test (61).
The evidence to support the use of these new tests as reliable 
biomarkers of PC is weak, and more research is required to further 
validate these tests.
Advantages of tissue blomarkers
• May be used as diagnostic and prognostic biomarkers
• Analysis of biomarkers is conducted directly from the prostate 
tissue
Disadvantages of tissue biomarkers
• Prostatic tissue is acquired after a biopsy or radical prostatectomy, 
which are highly invasive procedures
• Associated side effects due to these invasive procedures
• High cost
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1.6.3 Seminal fluid biomarkers
Prostatic and seminal fluid levels of PSA and other kallikrein-related 
proteases have been assessed for their role in the diagnosis and 
prognosis of PC (62). Kumar a/ recently reported that high-resolution 
magnetic resonance spectroscopy of prostate tissue; prostatic fluid, 
seminal fluid, serum and urine can be used for the detection of PC. This 
is based on their differences in metabolites, which could serve as useful 
biomarkers for PC (63).
Human kallikrein 4 is a proteolytic enzyme found primarily in prostatic 
tissue. It is secreted in seminal plasma, and may be used a novel 
prostatic biomarker (64).
A study by Hassan et a! showed that PSA, prostatic acid phosphatase 
(PAP) and ZAG protein obtained from seminal fluid were over expressed 
in PC patients (65).
Glycoprotein Dickkopf-related protein 3 obtained from seminal plasma 
and analysed using indirect immunoenzymometric assay was 
significantly elevated in TRUS biopsy-confirmed PC patients (66). 
Proteomic analysis of human seminal plasma found 17 prostate protein 
markers (67). Seminal plasma polypeptide can discriminate between 
Gleason score 7 and organ-confined disease or advanced disease with 
a sensitivity and specificity of 80 and 82% respectively (68).
Advantages of Seminal fluid biomarkers
• May be used as diagnostic and prognostic biomarkers
• Relatively non invasive
• Low cost
• Access to protein directly from the prostate
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Disadvantages of Seminal fluid biomarkers
• Applicable only to patients who are potent
• Semen sample storage can affect the reproducibility of the test
• The stickiness of seminal fluid sample necessitates dilution of the 
sample before they can be appropriately processed and assessed
• Variability among patients
1.6.4 Urine biomarkers
A) Prostate cancer antigen 3 (PCA3)
PCA3 is a non-coding RNA that is expressed at low levels in normal 
prostate tissue, but is highly expressed in PC (69). Formerly known as 
DD3, PCA3 in relation to PC was first described in 1999 (70). Using a 
quantitative reverse-transcriptase polymerase chain reaction assay of 
PCA3 on first pass urine after DRE suggested that PCA3 may predict 
biopsy outcomes (71;72). PCA3 score was significantly higher in 
patients with clinically significant PC compared to those with non­
significant disease (73;74). However, other studies have suggested that 
PCA3 fails to distinguish between significant and non-significant cancers 
(75;76). PCA3 scores did not correlate with tumour volume (p=0.96) or 
pathological stage (pT2 vs pT3, p=0.59).
Various studies have been performed to assess the diagnostic 
performance of PCA3 to predict prostate biopsy outcome. These studies 
reported a sensitivity ranging from 47-88% and specificity of 5-83%, 
with AUC ranging from 49-91% (77).
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B) Microseminoprotein-beta (MSMB)
MSMB is a urinary protein that is at an early stage in development as a 
PC biomarker. A genome-wide association study showed that urinary 
MSMB levels were more predictive of PC than are urinary levels of PSA. 
However, MSMB was not as accurate as serum PSA for diagnosing PC. 
Area under the curve (AUC) was 0.97 for serum PSA, and 0.77 for 
urinary MSMB (78).
C) Zinc a2-glygoprotein
More recently, zinc a2-glycoprotein (ZAG) protein in urine has been 
shown to have promising results for diagnosing PC (79). Receiver 
operating characteristic curve analysis for ZAG demonstrated AUC of
0.68, suggesting significant predictability. When ZAG was combined with 
PSA, a significant improvement in the predictive ability was noted, with 
an AUC of 0.75 (p=0.01).
D) TMPRSS2-ERG
TMPRSS2 is a trans-membrane protease serine. A recurrent 
chromosomal rearrangement in PC associated with TMPRSS2-ERG 
gene was first described in 2005 (80). It fuses with ERG, and this fusion 
gene is then regulated by androgens. It has also been shown that this 
fusion gene is an independent marker of PC progression (81). Urinary 
RNA of the TMPRSS2-ERG gene post DRE has shown high sensitivity 
and specificity for detecting PC (82). A study of 48 patients combining 
PCA3 with TMPRSS2-ERG in an algorithm suggested potential for PC 
detection. Individuals with 2/3 of the following criteria: PSA>10, positive 
urinary PCA3, or positive urinary TMPRSS2-ERG, were then
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recommended for a prostate biopsy. This combination had a sensitivity 
of 80%, specificity of 90%, and AUC of 0.88 (83).
The advantages and disadvantages of various biomarkers are described 
by Velonas et a! {M ).
Advantages of urinary blomarkers
• Non-invasive, hence more convenient for the patient and clinicians
• Show promise as both diagnostic and prognostic biomarkers of PC
• May distinguish between significant versus non-significant PC
• Low cost
• Large volume available for assay
Disadvantages of urinary biomarkers
• Digital rectal examination may be required
• Variable concentration of molecules available
• Small sample size in most studies
• Some studies have questioned their ability to distinguish between 
significant and insignificant disease
• The results may be inconsistent due to instability of urine during 
storage and transport before testing
The statistical parameters of the novel biomarkers of PC described in 
Section 1.6 are summarised in Table 4.
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Table 4 Summary of statistical parameters of novel prostate blomarkers
Serum biomarkers
Blomarker Sensitivity (%) Specificity (%) AUC
AMACR 62.6 71.8 0.78
PMSA 94.5 64.9
EPCA 92 94
Tissue blomarkers
KI67 75 87.5
BUBR1 66 100
E-CadherIn 50 100
Seminal fluid 
blomarkers
Seminal Plasma 
polypeptide
80 82
Urine blomarkers
PCA3 47-88 5-83 0.49-0.91
MSMB - - 0.77
ZAG - - 0.68-0.75
TMPRSS2-ERG 80 90 0.88
EN2 66 88.2 0.80
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1.7 HOX genes
1.7.1 Conventions for symbols for genes and proteins
By convention, gene symbols in humans are generally italicised, with all 
letters in upper case. The encoded proteins are named with the same 
letters in upper case, but are not italicised (85). In the mouse and rat, 
gene symbols are also italicised, but with only the first letter in upper 
case, the remaining letters being in lower case. Again, the encoded 
protein symbols are the same, but are not italicised (86).
1.7.2 Introduction and functions of Hox genes
The Hox genes were first described in the fruit fly Drosophila 
Meianogaster, and have subsequently been identified in many other 
species including mammals. These are shown in Figure 4, which is 
reproduced with permission from publisher: Springer License number 
3315321283450).
Hox genes play an important role in the orientation of the organism 
along its anterior-posterior axis. They determine the identity of cells and 
tissues during development and regulate the proliferation and 
differentiation of embryonic and adult stem cells (87).
Hox genes belong to a family of homeodomain-containing transcription 
factors. The homeodomain is a highly conserved 61-amino acid motif, 
which enables Hox proteins to bind to specific DNA sites, activating or 
repressing target genes. genes have been involved in a various 
biological pathways including homeostasis, cell differentiation, and the 
maintenance of organ function in adults (88). In humans, HOX genes are 
expressed in embryonic development and subsequently re-expressed by 
several types of cancers.
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There are 39 //oy genes in mammals. They are split into 4 paralogous 
clusters (A, B, C and D) located on 4 different chromosomes (89). Each 
of these clusters contains 9-11 genes arranged in 13 groups. This 
arrangement is based on the position of genes within the cluster and 
also on the homeobox sequence. Similar genes in the separate clusters 
are considered paralogs. These genes are expressed from the 3' to 5' 
(anterior to posterior) end of each cluster within specific tissues of an 
organism at specific times during development. The 3' genes code for 
structures in the anterior (cranial) portion of the organism, whereas the 
5' genes are expressed in the posterior (caudal) regions, where they are 
involved in the differentiation of genitourinary structures. Studies have 
shown that HOX gene expression is deregulated in various cancers 
including prostate, oral, lung, breast, colon, ovary, bladder and thyroid. 
(90-92).
Figure 4 Various Hox genes in Drosophila, Mouse and human.
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1.7.3 The role of Hox genes in the development of the prostate gland
Most of the male sex organs including epididymis, the ductus deferens, 
the ejaculatory duct, seminal vesicle are derived from Wolffian ducts, 
which are mesodermal embryological structures. The prostate gland 
itself is an endodermal structure originating from the urogenital sinus 
(93).
In the mouse, Hox genes play an important role in the normal 
development of prostate gland (94). The most posterior Hox genes are 
involved in the development of prostate gland in adult rats. A study using 
quantitative real-time PCR showed that the posterior 5' Hox genes 
{Hoxa9-11, Hoxa13, Hoxd13, and Hoxb13) were responsible for the 
development of the seminal vesicles, the epididymis and the different 
lobes of the prostate gland (95). In the adult rat, a unique Hox co6e is 
responsible for the organ-specific and prostate lobe-specific 
differentiation. The Hox code also participates in cellular differentiation 
and lobe specific identity within the prostate gland (95). In another study 
in the mouse by Hostikka et a!, it was shown that the Hoxc11 qex\e plays 
an important role in the development of urogenital sinus, which then 
gives rise to the prostate gland (96).
Nkx3.1 homeobox genes play a role in the normal differentiation of 
prostatic epithelium (97). The loss of this gene causes prostate 
carcinogenesis in mice and human (97).
Economides e/ a/ suggested that controls the development of
the ventral prostate in the mouse. Mice with a mutation of both Hoxb13 
and A/oy(7/J exhibit severe hypoplasia of the prostatic ducts, a change in 
epithelium from tall columnar cells to simple cuboidal cells, and the 
complete absence of ventral prostatic secretions, indicating an important
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role in ventral prostate morphogenesis. This suggests an important role 
for Hoxb13 in the differentiation pathway that gives rise to the ventral 
prostate epithelium (98).
The most posterior aspect of the mammalian Hox gene clusters is 
occupied by Hoxa13, Hoxb13, and HoxcH3, which are expressed in the 
developing prostate. Hoxa13 is expressed in both the epithelium and 
mesenchyme of the mouse urogenital sinus. (99). In human adults, 
HOXB13 \s expressed in the rectum and in all the epithelial glands of the 
prostate. There are no reports in literature on the expression of HOX 
genes or their role during human prostate gland development. However, 
there are studies on the expression of HOX genes in human adult 
prostatic tissues that have shown that these tissues express all HOX13 
paralogs in addition to several anterior A/ClYgenes (100; 101).
1.7.4 HOX genes and their role in prostate cancer
In the mouse prostate, A/oygenes play a role in the normal development 
of the gland and in tumour formation (94). The oncogenic and tumour 
suppressor signalling pathways associated with urogenital cancers 
which result in tumour formation and development of metastasis, 
converge on the HOX gene network (102).
Aberrant expression of HOXO genes has been detected in human PC 
cells, and in lymph node métastasés (103). Over-expression of HOXC4, 
HOXC5, HOXC6, and A/0%C<9 genes in malignant cell lines and in lymph 
node métastasés in PC has been shown with reverse transcription-PCR 
(103).
Aberrant expression of HOXC8 and HOXB13 has been shown in the 
development of PC. Over-expression of HOXC8 and down-regulation of
42
HOXB13 are associated with loss of differentiation in human PC cells 
(100;104). Significantly higher levels of HOXCSxwRHfK were detected in 
cells from tumours of higher Gleason score (>7) (104). By contrast, little 
or no HOXC8 mRNA was detected in normal prostate cells, or in cells 
from PC of low Gleason score.
HOX genes may also have a role in androgen receptor (AR) signalling, 
which regulates the growth and differentiation of normal and cancerous 
prostate cells (105). HOXB13 is highly expressed in normal prostate 
cells and AR-positive cell lines. However, its levels of expression in AR- 
negative cells are low, suggesting it acts in AR signalling (100; 106). 
Deregulation of HOXD13 has been demonstrated in breast cancer, 
melanoma, cervical cancer, and advanced PC with neuroendocrine 
differentiation (107). NKX3.1, another androgen regulated homeobox 
gene, is highly expressed in prostate carcinogenesis (108).
over-expression was demonstrated in human prostate tumours 
that had become castrate after initial treatment (109). It was 
demonstrated that inducing HOXB13 \w LNCaP prostate tumour cells to 
levels seen in normal prostate tissue markedly promoted cell 
proliferation. HOXB13 suppression inhibited tumour cell proliferation in 
an androgen free environment. This cell growth promotion appeared to 
be regulated by /?^/-mediated EiFsignalling (109).
A study of HOXB13 genes mutation and family history of PC showed 
that the HOXB13 G84E variant in the region of linkage at 17q21-22 is 
associated with a significantly increased risk of familial PC (110). Xu et 
a/confirmed this finding in another study that showed that the HOXB13 
G84E mutation is associated with PC risk, and is present in 
approximately 5 % of PC families, predominantly of European descent,
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(111). A similar study by Lin ef a/showed that the mutation G135E\n 
HOXB13 gene was associated with increased PC risk among Chinese 
men (112).
The role of HOX genes has also been evaluated in PC progression. In a 
study by Truong et at, it was postulated that even-skipped homeoboxi 
{EVX1) gene méthylation is altered during the progression of PC (113). 
High grade cancers demonstrated increased méthylation when 
compared to intermediate grade PC. It was also demonstrated that 
hypermethylation of EVX1 genes predicted treatment failure in PC 
patients with moderate risk disease.
In another study, prostatic tissue was derived from patients who had 
undergone radical prostatectomy. It was demonstrated that the genomic 
analysis of MEIS1, MEIS2, PBX1 and HOXA9 oer\ detect survival 
differences in patients on watchful waiting, and can also help predict 
biochemical failure after radical prostatectomy (114). The expression of 
yVoYgenes during normal prostate gland development in the mouse, and 
the aberrant expression of HOX genes in PC in humans are shown in 
Table 5.
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Table 5 Expression of Hox genes during normai prostate gland
development in the mouse and aberrant expression of HOX 
genes in prostate cancer in humans
Genes expressed during normal prostate 
development in the mouse
Hoxa 9-11
HoxalS
HoxblS
HoxdlS
Hoxcll
Genes expressed aberrantly in prostate H0XC4
cancer in humans H0XC5
HOXC6
HOXCS
H0XB13
H0XA9
1.8 Engrailed genes
1.8.1 Introduction and functions
The Engrailed (En) genes are also members of the homeodomain- 
containing transcription factors family, which show a high degree of 
functional conservation during embryonic development (115). En gene 
was first described as a Drosophila mutation that resulted in a failure of 
the border dividing the anterior and posterior wing compartments (115). 
Vertebrates have two Engrailed genes, En1 and En2, which appear 
functionally equivalent (116;117).
En2 protein has been shown to have some additional functionally 
important properties, including the ability to be secreted by some cell 
types, and to be internalized by others (118; 119).
The EA/gene is involved in the determination of the midbrain/hindbrain 
border, which acts as an important organizing centre during brain
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development. High levels of En1 and En2 dxe expressed by the alar 
(dorsal) cells. Transplantation of these cells to other areas of the 
developing brain, which do not usually express En, induces En 
expression. These implanted regions later develop the characteristics of 
the transplanted tissue (120; 121).
The secretion of En2 protein, and its uptake by extending axons, 
influences axonal guidance. En2 protein acts as an attractant for the 
nasal axons and a repellent for the retinal axons. This property helps 
these axons during the brain development (122).
EN2 may influence the survival of dopaminergic neurons within the 
human adult nervous system. These neurons express high levels of EN2 
during embryonic development and adult life (123).
EN2 has also been shown to have an oncogenic role in breast cancer 
and PC. Martin et a! demonstrated that non-tumourogenic murine 
mammary cell lines underwent malignant transformation after they were 
forced to express EN2 (124). Bose demonstrated that EN2 \s over­
expressed in human PC cells, as compared to normal prostate epithelial 
cells, and suggested that EN2 may contribute to prostate tumour 
formation. (125)
1.9 EN2 as a urinary blomarker for prostate cancer
Recent studies have suggested that EN2 may have a clinically useful 
role as a specific diagnostic marker for PC. PSA, DRE and TRUS 
biopsies of the prostate, all have significant limitations (126; 127) (see 
Section 1.3 for these limitations). Incorporating EN2 into PC screening 
may overcome of these limitations. Serum PSA is prostate-specific, but 
not PC-specific, since it may be elevated in benign conditions. Urinary
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EN2 and other novel blomarkers have the potential to overcome these 
limitations.
Morgan et a! recently evaluated the role of EN2 in the diagnosis of PC 
(51). In a study on 84 men with PC and 102 men without PC, it was 
shown that EN2 was secreted into the urine by PC cells but not by 
normal prostatic tissue (51). Semi-quantative real time PCR confirmed 
EN2 expression in PC3, DU145, and LNCaP PC cell lines and in PC 
tissue from prostate biopsy cores. Non-cancerous prostate biopsy cores 
did not express EN2. The high expression of EN2 by PC tissue was 
confirmed by immunohistochemistry. Normal prostatic tissue and high 
grade prostatic intraepithélial neoplasia (HGPIN) did not express EN2. 
First pass early morning urine samples (5-1 Omis) were collected. EN2 
levels were measured using ELISA. Finding that EN2 remained stable at 
room temperature for up to 4 days enabled subsequent recruits to 
provide their urine samples by post. Using a cut off of 42.5 ng/ml, 
sensitivity of 66% and specificity of 88.2% were reported for detecting 
PC by urinary EN2. Prior DRE was not required. Based on these 
findings, it was suggested that EN2 has the potential to be used in 
conjunction with PSA as a diagnostic test for PC in the community and 
out-patient settings (51).
Many patients with clinically low-risk localised PC face a difficult choice 
between AS and treatments such as RP, BXT or EBRT. A non-invasive 
test that could reliably predict tumour burden within the prostate gland 
would inform such treatment decisions. Previous studies failed to show 
an association between prostate tumour volume and serum PSA 
(128;129).
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In 2012, a study by Pandha e/a/demonstrated the relationship between 
urinary EN2 levels and PC volume in men who had undergone RP for 
PC (130). This retrospective study assessed archived pre-treatment mid­
stream urine samples, obtained without preceding prostatic massage, 
from the Aarhus Prostate Cancer Project, Denmark. Urinary EN2 levels 
were measured by ELISA. The results showed no significant relationship 
between urinary EN2 levels and serum PSA levels. PSA levels showed 
no correlation with tumour stage, combined Gleason grade, total 
prostatic weight or cancer volume. However, a strongly significant 
correlation was noted between urinary EN2 and tumour volume by linear 
regression (p= 0.006). A significantly higher level of EN2 was detected in 
the T2 cancers (p= 0.027), when comparing T1 vs all T2 cancers. As no 
prior DRE is required, and the ELISA is a simple, low cost and robust 
test, it was suggested that EN2 has the potential of becoming not only a 
useful diagnostic biomarker for PC but may also help in risk stratification 
and management by indicating the burden of tumour volume (130).
A recent study by Morgan et at, showed that urinary EN2 is also 
secreted by the transitional epithelium in the bladder, and may be used 
as a biomarker for non-muscle invasive bladder cancer. Urinary EN2 
was reported to have sensitivity and specificity of 82 and 75%, 
respectively, for the detection of superficial bladder cancer (131).
1.10 Imaging modalities for the diagnosis of prostate cancer
Another approach to improving the diagnosis of PC is the use of imaging 
modalities. Several imaging modalities have been assessed for their 
ability to detect PC. Recently, contrast enhanced ultrasonography (132), 
elastography (133; 134) and multiparametric magnetic resonance
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imaging (mpMRI) (135-137) have been assessed for their ability to 
improve the accuracy of diagnosis of PC (Table 6).
Table 6 Sensitivity and specificity of various imaging techniques used 
in prostate cancer detection.
Imaging
technique
Sensitivity% Specificity% References
Contrast
enhanced
uitrasonography
93 79 (138)
Eiastography 75 77 (139)
Histoscanning 37 71 (140)
mpMRI 86-90 88-94 (135:141)
1.10.1 Potential advantages of imaging techniques in prostate 
cancer
• Detection and localisation of PC
• Identification of suspected tumour foci, which may be targeted with 
prostate biopsies, thus reducing the number of biopsies
• Fewer biopsies mean potentially fewer risks and complications
• Staging the disease
• Convenient for the patients and clinicians, as they can be performed 
in the out-patient clinic
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• Use for post-treatment monitoring and follow up to detect disease 
recurrence
1.10.2 Disadvantages of imaging techniques 
Ultrasound
• Ultrasound-based modalities lack the ability to assess the anterior 
gland in large prostates, owing to lack of ultrasound wave penetration
• Intra-prostatic calcifications produce artefacts that obscure the distal 
prostate tissue, which can lead to incomplete assessment of the 
prostate gland
MR!
• Imaging modalities are expensive
• Requires the input of a radiologist
1.10.3 Prostate Histoscanning™ in the diagnosis and 
characterisation of prostate cancer
Prostate H is to s c a n n in g ™  (PHS) has recently been assessed as a novel 
imaging technique in PC detection and localisation.
An un-blinded study by Braeckman et al in 2008 on 14 patients 
suggested that PHS can identify and characterize the index lesions, 
multifocal PC, and extra prostatic extension (142). Another blinded study 
by the same group on 13 patients reported sensitivity and specificity of 
PHS of 100 and 82%, respectively, for detecting tumour lesions >0.5ml 
(143).
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In a more recent un-blinded study on 27 patients, sensitivity and 
specificity for detecting tumour lesions of >0.5ml were 90 and 70%, 
respectively, when compared with whole-mount radical prostatectomy 
histology (144).
1.10.4 Principles of prostate Histoscanning™
PHS is an ultrasound-based technique that involves scanning the 
prostate gland with a trans-rectal bi-planar ultrasound motorised probe. 
The ultrasound reflection from different tissue types may be 
characteristic, and these back-scattered data are analysed by the PHS 
software. The manufacturers claim that their software distinguishes 
between the radiofrequency signatures of cancerous and benign 
prostate tissue. It would be highly desirable to detect tumour foci using a 
non-invasive imaging technique. Such a technique would improve PC 
screening and management of AS patients. It would reduce the risk of 
complications from repeated biopsies, and could aid in the follow up 
after radical EBRT and BXT treatment.
1.10.5 Rationale for assessing prostate Histoscanning™
The diagnosis of clinically significant PC is important. Urinary EN2 may 
be a reasonable substitute for serum PSA for the detection of clinically 
significant PC. However, the accurate location of PC is essential for its 
management. An imaging technique that can detect and accurately 
localise PC may help clinicians to plan appropriate treatment options. 
Detection of focal and localised disease may also help in targeted 
treatment of the cancer lesion with reduced side effects. Focal therapy 
studies are underway to determine the effectiveness of such treatments 
and the associated quality of life (145-147).
51
1,11 Summary of studies and their objectives
The current diagnostic tests for PC including serum PSA, DRE and 
prostate biopsies have limitations, and have associated risks. A 
biomarker with better sensitivity and specificity, fewer complications and 
better tolerability is required.
The aim of the work described in this thesis was to evaluate the roles of 
EN2 (a novel PC biomarker) and prostate H is to s c a n n in g ™  (a new trans- 
rectal ultrasound imaging technique) in improving the detection and 
localisation of PC and the follow up of patients after radical treatment.
The following patient groups were studied in this thesis.
Urinary EN2 groups
1. Healthy Volunteers: The objective of studying this cohort of men 
was to assess the expression of urinary EN2 in a population of 
healthy men, and how it compared with serum PSA, for the 
detection of PC.
2. Active Surveillance group: The objective of studying this group was 
to assess the expression of urinary EN2 in men with low risk and 
low volume PC. Urinary EN2 levels in this cohort may help in 
decision making process for the management of PC.
3. Pre-radical prostatectomy group: The objective of studying this 
cohort was to prospectively determine the relationship of pre­
prostatectomy urinary EN2 levels with tumour volume and stage in 
RP pathology specimens. That would indicate if EN2 could 
potentially be used to select patients suitable for radical treatment 
versus active surveillance.
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4. Post radical treatment group: The objective of studying this cohort 
was to assess urinary EN2 levels in men who had completed 
radical treatment and were deemed cured of PC.
5. Pre- and post-brachytherapy group: The objective of studying this 
cohort was to assess the difference in expression of urinary EN2 
before and after Iodine-125 low dose rate prostate BXT. Urine 
samples were collected from patients prior to their BXT implant, 
and six months after the implant.
6. Pre-and post-hormone group: The objective of studying this cohort 
was to determine the difference in expression of urinary EN2 
before and after hormone therapy for PC.
7. PC relapse group: The objective of analysing this group of patients 
was to assess the expression of urinary EN2 levels in patients with 
PC recurrence.
Semen EN2 group
EN2 is secreted from PC cells into the urine as it passes through the 
prostatic urethra. Seminal fluid passes through the prostate gland itself 
before being ejected into the prostatic urethra through the ejaculatory 
ducts, and therefore contains prostatic secretions. Thus, the 
concentration of EN2 in patients with PC is likely to be higher in the 
seminal fluid than in urine. If that were the case, the assay of EN2 in 
seminal fluid, in conjunction with the urine test, could be particularly 
useful in men with a low volume of tumour in the prostate.
The objective of including this cohort of men was to determine if semen 
EN2 can be used as a biomarker for the detection of PC. The expression 
of EN2 in the semen was assessed in the following groups:
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1. Healthy volunteers
2. PC patients
Prostate Histoscanning™ group
This cohort was included to evaluate the utility of prostate 
Histoscanning™ in routine clinical practice as a non-invasive means of 
detecting clinically significant foci of PC and its ability to predict RP 
findings, and inform surgical decision making.
Hypothesis
I propose the hypothesis that urinary and seminal EN2, and prostate 
Histoscanning™, will improve upon current methods of diagnosing PC, 
and may be used for risk stratification and monitoring following radical 
PC treatments.
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Chapter 2
Materials and Methods
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2 Materials and methods
2.1 Urine sampie coiiection
Healthy volunteers (HVs) and PC patients were identified and recruited 
from Urology clinics at Royal Surrey County Hospital, Frimley Park 
Hospital, and Basingstoke and North Hampshire Hospital. All men 
participated after giving informed written consent.
Packs with urine specimen bottles and pre-paid return envelopes were 
posted to HVs and patients. First pass urine samples (10 ml), without 
prior DRE, were donated by healthy volunteers (HVs) and PC patients at 
their home, and posted to the laboratory. Our group has previously 
reported that EN2 protein is stable in urine at room temperature for at 
least 4 days (51), and all urine samples were received for processing 
within 30 hours post donation. Upon receipt in the laboratory, samples 
were divided into 1.5 ml aliquots, centrifuged 10,000g for 5 minutes, and 
the supernatant removed and stored at -80°C.
2.2 Seminai fiuid coiiection
HVs and PC patients were identified and recruited from Urology Clinics 
at the Royal Surrey County Hospital (RSCH). All men participated after 
giving written informed consent. Seminal fluid was donated by HVs and 
PC patients at home.
The samples were brought to the laboratory by the men on the day of 
donation. Upon receipt in the laboratory, samples were divided into
1.5 ml aliquots, centrifuged 10,000 g for 5 minutes, and the supernatant 
removed and stored at -80°C.
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First-pass urine samples for the assay of EN2 were also collected from 
the HVs and PC patients. In the case of the PC patients, urine samples 
were taken at least 21 days after they had had a prostate biopsy that 
confirmed the presence of cancer. We then collected a sample of 
seminal fluid from those patients, on the following day. All samples were 
stored at the tissue bank at the Department of Oncology at the Leggett 
Building, University of Surrey, Guildford, U.K.
2.3 Laboratory Tests
2.3.1 EN2 protein detection-Enzyme linked Immunosorbent 
Assay of urine samples
A modified version of ELISA, which was reported in a previously 
published study (51) by our group, was used.
Materials
• Lightning Link Alkaline Phosphatase Conjugation Kit (Innova 
Biosciences 702 0010 322)
Standard immunosorb plates (Nunc)
PBS (Sigma P4417-100TAB)
TBS (Sigma T5030)
Thermo-Fisher T20 protein free blocker cat# 37573 
Invitrogen PNPP 100ml, cat# 00-2212 
0.1% Tween 20
Synthetic protein corresponding to the C-terminal 100 amino acids of 
EN2 as a standard.
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Methods
• Alkaline Phosphatase Conjugation - Prepared according to 
manufacturer’s instructions using 100pl of 1 mg/ml APS1. Conjugated 
material stored at + 4°C.
• EN2 peptide dilutions were prepared in PBST (Phosphate Buffered 
Saline Tween) for the standard curve. Typically these are 2000ng/ml, 
400ng/ml, 80ng/ml, 16 ng/ml and 0 ng/ml. (Figure 5)
100 pi of the EN2 standards were added to appropriate wells in 
duplicate on a 96-well plate.
100 pi of urine sample was added in duplicates.
The 96-well plate is then incubated for 2 hours at room temp whilst 
shaking 550 rpm.
Washes x8 performed with PBST.
Plate is then blocked by the addition of 350ul Thermo T20 block.
The plate was then incubated for 60 minutes at room temp whilst 
shaking 550 RPM.
Plate is then washed 4 times with PBST.
APS1-Alkaline Phosphatase was prepared at 1:250 dilution in PBST.
100 pi APSI-Alkaline Phosphatase detection antibody was added to 
appropriate wells.
Plate was then incubated for 15 minutes at room temp whilst shaking 
550 RPM.
• Washes x4 with PBST were then performed.
• Wash x1 with TBS was then performed.
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• 100 pi PNPP substrate was then added (pre-warmed to room 
temperature).
• The plate was then incubated in the dark at room temperature, 
shaking at 550 RPM for 20 minutes.
• Absorbance at 405 nm using a Beckman-Coulter DX880 was read.
• A standard curve was generated from dilution series to allow the 
concentration of EN2 in each sample to be measured using the 
following formula
EN2 ng/ml= (Mean ODxSlope)-y-lntercept
The values of slope and y-intercept are derived from the linear 
regression analysis. The median R2 value was 0.995 (range 0.988- 
0.999). If necessary, background values were subtracted. An EN2 cut off 
value of 42.5 ng/mL was used, as reported by Morgan etal, who initially 
described the EN2 ELISA method (51).
2.3.2 EN2 protein detection-Enzyme linked Immunosorbent 
Assay of semen samples
For semen ELISA, the method described above was used. Initial 
attempts by the group, and subsequently by the author, of diluting 
semen samples with 1 in 10 and 1 in 100 PBS with 0.1% Tween 20 were 
unsuccessful. However, when the author diluted the semen samples 
with 1 in 1000 using PBS with 0.1% Tween 20, ELISA was successful. 
The EN2 values were multiplied by 1000 to compensate for dilution, to 
obtain the corrected values.
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Figure 5 Linear regression analysis for generating standard curve 
using optical densities
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Standard curve showing linear relationship between mean optical 
densities and EN2 concentrations.
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2A Statistical Analysis
In all the study groups, GraphPad Prism version 6 and R version 3.0.2 
were used for statistical analysis. The author performed all the statistical 
analyses, with the exception of the pre-radical prostatectomy group and 
prostate Histoscanning™ studies, which were performed by Richard 
Morgan and Sabeena Beveridge respectively.
2.5 Ethical Approval
Approval by the South East Coast-Surrey Ethics Committee and Royal 
Surrey County Hospital NHS Foundation Trust Research and 
Development Group was obtained prior to commencement of the 
studies. All approved consent forms and patient information sheets are 
presented in Appendix 1.
2.5 immunohistochemistry staining (mouse/rabbit primary 
antibody)
Day 1 -  Deparaffinization and Antigen Retrieval
• Tissue sections were deparaffinized in 3 changes of 100% Xylene 
for 5 minutes each.
• While waiting, 1 L 0.01 M citrate buffer was prepared.
• 2 washes in 100% Ethanol were performed.
• Slides were placed in 0.3% methanol/H202for 20 minutes.
• Citrate buffer (Citrate 10 mM buffer at pH6) was boiled in the 
microwave on high for 20 minutes whilst the slides were in 
methanol/H202. 1 L citrate buffer was used to submerge the slides 
completely.
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After 20 minutes, slides were washed in 100%, 70%, then 50% 
ethanol, and left in distilled water.
Slides were placed in boiling citrate buffer in microwave for 
12 minutes.
These were then left to cool for 1-2 hours.
Slides were washed in distilled water for 3 minutes.
Then washed 2 x in PBS for 3minutes each time.
Dako pen was used to draw around the sections and then placed 
in moist chamber.
Horse serum (Vectastain Elite ABC kit R.T.U) was added to cover 
entire section; chamber was closed for 15 mins.
After 15 minutes, excess horse serum was removed and Avidin 
(Vectastain Avidin/Biotin blocking kit) solution was placed onto 
each section, and left for another 15 minutes.
After 15 minutes, excess solution was removed, and slides were 
placed in a rack and dipped immediately in PBS for a wash. The 
slides were then dried and placed back in the chamber.
Biotin (Vectastain Avidin/Biotin blocking kit) was added onto each 
section; the chamber was closed for 15minutes.
After 15 minutes, excess biotin was removed and 200 pi 
appropriate antibody dilution (negative control was PBS1% BSA) 
was added to the section. Slides were left overnight at room 
temperature in moist chamber with lid closed.
Day 2
Excess solution was removed, and 3 washes were performed in 
PBS for 3 minutes each.
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Slides were gently dried and left in the chamber. Universal 
secondary antibody (Vectastain Elite ABC kit R.T.U) was added, 
and chamber was closed for 30 minutes.
3 washes in PBS for 3 minutes each time were performed.
ABC reagent (Vectastain Elite ABC kit R.T.U) was added and 
chamber was closed for 30 minutes.
Excess reagent was removed, 3 washes were performed in PBS 
for 3 minutes each.
DAB (DAB Peroxidase substrate kit) was prepared according to kit 
instructions.
DAB was added for 4 minutes.
Wash in distilled water was performed for 5 minutes.
Counter stain was performed with Haematoxylin for 45 seconds. 
Wash in running tap water was performed for 5 minutes.
Slides were dehydrated in 50% ethanol, 70%, 100%, 100%, 100%, 
then 3 xylene washes were performed.
Slides were left to dry, and then covered and stored at room 
temperature.
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2.7 Study groups
2.7.1 Urinary EN2 Groups
2.7.1.1 Heaithy volunteers
A. Group 1
Men attended a community drop-in centre, and provided a urine sample 
to be tested for EN2. They also had a PSA test. There was no selection 
bias.
B. Group 2
HVs in this group were identified though health screening by the GPs 
based on the following inclusion criteria:
• PSA < 2.0 ng/ml
• Normal DRE
• No family history of PC
• No lower urinary tract symptoms
• Age > 40 years.
These men were recruited between September 2010 and January 2011.
2.7.1.2 Active surveiiiance group
Patients were identified and recruited from urology clinics at the RSCH, 
Frimley Park Hospital and the Basingstoke and North Hampshire 
Hospital. Men on an AS program following template biopsy confirmation 
of small volume disease were evaluated. Samples were collected 
between September 2011 and October 2012. The following inclusion 
criteria were used for the AS patients:
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age <75 years 
combined Gleason score <6 
PSA <15 ng/ml,
<8 positive cores on template biopsies 
maximum core length <8 mm on template biopsies
2.7.1.3 Pre-radical prostatectomy group
The patients were recruited between December 2010 and February
2012. Patients were identified in uro-oncology clinics from the RSCH 
Guildford, and Frimley Park Hospital, Frimley, UK. Patients were 
recruited prospectively and consecutively.
Inclusion criteria
♦ Planned RP (laparoscopic or robotic) for clinically localised PC.
♦ Histologically confirmed diagnosis of PC based on 8-12 core 
trans-rectal sextant and/or template biopsies.
Exclusion criteria
Patients with a urinary tract infection 
Patients on any therapy for PC 
Patients on 5 alpha reductase inhibitors 
Patients with non-organ confined disease 
Any histologically confirmed second malignancies
First pass urine samples were collected without DRE at least 3 weeks 
after any prostate biopsies (sextant or template) and 1-14 days before 
RP. Serum PSA was measured prior to urine procurement.
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All RP specimens and biopsies were evaluated by a dedicated uro- 
pathologist at RSCH. Tissue samples were fixed in 10% formalin, 
paraffin embedded, and sectioned at 5-mm intervals. The cone method 
was used for assessment of the apex and the base of the prostate. The 
Gleason grading system (International Society of Urological Pathology 
revised version) along with TNM classification for staging was used. 
Each focus of PC was outlined on the histology sections and tumour 
volume calculated by multiplying the area by the thickness of the 
section. The volumes of the individual tumours were calculated and 
combined to give the total tumour volume (148). The urine EN2 ELISA 
on pre-prostatectomy samples was performed by Richard Morgan.
2.7.1 A  Post radical treatment group 
This group was further divided into three sub groups.
• Post-BXT
• Post-RP
• Post-EBRT
Inclusion criteria
• >5 years post radical treatment 
PSA <0.1 ng/ml post BXT or 
PSA <0.1 ng/ml post RP or 
PSA <0.3ng/ml post EBRT
66
2.7.1.5 Pre- and post-brachytherapy group
Urine samples were collected from patients prior to their BXT implant, 
and at six months after the implant. The urine samples for this group 
were collected between October 2011 and May 2013.
Inclusion criterion
Patients undergoing BXT (monotherapy) implant for treatment of 
localised PC.
Exclusion criterion
Patients treated with neoadjuvant hormones or EBRT prior to BXT 
implant.
2.7.1.6 Pre- and post-hormone therapy group
Patients in this cohort received neoadjuvant hormones with EBRT or 
BXT. When patients are assessed for BXT, and prostate gland volume is 
more than 60 ml (causing pubic arch interference), they may be offered 
prior androgen deprivation therapy for 4 months, to reduce the volume of 
the gland.
The hormone treatments included: anti-androgen tablet (Bicalutamide) 
50 mg once daily for three weeks; leutinizing hormone releasing 
hormone (LHRH) injections ten days after starting anti-androgen tablets, 
either as a monthly injection or a three monthly injection. In the case of 
the BXT patients, 0.5 mg Dutasteride was additionally given once daily 
until 3 months after the BXT implant, for prostate volume reduction. 
Patients on hormones for metastatic disease were also included in the 
study.
Urine samples were collected prior to starting hormones and then at 
Days 1, 2, 3, 4, 5, 14, 21, 30 after starting hormones. The last urine
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sample was collected at three months after the first injection prior to BXT 
or start of EBRT. The urine samples were collected between January 
2012 and January 2013.
2.7.1.7 Prostate cancer relapse group
The objective of analysing this group of patients was to assess the 
expression of urinary EN2 levels in patients with PC recurrence. The 
urine samples were collected between September 2011 and March
2013.
Inclusion criteria
• PSA>0.1 ng/ml post radical prostatectomy or
• PSA > nadir+2 post BXT (ASTRO definition)
Exclusion criterion
Any treatment for PC recurrence, including hormones
2.7.2 Semen EN2 groups
HVs were approached through the General Urology Clinic at the RSCH. 
These included men who were listed for an elective circumcision. PC 
patients who fulfilled the eligibility criteria were also approached in 
Urology Clinics. These men were recruited between February and 
December 2012.
Patients 
Inclusion criteria
• Recent diagnosis of localised PC
• At least 7 days post prostate biopsy
• Potent
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• <65 years old
Exclusion criterion
Any prior treatment for PC.
HVs (controls)
• Potent
• <30 years old
• No family history of PC
2.7.3 Prostate Histoscanning™ Group 
Inclusion criteria
• Men undergoing RP who were > 40 years old
• Histologically-proven PC
• Clinically-localised PC
Exclusion criteria
• Any prior treatment for PC, including hormone therapy
• Major calcification noted during the diagnostic TRUS (diameter >5 
mm, spread all over the prostate, adversely affecting ultrasound 
signal quality).
In our series, no patient had significant calcification. Men with previous 
transurethral resection of the prostate were eligible. PHS was performed 
using a BK 8818 motorised probe, prior to RP (Figure 6).
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Figure 6 BK8818 motorised probe used for PHS
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2.73.1 Patient recruitment
41 patients scheduled for RP were screened between July 2011 and 
Jan 2012. 31 patients were eligible, but 7 of these were not suitable for 
analysis. Thus 24 patients were examined in this study (Figure 7).
Figure 7 Screening and recruitment for Prostate Histoscanning study
Suitable for 
analysis n=24
Unsuitable for 
analysis n=7
Eligible for inclusion 
n = 31
Patients excluded 
n = 10
Patients screened for SHS-02 
n = 41
• Anal stenosis (1)
•Ana l fissure (1)
Did not fulfill inclusion criteria
• Patient aged <40 years (1 )
• On hormone therapy prior to 
RP{3)
• Patient refused to consent (4)
Reasons for exclusion 
(number of patients)
• Difficulty in 3D acquisition owing to 
patient anxiety (1)
• Transurethral resection of bladder 
tumQ-Urperformed instead of RP (1 )
• Optical UiethlQ tom y performed instead 
of RP(1)
• Pathology protocol violation (4)
Reasons for unsuitability 
(number of patients)
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The prostate gland was divided into 6 regions (Right and Left, Apex, Mid 
and Base).
2.7.3.2 Reference Standard
The reference standard for this study, as for other similar studies 
(142;143;149), and in accordance with the STARD initiative (150), was 
analysis of the whole-mount step-section prostatectomy specimens.
2.7.3.3 Analysis ofRP specimens
A dedicated uro-pathologist, blinded to the PHS results, processed and 
analysed all the prostatectomy specimens at Bostwick Laboratories 
(London, UK). After 48 hours of fixation in formalin, the prostatectomy 
specimens were processed according to standard operating procedure, 
each cut into 3 mm sections. The cone method was used to examine the 
apical and basal margins. Sagittal sectioning was used to assess tumour 
at the limits. All sections were scanned (Figure 8). Each specimen was 
divided into six sextants as follows:
Left and Right: Each scanned section image was divided into left and 
right sides by an anterior-posterior line drawn through its midpoint.
Apex, Mid and Base: The length of each prostatectomy specimen was 
divided into thirds: the Base, the Apex and the Mid-gland. Sections that 
overlapped two regions were assigned to the one that contained more of 
its thickness. Tumour volume was calculated using Paint Shop Pro™ 
V.7, (Jasc Software, Inc. Minnesota) as the sum of product of the tumour 
area on each scanned transverse section and the section thickness. The 
location and volume of the Index Lesion in each prostatectomy 
specimen, and the presence or absence of extra prostatic extension
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(EPE), and its location, were recorded. This method has been described 
in our recently published paper (140).
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Figure 8 Histological analysis of RP specimens.
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2.7.3.4 Index Test: Prostate Histoscanning™
PHS software (Version 2.1, Advanced Medical Diagnostics, AMD Ltd, 
Waterloo, Belgium) was used to analyze radiofrequency back-scatter 
data. The author and another research clinician performed and acquired
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3D PHS data respectively immediately prior to prostatectomy. Both 
research clinicians were trained by AMD Ltd in PHS and had substantial 
experience in TRUS scanning, image analysis and interpretation in the 
context of prostate brachytherapy. More than 100 3D Histoscans in other 
clinical studies had been acquired and analysed prior to this study. PHS 
analysis was performed immediately after acquisition of 3D data, or at a 
later stage, but always prior to receiving the pathology results (blinded to 
pathology results).
The apex and the base of the prostate gland were identified using the 
PHS device, which is shown in Figure 9. The PHS software then 
automatically outlined the gland. This outline was designated the volume 
of interest (VOI). The VOI could be refined manually, as necessary, by 
the author while performing the analysis. PHS software then performed 
tissue characterisation sequences to identify areas suspicious of cancer. 
These areas appeared red on the PHS screen and could be refined 
manually as well. The software calculated the total volume of the red 
areas. The prostate was then divided into sextants: right and left apex, 
mid-gland and base. The software measured sextant volumes of the 
suspicious lesions (Figure 10).
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Index and standard reference tests were compared as follows:
Whole gland analysis: Total tumour volumes from the index and 
reference standards were compared using Pearson correlation 
coefficient.
Sextant Analysis: Using thresholds of >0.5ml and >0.2ml, total tumour 
volumes in each sextant were compared.
Index Lesion Analysis: The volumes of the index lesions on PHS and 
histology and their location were compared in 144 sextants.
EPE analysis: EPE was considered present on PHS where red areas 
were in contact with the VOI edge. The presence and location of EPE 
were compared between PHS and histology.
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Figure 9 Histoscanning and BK PROFOCUS Uitrasound machine
Prostate Histoscanning machine BK PROFOCUS Ultrasound machine
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Figure 10 PHS data analysis and tumour volume estimation
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3 RESULTS
3.1 Urinary EN2
3.1.1 Healthy volunteers
A. Group 1
A total of 72 healthy volunteers were tested for their urinary EN2. The 
mean age was 67 years; median age was 70 (range 51-82).
4 (6%) men were positive (EN2 level > 42.5 ng/ml ) as described in 
study by Morgan et al (51). All these 4 volunteers had a PSA >4 ng/ml.
68 (94%) men had a negative EN2 level (EN2 < 42.5 ng/ml) as shown in 
Table 7a. The results of EN2 ELISA on all 72 healthy volunteers are 
shown in Figure 11.
B. Group 2
A total of 84 healthy volunteers were tested for their urinary EN2. The 
mean age was 69 years; median 68 (range 50-89). The mean PSA was 
0.9 ng/ml; median 0.9 ng/ml (range 0.2-2.0).
14 (17%) men were positive for EN2 (EN2 level > 42.5 ng/ml ). 70 (83%) 
HVs had a negative EN2 level (EN2 < 42.5 ng/ml) as shown in Table 7b. 
The results of EN2 ELISA on all 84 HVs are shown in Figure 11.
We compared urinary EN2 levels in all 156 healthy volunteers with the 
cohort of 57 men diagnosed with PC who underwent RP (151). This 
cohort of pre-prostatectomy urine samples is discussed later in this 
chapter. We found statistically significant higher concentrations of 
urinary EN2 in the pre-prostatectomy group compared to the healthy
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volunteers (p<0.0001), using the unpaired /-test with Welch’s correction 
(Figure 12).
In the graphs comparing various groups of EN2 levels, the height of the 
bar represents the mean and the error bar represents the standard error 
of the mean.
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Table 7 EN2 positives vs EN2 negatives in healthy volunteers
(a) Group 1
EN2 &42.S ng/ml (Positive) EN2 <42.5 ng/ml (Negative)
4/72 (6%) 68/72 (94%)
(b) Group 2
EN2 &42.S ng/ml (Positive) EN2 <42.5 ng/ml (Negative)
14/84 (16.7%) 70/84 (83.3%)
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Figure 11 Concentrations of urinary EN2 in Healthy Volunteers
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Figure 12 Scatter plot comparison of urinary EN2 concentrations of 
healthy volunteers and the pre-prostatectomy group.
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3.1.2 Active surveillance group
A total of 38 patients in the AS cohort were assessed based on the 
criteria in Table 8. Thirty-four of 38 patients (89%) were positive for 
urinary EN2 (level above 42.5 ng/ml as reported previously (51)) . Four 
out of 38 patients (11%) were negative for urinary EN2 levels. In men 
who were positive for urinary EN2, the mean EN2 level was 
175.47 ng/ml, median 149 (range 56-723). The age, PSA and EN2 
levels of patients who were positive or negative for EN2 secretion are 
shown in Table 9.
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There was a statistically significant difference (p<0.0001) between the 
EN2 levels of the two groups (Figure 13). A comparison of the urinary 
EN2 levels in the AS cohort (n=38), and the 57 men in the pre-radical 
prostatectomy group (148) was done. We found significantly higher 
urinary EN2 concentrations in the pre-prostatectomy group, compared 
with the AS cohort (p<0.0001) (Figure 14).
Figure 13 Scatter plot comparing urinary EN2 concentrations in EN2 
producers vs EN2 non-producers.
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A comparison of the EN2 levels in AS cohort of patients with low risk low 
volume PC and the HVs (Groups 1 plus 2) showed a statistically 
significantly higher concentration of urinary EN2 levels of the groups in 
the former group (p<0.0001) (Figure 15).
Table 8 Active Surveillance criteria and cohort characteristics
n=38 Mean Median Range
Age £75 years 66 67 47-75
PSA £15 7.5 6.9 1.1-15
Gleason score 
£6 6 6 5-6
Positive cores 
£8 on template 
biopsies 2 2 1-6
Maximum core 
length £8 mm 
on template 
biopsies 1.83 1.4 0.4-7
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Table 9 EN2 producers and non-producers in the AS cohort.
EN2 non-producers 
(42.5 ng/ml n=4 (11 %)
EN2 producers 
^42.5 ng/ml 
n=34(89%)
Age (years)
Mean 69 65
Median 69 66
Minimum 66 47
Maximum 72 75
PSA ng/ml
Mean 10 7.3
Median 10 6.7
Minimum 6.3 1.1
Maximum 15 15
EN2 ng/ml
Mean 7.5 175.47
Median 0 149
Minimum 0 56
Maximum 30 723
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Figure 14 Scatter piot comparing urinary EN2 concentrations in the AS 
and pre-prostatectomy groups.
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Figure 15 Scatter plot comparing urinary EN2 concentrations of healthy 
volunteers and the AS group.
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3.1.3 Pre-radical prostatectomy group
3.1.3.1 Patient Characteristics
There were a total of 57 men in this study. Their characteristics are 
summarized in Table 10. Thirty-six, 8, 8, 4 and 1 men were reported to 
have clinical stages Tic, T2a, T2b and T3a, respectively. The mean 
number of positive cores was 5, median 5, (range 1-19). The median 
combined Gleason score in biopsies and RP specimens was 7. 
Seventeen patients had their Gleason score upgraded after RP. Two 
patients were downgraded at final whole mount pathological analysis. 
The following Gleason scores were reported on RP specimen analysis: 
3+3 (n = 15); 3+4 (n = 33); 4+3 (n = 5); 4+4 (n = 0); 3+5 (n = 3); and 4+5 
(n = 1). The following percentages of Gleason scores were noted: 
Gleason 6 (26.3%); 7 (66.6%), 8 (5.2%) and 9 (1.7%).
3.1.3.2 EN2 producers and non-producers
The mean tumour volume in the RP specimen was 4.92 ml, median 
4.35 ml, (range 0.15-14.8 ml) (Table 10). 48 of 57 men (84%) were 
positive for EN2 in their urine, having levels > 42.5 ng/ml, as previously 
discussed. Nine of 57 men had negative EN2 levels. In men who were 
positive, the mean EN2 level in urine was 411.52 ng/ml, median 331.5 
(range 68-1129) ng/ml.
Table 11 shows the demographic and pathological features of PC 
patients who were positive or negative for EN2 secretion. These two 
groups differed only on the basis of tumour volume. Higher EN2 
secretion was associated with larger tumour volume at prostatectomy. 
There was a statistically significant difference between the EN2 levels in 
the two groups (p= <0.0001, using /-test with Welch's correction;
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Figure 16). There was also a significant difference (p= <0.0001) between 
the tumour volumes in the two groups (Figure 17). This statistical 
analysis was performed using /-test with Welch’s correction.
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Figure 16 Comparison of urinary EN2 concentrations in EN2 producers 
vs EN2 non-producers in pre-radicai prostatectomy group
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Figure 17 Comparison of tumour volume in EN2 producers vs EN2
non-producers in pre-radical prostatectomy group (p<0.0001)
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In all nine men who did not secrete EN2, one or more of their original 
diagnostic prostatic biopsies or the tumour section from their RP were 
positive for EN2 staining (Figure 18).
Table 10 Patient characteristics of the pre-RP group.
Mean Median Range
Age (years) 64.8 66 48-77
PSA concentration (ng/ml) 9.1 8 2.4-27
EN2 concentration (ng/ml) 347.73 265 0-1129
Tumour volume (ml) 4.92 4.35 0.15-14.8
Total prostatic volume (ml) 46.2 40 13.7-160
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Table 11 Demographic and pathological features of patients who were 
positive or negative for urinary EN2.
EN2 non-producer 
<42.5ng/ml n=9 (16%)
EN2 producers 
>42.5ng/ml n=48 (84%)
Age (years)
Mean 64.3 64.9
Median 67 66
Minimum 49 48
Maximum 73 77
PSA ng/ml
Mean 8.08 9.81
Median 6.4 9.1
Minimum 4.47 2.4
Maximum 23 29
EN2 ng/ml
Mean 7.5 411.52
Median 0 331.5
Minimum 0 68
Maximum 36 1129
Tumour volume on RP 
ml
Mean 1.06 5.65
Median 0.82 5.2
Minimum 0.15 0.3
Maximum 2.75 14.8
Prostate Volume ml
Mean 47 46
Median 49 40
Minimum 21 13.7
Maximum 90 160
Gleason score on biopsy
Mean 6 7
Median 6 7
Minimum 6 6
Maximum 7 7
Gleason score on RP
Mean 7 7
Median 7 7
Minimum 6 6
Maximum 7 9
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Figure 18 EN2 staining of prostate cancer tissue from biopsies and 
radical prostatectomy specimens.
a) Normal bladder tissue (positive control). Magnification x io
m m #
EN2 positive Transitional epithelium  
of the bladder (brown)
b) Positive EN2 staining of prostatic adenocarcinoma. Magnification x 
100
* *
A biopsy core containing 
prostatic adenocarcinoma 
stained w ith  anti-EN2 
antibody. EN2 positive 
staining (brow n) is present in 
tum or cells.
EN2 is present in the 
cytoplasm o f tum or cells, 
w ith  strongest staining at the 
lum inal border.
The nucleus is stained blue.
EN2 staining Performed by Francesca Launchbury.
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3.1.3.3 Correlation between serum PSA and urinary EN2
We found no correlation between serum PSA level and levels of urinary 
EN2 in pre-operative samples (p = 0.07) using linear regression analysis 
(Figure 19).
3.1.3.4 Correlation ofEN2 with clinical stage, pathological stage, 
margin positivily and perineural invasion
EN2 levels were higher in the more advanced clinical stage (all T2 
versus Tic), but this did not reach significance (p = 0.19, using the 
unpaired /-test with Welch's correction; Figure 20). When assessing the 
pathological stage, significant differences were noted in levels of EN2 in 
pT2 (n = 38) vs pT3a (n = 21) (p = 0.006, using the unpaired /-test with 
Welch’s correction; Figure 21). Men with positive margins (n=14) had 
significantly higher levels of EN2 (p=0.007) than did patients with 
negative margins (n=43) (Figure 22). Patients with perineural invasion 
showed the same trend against patients with no perineural invasion, 
(p=0.003) (Figure 23).
3.1.3.5 Correlation ofEN2 and PSA with Gleason grade of prostate 
biopsies and RP specimens
The relationship between urinary EN2 and serum PSA and Gleason 
grading of biopsies and RP specimens was also assessed. In the 
prostate biopsies, Gleason 7 disease was associated with higher levels 
of EN2, as compared with Gleason 8 disease, although the numbers of 
Gleason 8 cases were far lower. In the RP specimens, there were 
equally high EN2 levels in specimens with Gleason 6 and 7 PC, and 
again lower levels associated with Gleason 8. These differences in EN2 
levels did not reach statistical significance in either the prostate biopsy
97
or RP specimen groups. PSA levels did not reach statistical significance 
in relation to Gleason grading in biopsy and RP specimens.
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Figure 19 Correlation between levels of serum PSA and pre­
prostatectomy urinary EN2 (p=0.07)
1500n
1000-
PSA (ng/ml)
99
Figure 20 Comparison of urinary EN2 concentration in patients with 
clinical Stages cT1 (n=35) and cT2 (n=21), p=0.19
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Figure 21 Comparison of urinary EN2 concentrations in patients with 
pathological stage pT2 (n=38) and pT3a (n=19) tumours,
p=0.006
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Figure 22 Comparison of urinary EN2 concentrations in patients with 
positive (n=14) and negative (n=43) surgical margins, 
p=0.007
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Figure 23 Comparison of urinary EN2 concentrations in patients with 
perineural invasion (n=47) vs no perineural invasion (n=10), 
p=0.003
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3.1.3.6 Correlation between pre-prostatectomy serum PSA and total
prostate and prostate cancer volume
No significant correlation was seen between serum PSA level and total 
prostate gland volume (p = 0.28) or PC volume (p = 0.09) (Figures 24a 
and b respectively) using linear regression analysis in our cohort of 
57 patients.
Figure 24 Correlation between pre-prostatectomy serum PSA levels 
and (a) prostate volume, and (b) total prostate tumour 
volume (p=0.09).
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3.1.3.7 Correlation between pre-prostatectomy urinary EN2 and 
total prostate and prostate cancer volumes
There was no correlation demonstrated between EN2 levels and 
prostate gland volume (p=0.97) (Figure 25a).
However, a very strong correlation was identified between total prostate 
tumour volume and EN2 levels (p < 0.0001) (Figure 25b). These 
analyses were performed using linear regression in the cohort of 
57 patients.
Figure 25 Correlation between pre-prostatectomy urinary EN2
concentration and (a) prostate volume (p=0.97) and (b) 
tumour volume (p<0.0001)
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3.1.3.8 Patients with 'significant' vs 'insignificant' disease and the 
difference between their serum PSA and urinary EN2 levels.
Small volume and low Gleason grade PCs are unlikely to show local 
progression and metastasize (152; 153), therefore such tumours may 
represent ‘insignificant’ disease not requiring immediate treatment. 
Based on these previous studies (154; 155), 3 volume cut offs of 0.5 ml.
The ability of serum PSA and urinary EN2 levels to differentiate 
significant versus non-significant disease was tested. Serum PSA could 
not distinguish between significant and insignificant disease using cut 
offs of 0.5 ml (p=0.62) and 1.3 ml (p=0.37) (Figure 26a and b), using 
unpaired Atest with Welch’s correction. There was a significant 
difference in PSA concentration using a cut off of 2.5 ml (p=0.04; Figure 
26c).
Flowever, there was a highly significant difference between urinary EN2 
levels of significant versus insignificant tumours using all three cutoff 
levels (p < 0.0001 at all cutoffs; Figure 27).
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Figure 26 Relationship between serum PSA levels and prostate tumour 
volumes
(a) Cut off points of <0.5 ml (n=6) and > 0.5 ml (n=51); p=0.62
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T
(b)Cut off points of < 1.3 ml (n=8) and > 1.3 ml (n=49) ; p=0.37
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(c)Cut off points of < 2.5 ml (n=16) and > 2.5 ml (n=41); p=0.04
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Figure 27 Relationship between pre-prostatectomy urinary EN2 
concentrations and prostate tumour volume
(a)Cut off points of < 0.5 ml (n=6) and > 0.5 ml (n=51); p <0.0001
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3.1.4 Post radical treatment group
A total of 51 patients were assessed in this group. The mean age of 
patients was 73 years; median 73 (range 56-86). These patients were 
subdivided into following three groups.
• n=21 in the post BXT group,
• n=19 in the post RP group and
• n=11 in post EBRT group.
The mean age in the Post BXT group was 75 years, median 77 years
(range 66-82 years). The mean age in post RP group was 67 years, 
median 67 years (range 56-78 years). Finally the mean age in the post 
EBRT group was 77 years, median 77 years (range 69 to 86 years). The 
expression of urinary EN2 in all 51 patients is shown in Figure 28.
Figure 28 Expression of EN2 in all three post radical treatment groups
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A comparison of expression of EN2 among these three groups was 
made. This analysis performed using unpaired t-test with Welch’s 
correction showed a statistically significant difference between the post 
BXT and post RP groups (p=0.04) (Figure 29a) and between the post 
BXT and post EBRT groups (p=0.003) (Figure 29b). Data on post BXT 
patients was analysed after excluding patient (*). No significant 
difference was seen between the post RP and post EBRT groups 
(p=0.08) (Figure 29c).
Figure 29 Differences in EN2 levels among all three post radical 
treatment groups
(a) Post BXT (n=20) compared with post RP (n=19)(p=0.04)
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(b)Post BXT (n=20) compared with post EBRT (n=11)(p=0.003)
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Apart from three patients in the post BXT and post RP groups, all the 
patients had urinary EN2 levels below the 42.5 ng/ml cut off described 
previously. One patient post BXT (*) had an EN2 level of 406 ng/ml. He 
was subsequently found to have early superficial bladder cancer 
(Figures 28 & 30). Of the two other patients, one was post BXT, and the 
other was post RP. They had urinary EN2 levels of 50.54 ng/ml and 
54.45 ng/ml respectively. These two patients underwent a flexible 
cystoscopy to assess the bladder, prostatic and penile urethra and a CT 
urogram to assess the upper tracts. All these investigations were 
normal. 6 patients in the post EBRT group had positive EN2 levels 
(45.43, 43.10, 47.48, 48.23, 46.46, 66.38 ng/ml). These patients were 
not investigated further.
Figure 30 Detection of bladder cancer in a patient 5 years post BXT
This patient (*) was 5 years post BXT. His initial urinary EN2 
concentration was 406 ng/ml (cut off value 42.5 ng/ml).
(A) (*) Patient was investigated with a flexible cystoscopy, which 
confirmed presence of asymptomatic superficial transitional cell 
carcinoma of bladder. Patient underwent transurethral resection of 
bladder tumour (TURBT). Post TURBT EN2 concentration was 0 ng/ml.
Ill
(B) Positive EN2 staining of the TURBT specimen (Brown colour) 
magnification x40 (Performed by Francesca Launchbury)
#
(C) Negative control. TURBT specimen without EN2 antibody, 
magnificationx40 (Performed by Francesca Launchbury)
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There was no statistically significant difference between the urinary EN2 
levels in healthy volunteers group and the post radical treatment group 
(p=0.18) (Figure 31). A comparison of the post radical treatment group 
with the AS cohort showed that the urinary levels of EN2 in the post 
radical treatment group were significantly lower than in the AS cohort 
(p<0.0001) (Figure 32). A comparison of urinary EN2 levels in the post 
radical treatment group with the pre-prostatectomy cohort (148) showed 
that the levels of EN2 in the former group were significantly lower than in 
the latter group (p<0.0001) (Figure 33). All these analyses were 
performed using unpaired t-test with Welch’s correction.
Figure 31 Comparison of urinary EN2 concentrations in the urine of 
healthy volunteers (n=156) and the post radical treatment 
group (n=50), p=0.18
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Figure 32 Comparison of urinary EN2 concentration of ttie post radical 
treatment group (n=50) and the AS cohort (n=38), p<0.0001
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Figure 33 Comparison of urinary EN2 concentrations in the post radical 
treatment (n=50) and pre-prostatectomy groups (n=57),
p<0.0001
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3.1.5 Pre and post brachytherapy group
A total of 27 patients were assessed in this cohort of patients. The mean 
age was 66 years; median 66 (range 56-76). The mean presenting PSA 
was 7.4 ng/ml, median 6.7 (range 1.8-15). The Gleason scores, number 
of cores positive, total cores taken, pre-BXT and post-BXT EN2 levels 
are shown in Table 12. A comparison of the pre BXT and six months 
post BXT urinary EN2 levels was done. No statistically significant 
difference between the pre and six months post BXT urinary EN2 levels 
was found in this cohort (p=0.67) using the Wilcoxon matched pairs 
signed rank test (Figure 34).
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Table 12 Patients with pre and post BXT EN2 concentrations.
Patient
Age
(years)
RSA
(ng/ml)
Gleason
Score
Positive
cores
Total
Cores
Pre BXT 
EN2 
(ng/ml)
6 months 
post BXT 
EN2 
(ng/ml)
1 58 2.9 6 3 40 9.86 31.67
2 73 9.5 6 13 43 50.07 36.60
3 64 4.7 6 3 12 30.54 45.52
4 69 10.0 6 7 10 46.09 57.47
5 56 1.8 6 6 46 75.10 31.48
6 64 4.8 6 4 10 43.24 49.50
7 69 15.0 6 1 10 58.97 44.00
8 72 10.0 6 3 10 58.97 47.04
9 70 14.0 6 2 8 34.90 33.38
10 70 3.9 6 3 12 30.35 62.02
11 76 5.8 6 3 12 58.41 112.65
12 65 5.8 6 11 51 249.20 108.67
13 66 10.0 6 2 14 49.50 40.78
14 64 3.9 7 4 12 51.97 201.98
15 69 6.0 7 13 53 52.16 63.72
16 58 5.0 6 10 77 52.35 97.29
17 69 8.2 7 2 12 69.91 115.62
18 65 8.1 6 1 8 90.61 356.18
19 70 7.9 7 10 12 133.96 55.49
20 56 12.0 6 4 14 27.34 33.97
21 67 6.6 7 4 13 53.12 57.02
22 69 8.2 6 7 33 42.18 49.60
23 58 8.6 6 5 30 39.45 63.66
24 60 5.4 6 1 10 52.33 55.46
25 67 5.4 7 12 32 92.56 33.59
26 63 6.7 7 2 10 49.60 0.00
27 66 9.4 7 11 35 116.38 66.00
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Figure 34 Comparison of urinary EN2 concentrations pre- and 6 
months post-BXT, p=0.67
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3.1.6 Pre- and post-hormone group
A total of 15 patients were assessed in this cohort. The mean age of the 
patients was 70 years, median 71 years (range 57-83 years). The mean 
PSA was 15.35 ng/ml, median 11.0 (range 2.90-54.0 ng/ml). The mean 
sum Gleason score was 7, median 7 (range 6-7; Table 13).
No statistically significant correlation was found between urinary EN2 
pre-hormones and 1 day post hormones (p = 0.92; Figure 35a), 5 days 
post hormones (p = 0.89; Figure 35b), 30 days post hormones (p = 0.95; 
Figure 35c) and 3 months post hormones (p = 0.73; Figure 35d). These 
analyses were performed using unpaired t-test with Welch’s correction.
Table 13 Patients in hormone group, with demographics, PSA and 
Gleason score.
Patient Age (years)
Presenting PSA 
(ng/ml)
Gleason
score
1 73 2.9 6
2 71 54 7
3 76 23 7
4 71 14 7
5 57 9.4 6
6 70 9.1 7
7 67 17.1 6
8 83 11 7
9 71 30 9
10 66 14.7 6
11 64 5.1 7
12 77 14.3 6
13 65 5.7 6
14 68 9 7
15 71 11 7
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Figure 35 Comparison of urinary EN2 levels pre-hormones and
(a) 1 day (p=0.92), (b) 5 days (p=0.89), (c) 30 days (p=0.95) 
and (d) 3 months (p=0.73) post hormones
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3.1.7 Prostate cancer relapse group
A total of 9 patients were assessed in this small cohort. Five patients 
had PC recurrence post BXT, and four had disease recurrence post RP.
The mean presenting PSA in this group was 12.85 ng/ml, median 12 
(range 5.9-33) ng/ml. The mean PSA at the time recurrence was 
4.9 ng/ml, median 3.7 (range 0.3-13) ng/ml. The mean Gleason score at 
diagnosis was 7, median 7 (range 6-7). The mean urinary EN2 levels in 
this cohort was 41.49 ng/ml, median 44.57 (range 14.04-60.88) ng/ml. 
Using unpaired t-test with Welch’s correction, there were significantly 
lower levels of urinary EN2 in the post radical treatment group described 
previously versus this cohort of patients with PC recurrence (p=0.02; 
Figure 36).
Figure 36 Comparison of urinary EN2 levels in relapse (n=9) group and 
post radical treatment (cured) group (n=50), (p=0.02)
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3.2 Semen EN2 group
A total of 10 PC patients and 2 HVs were assessed in this study. Seven 
patients had positive urinary EN2 levels. The concentration of semen 
EN2 in all patients and HVs are shown in Table 14. The two HVs had 
urinary EN2 below 42.5 ng/ml.
There was a significantly higher EN2 concentration (corrected) in semen 
than in urine in the 10 PC patients (p=0.002) using the Wilcoxon 
matched pair signed rank test (Figure 37).
As explained in the methods section, initial attempts by the author using 
1 in 10 and 1 in 100 dilution with PBST were unsuccessful. However, 
when the semen samples were diluted to 1 in 1000 PBST, ELISA was 
successful.
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Table 14 Urinary and semen (corrected) EN2 concentrations in prostate cancer patients and healthy 
volunteers.
Study Code 
Cancer Patients
1
2
3
4
5
6
7
8 
9
10
Healthy Volunteers 
1 
2
Presenting PSA
6
8
IS
4.1
7.5
4.7 
9.03
6.8
8.6 
5.7
Pri.
Gleason
Sec.
Gleason
Sum
Gleason
Cores
positive
Total biopsy 
cores
Urine EN2 
ng/ml
Semen EN2 
ng/ml
5 11 43.8 40123
2 12 45.16 107149
12 31 49.13 25331
6 14 51.33 8043
5 75 49.45 42527
6 12 30.32 11556
10 42 38.78 5547
3 12 49.13 40770
3 12 47.67 31063
3 62 38.68 461048
24.35 10354
25.08 32912
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Figure 37 Comparison of EN2 concentration in semen (corrected) and 
urine in PC patients, p=0.002
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3.3 Prostate Histoscanning^"  ^group
This published study (140) included a total of 24 patients in the final 
analysis of this group. The mean age of patients was 67 years (range 
49-77). Mean PSA was 9.9 ng/ml (range 2.5-22). Patient and 
pathological characteristics are shown in Table 15.
Table 15 Total cancer and index lesion volumes at PHS, and 
pathology.
Patient
ID
PSA
Level,
ng/ml
Gleason 
grade at 
TRUS 
biopsy
Gleason 
grade at 
RP
Total 
cancer 
volume at 
pathology, 
m l
Total 
cancer 
volume 
using 
PHS, m l
Index 
lesion 
volume at 
pathology, 
m l
Index 
lesion 
volume 
at PHS, 
m l
1 13.7 3+3 3+4 15.5 1.9 12.9 0.8
2 6.6 3+4 3+4 6.9 1.2 6.6 0.7
3 12.0 3+3 3+3 4.6 2.0 2.3 0.5
4 13.0 3+4 3+4 4.0 0.8 3.8 0.7
5 9.8 4+3 4+3 4.4 6.3 3.2 3.9
6 5.5 3+3 3+3 5.4 1.6 2.9 1.0
7 8.1 3+3 3+4 3.0 9.0 1.3 3.8
8 11.0 3+3 3+4 3.6 2.3 2.0 0.8
9 8.9 3+3 3+4 2.4 0.2 1.6 0.1
10 6.5 3+3 3+3 0.8 5.2 0.4 1.7
11 14.0 3+4 4+3 4.3 2.0 3.0 0.5
12 2.5 3+3 3+3 1.5 7.1 0.5 4.9
13 17.0 3+4 3+4 5.9 1.7 5.4 1.2
14 7.1 3+4 3+4 5.7 3.0 5.7 1.3
15 5.8 3+4 3+4 1.7 0.7 1.0 0.1
16 22.6 3+3 3+5 5.0 1.6 3.3 0.7
17 2.6 4+3 3+4 1.4 1.1 1.4 0.4
18 9.7 4+3 4+3 1.8 0.1 1.3 0.1
19 4.5 3+3 3+3 0.5 0.7 0.3 0.3
20 12.0 3+3 3+3 0.8 2.8 0.3 0.9
21 4.6 3+3 3+4 1.0 3.8 0.7 2.7
22 17.0 4+3 4+5 6.5 2.8 6.0 1.3
23 13.4 3+3 3+4 0.5 2.6 0.5 0.5
24 11.4 3+3 3+4 7.1 4.1 7.1 2.5
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The following analyses were performed and PHS was compared to 
pathology.
• Whole gland analysis
• Sextant analysis
• Index lesion analysis
• EPE analysis
3.3.1 Whole gland analysis
We compared total tumour volumes in all 24 patients in pathology vs 
PHS. We found no correlation between the total tumour volume in the 
whole gland identified by PHS and pathology (Pearson correlation 
coefficient = -0.09; Figure 38). Prostate gland shrinkage occurs during 
formalin fixation. To account for this, the total PHS cancer volume was 
multiplied by the total RP prostate volume, and divided by the total PHS 
prostate volume. Corrected total cancer volumes at PHS and pathology 
also showed poor correlation (Pearson correlation coefficient = -0.07; 
Figure 39).
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Figure 38 Scatter plot of the total cancer volume comparing PHS and 
pathology In the whole gland.
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Figure 39 Scatter plot of the total cancer volume at PHS corrected for 
volume of the prostate and the total cancer volume at 
pathology, comparing the whole gland.
18
16
I  14
Io
T5 10Q.
m
I  8 
s
> 6 
1 .
O
Q
® <
%
Q O
Q
Q
1 2 3 4 5 6 7 8 9  
Total volume at PHS corrected with volume ratio, mL
10 11
Pearson correlation coefficient= -0.07
128
3.3.2 Sextant analysis
Analysis of 144 sextants from 24 patients (24 x 6 regions) was 
performed. Tumour volume in each sextant was measured by PHS and 
pathology. The Pearson correlation coefficients for each sextant (Right 
apex, mid, base and left apex, mid and base) were 0.03, 0.33, 0.17, 
-0.17, -0.18, and 0.33, respectively. No correlation was seen between 
PHS and pathology in assessing cancer volumes in prostate sextants as 
the Pearson correlation coefficient for all the sextants was 0.14 
(Figure 40).
Figure 40 Volume of cancer seen on PHS compared to the volume of 
cancer seen In pathology for 144 sextants of the prostate.
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Tumour volume thresholds of >0.5 ml and >0.2 ml were used to assess 
the ability of PHS to detect tumours within these thresholds. For volume 
threshold^ 0.5 ml, sensitivity and specificity were 37% and 71%, 
respectively (Table 16). For tumour volume threshold of >0.2 ml, 
sensitivity and specificity were 63% and 53%, respectively (Table 16). 
This suggested that PHS had a poor ability to detect cancer lesions 
>0.2 ml, and a correct diagnosis would probably be made by chance.
Table 16 Sextant analysis for PHS at volume thresholds of >0.20 mL 
and >0.50 mL.
Volume Threshold for 
detection
>0.20 mL >0.50 mL
Sensitivity % 63 37
Specificity % 53 71
P P V % 64 41
N P V % 52 67
3.3.3 Index lesion analysis
There was no correlation between index lesion volume identified at 
pathology and by PHS (Pearson correlation coefficient -0.06; Figure 41). 
To determine how well PHS matched pathology results for index lesion 
location, a comparison was made of sextant data from all patients, using 
a binomial analysis comparing PHS with pathology for the location of 
index lesion. This showed poor results (Figure 42). The sensitivity and
130
specificity were 61% and 53%, respectively, and the PPV and negative 
predictive value (NPV) were 58% and 56%, respectively.
Figure 41 Comparison of the index lesion volume for each patient 
between PHS and pathology.
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Figure 42 Analysis of sextants showing index lesion Involvement In 
PHS and pathology.
Numbers shown in each square are the patient ID numbers. If a patient 
showed index lesion involvement in both PHS and pathology, their 
square was coloured in green (32% match). If a patient showed no index 
lesion involvement in both PHS and pathology, their square was 
coloured in orange (25% match). If a patient’s PHS did not match with 
pathology (either PHS had index lesion involvement and pathology 
didn’t, or vice versa), the square was left white (43% match).
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3.3.4 Analysis of extra prostatic extension
We assessed the ability of PHS to detect and locate EPE using the 
pathology results as the reference standard. A binomial analysis of the 
location of EPE according to prostatic sextant was performed. This 
showed a sensitivity and specificity of 78% and 68%, respectively 
(Figure 43). However, when pathological EPE in whole gland RP 
specimen was compared with PHS (Table 17), specificity and sensitivity 
were 24% and 100%, respectively. There was a match for the presence 
of any EPE among 11/24 patients between the pathology and PHS 
results. This suggested that PHS is not a reliable indicator of EPE.
Figure 43 Analysis of EPE data for each of the sextants, comparing 
PHS and pathology results
Numbers shown in each square are the patient ID numbers. If a patient 
showed evidence of EPE in both PHS and pathology, their square was 
coloured in red (4.9% match). If a patient showed no EPE in both PHS 
and pathology, their square was coloured in blue (62.5% match). If a 
patient’s results did not match between PHS and pathology (either PHS 
had EPE and pathology didn’t have EPE, or vice versa), the square was 
left white (32.6% match).
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Table 17 Comparing patient results with EPE between pathology and 
PHS.
Pathology
Positive Negative Total
PHS
Positive 7 13 20
Negative 0 4 4
Total 7 17 24
3.3.5 Quality Checks
To verify our results, PHS scans from 5 randomly-selected patients were 
sent to AMD Ltd for independent PHS analysis. AMD’s analysis of 
tumour volumes was consistent with ours. The Pearson’s correlation 
coefficient was 0.93 (Figure 44).
The mean distance from ultrasound probe to the posterior prostate 
capsule is known as the compression zone distance (CZD) which may 
influence the quality of the PHS images. In our series, the mean CZD 
was 2.4 mm (median 2.03 mm; range 0.79-6.05 mm).
To verify the accuracy of our PHS technique, the author visited another 
centre in London to observe their PHS technique, in the presence of a 
senior member of the AMD team. There was no significant difference 
between our PHS techniques and those of the other centre.
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Figure 44 A comparison of sextant data from 5 patients as measured 
by AMD Ltd and RSCH
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4 Discussion
The measurement of serum PSA for monitoring the progression of PC in 
the US was approved by the FDA in 1986. In 1994, it was approved, in 
conjunction with DRE, for screening asymptomatic men for PC 
(156). Since then, PSA has been used for screening and follow up after 
treatment for PC. Serum PSA values vary with prostate volume and age, 
and can be elevated in non-cancerous conditions such as urinary tract 
infections and prostatitis. PSA can also vary with the grade, stage or 
volume of PC (51).
Several modifications of serum PSA measurements and its kinetics have 
been evaluated in an attempt to improve its predictive value (40;41). 
These include: free to total PSA ratio, PSA density and velocity and 
various PSA isoforms. This has resulted in minimal clinical benefit in 
improving the sensitivity and specificity of PSA and its isoforms in the 
detecting PC.
In the PC prevention trial (PCPT), men with a PSA >4 ng/mL had a 
sensitivity and specificity of 24 and 93%, respectively, for detection of 
PC in prostate biopsies (157). In a trial by Thompson et al, men whose 
serum PSA was between 3.1 and 4 ng/ml, 27%were found to have PC. 
In men whose PSA was <0.5 ng/ml, 6.6% were still found to have PC on 
prostate biopsies (34). These trials confirmed that PC cannot be totally 
excluded in men with very low PSA levels. Owing to these limitations in 
the sensitivity and specificity of serum PSA, there remains an unmet 
need to improve the accuracy of diagnosis of PC. This has prompted 
research into a number of promising new biomarkers for PC that have 
diagnostic and prognostic utility, which can aid the process of treatment 
decision making, and can help predict response to treatment.
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Various potential PC biomarkers have previously been evaluated. These 
include biomarkers in serum (DNA/RNA, miRNA, PSA and exosomes), 
tissue (AMACR, immunohistochemistry and Gleason score), urine 
(PCA3, TMPRSS2-ERG and proteins) and semen (prostasomes, 
exosomes and proteins) (84; 158). The protein biomarkers include 
Prostate specific membrane antigen (PSMA) (84; 159; 160), Annexin A3 
(ANXA3) (161; 162) and beta-microseminoprotein (MSMB) (78; 163).
Urinary PCA3 has been reported to have sensitivity and specificity of 
61-82% and 76-89%, respectively. The limitation is that PCA3 analysis 
requires urine after DRE (164). Low PCA3 scores have been shown to 
be associated with low risk PC (165; 166), but not with higher volume 
and stage disease, in the largest prospective study to date (167). Other 
studies have shown no correlation between PCA3 and prostate tumour 
volume or grade of the disease (168; 169).
Multiplexed matrix modelling of multiple urinary PC biomarkers (AMACR, 
ERG, G0LPH2, PCA3, SPINK1, TFF3, and TMPRSS2:ERG) has also 
been assessed. Laxman et ai, reported sensitivity and specificity of 
65.9% and 76.0%, respectively, with positive and negative predictive 
values of 79.8% and 60.8%, respectively (170).
The Sunnybrook nomogram-based PC risk calculator and the Prostate 
Cancer Prevention Trial-based risk calculator, which incorporate serum 
PSA, have also been used to predict the presence of PC. However they 
have been of limited clinical benefit (171).
Urinary EN2 has several practical advantages as a PC biomarker. EN2 
can be measured using only 5-10 ml urine supernatant. DRE is not 
required, and EN2 is stable in urine at room temperature for at least 
4 days. Samples can be collected by patients at home, and posted to the
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laboratory (51). Archived pre-prostatectomy urine specimens from a 
Danish high-risk cohort demonstrated a strong correlation between 
urinary EN2 levels and prostate tumour volume (130). Thus, urinary EN2 
could potentially be used to stratify patients as having clinically 
significant or insignificant disease, based on estimated prostate tumour 
volume. The results of our prospective study of RP patients support this 
finding (148).
Stamey et a! reported an 8% lifetime risk of being diagnosed with 
clinically significant PC (172). In our study, the evaluation of the Group 1 
HVs who were participants of a community screening programme 
without any selection bias revealed 6% (4 men) who were positive for 
urinary EN2 (EN2 concentration > 42.5 ng/ml). All these individuals had 
serum PSA above 4 ng/ml (4.3, 5.2, 6.6 and 10.3 ng/ml). All HVs in 
Group 2 had a PSA < 2.0 ng/ml. 17% (14) men were EN2-positive 
(urinary EN2 concentration >42.ng/ml). The Prostate Cancer Prevention 
Trial (PCPT) also reported that 17% of the trial patients with PSA < 2.0 
ng/ml were found to have PC (34).
Seminal and prostatic fluids have been previously assessed for the 
presence of potential biomarkers for PC (63; 173). Initial attempts by our 
group to detect EN2 in seminal fluid failed due to the very sticky nature 
of seminal secretions. These blocked the ELISA plate, thereby 
preventing measurement of EN2. In seminal EN2 pilot study, the author 
overcame this hurdle by diluting the seminal fluid to 1:1000 PBST. This 
resulted in detection of EN2 in seminal fluid among patients with low to 
intermediate risk PC. Significantly higher levels of EN2 in seminal fluid 
were found, when compared to urinary EN2 levels. The author therefore 
concluded that seminal fluid may also be used as a medium for the 
detection of EN2 in men who are sexually active. Based on this pilot
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study, a larger study comparing the levels of EN2 in urine and seminal 
fluid in PC patients and age matched healthy volunteers has been set 
up. This study will help to better understand the relationship between 
urinary and seminal fluid EN2 in PC.
Despite its limitations, serum PSA still remains the most sensitive tool for 
measuring the outcomes of PC treatment (174). Prostate BXT, EBRT 
and RP have similar disease-specific outcomes for organ-confined low 
risk PC in historical series (mostly non-randomised studies), in terms of 
PSA relapse free survival and overall survival (175). However, in 
prostate BXT, the phenomenon of PSA bounce is also seen, whereby 
serum PSA fluctuates in the first 12 months to 2 years following prostate 
BXT (176). The exact aetiology of the PSA bounce is not known (177). 
We evaluated the effect of prostate BXT on urinary EN2 concentrations 
in 27 patients with low to intermediate PC. We found no significant 
difference in urinary EN2 concentrations pre- and post-BXT. This could 
be due to the limitation of a sample size of 27 patients. Also, it may be 
that urinary EN2 takes longer than 6 months to decrease following 
prostate BXT. We have designed a longitudinal study of prostate BXT 
patients measuring urinary EN2 levels before BXT, and 6-monthly during 
the first 5 years of follow up. This study will help us to characterise 
urinary EN2 following prostate BXT.
AS is an important treatment option selected by patients with low risk PC 
(178). One of the key objectives of the AS programme is to identify 
suitable patients and to continuously assess them during regular follow 
up, to decide treatment option, i-e to continue AS, or offer radical 
treatment. Various biomarkers including PCA3 (179), TMPRSS2:ERG 
fusion (180) and genetic biomarkers such as BRCA1 and BRCA2 (181) 
have previously been assessed for their role in AS patients. However,
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there are still no reliable markers of progression from low volume, low 
risk disease to higher volume or higher risk disease among these 
patients, including serum PSA.
In our AS cohort, 89% patients were positive for urinary EN2 (urinary 
EN2 concentration >42.5 ng/ml). This was a very encouraging result; 
showing that EN2 could be detected in a majority of patients with low 
risk and low volume disease. Significantly higher levels of urinary EN2 in 
the AS cohort when compared to HVs, and significantly lower levels 
when compared to the pre-radical prostatectomy group were noted. This 
supported the notion that urinary EN2 could be useful in stratifying 
patients with clinically significant disease requiring radical treatment, and 
those with clinically insignificant disease, who could be managed safely 
with AS.
Serum PSA and prostate tumour volume have been proposed as 
independent predictors of clinical significance and outcome. The 
relationship between PSA and tumour volume has been extensively 
investigated (172;182-187). Our study evaluated an RP cohort, 
representative of contemporary practice, with 63% of men presenting 
with T1c disease. 84% of men had positive urinary EN2 levels. Serum 
PSA levels showed no correlation with either tumour volume or total 
prostatic volume. A strong correlation was observed between EN2 and 
prostate tumour volume (p < 0.001), and pathological stage (pT2 versus 
pT3a p<0.006). There was also a significant correlation with surgical 
margin positivity (p=0.007). No correlation was found between EN2 and 
Gleason grades, as the small cohort of patients in this study were mainly 
low risk. Such a correlation between urinary EN2 and Gleason score 
would be better explored with a larger cohort of patients. There are 
larger prospective studies on going in centres in Europe and the USA to
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assess this relationship. In the PROMIS study in the U.K.
(http://www.controlled-trials.eom/ISRCTN16082556), EN2, together With Other Uhne
and serum biomarkers, is being evaluated concurrently with MRI 
imaging (148).
The prostate tumour volume cut-off of < 0.5 ml is considered to 
represent insignificant PC, but the same study on prostatectomy patients 
studied 1.3 ml and 2.5 ml cut-offs of tumour volume for significant 
disease (188). Urinary EN2 has shown promise as biomarker for pre­
treatment tumour volume. This may have a clinical role in identifying and 
assessing patients suitable for AS, and EN2 may potentially be used in 
nomograms (189). Highly significant differences in urinary EN2 levels 
were noted when using any of the three tumour volumes, above and 
below these cut offs (148). These results support the development of a 
larger multicentre trial for the evaluation of urinary EN2 levels as a 
biomarker of clinically significant PC.
Defining biochemical failure with a PSA cut off of 0.2 ng/ml following 
BXT and EBRT, 81% disease free survival has been reported at 5 years 
(190). In our post radical treatment group, despite extremely low PSA, 
and potentially being cured of PC, these patients still expressed low 
levels of urinary EN2. EN2 is not expressed by non-cancerous prostate 
tissue (51). Its low expression in this group may suggest the presence of 
active but insignificant PC in patients following BXT and EBRT, or from 
the normal bladder and upper tract urothelium in patients following RP. 
Studies where prostate biopsies have been undertaken following BXT, 
EBRT, or combination therapy have shown positive biopsies rate of 
11.5% at 2 years, and 32% at 10 years after completion of treatment 
(191;192).
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One of the patients in the post BXT cohort had a very high urinary EN2 
concentration of 406 ng/ml. This was confirmed by a repeat analysis. 
The patient’s PSA was normal, at 0.1 ng/ml. There was no clinical 
evidence of PC recurrence. We investigated this patient further with a 
flexible cystoscopy, and found an asymptomatic early superficial 
transitional cell carcinoma (TCC) of the bladder. Transurethral resection 
was performed and Immunohistochemistry of TCC confirmed positive 
staining for EN2. This important finding was consistent with our results 
published in a study on the diagnostic ability of EN2 in non-muscle 
invasive bladder cancer (131). This study showed that EN2 had an 
overall sensitivity and specificity of 82% and 75%, respectively, and has 
the potential to be used as a biomarker for non-muscle invasive bladder 
cancer. The comparison of the post radical treatment group against HVs 
showed no significant difference of urinary EN2 between the two groups. 
However, 8 patients in the post radical treatment group had urinary EN2 
levels that were just above the cut-off level of 42.5 ng/ml. This may 
suggest that following radical treatment, some active but insignificant 
disease may still be present, or that EN2 is secreted by normal 
urothelium, resulting in very low expression of urinary EN2.
EN2 levels in the post-radical treatment group were compared with 
those in both the AS and pre-prostatectomy groups. EN2 levels were 
significantly lower in the post-radical treatment group than in the AS and 
pre-prostatectomy groups. This demonstrated a higher tumour burden in 
the AS and pre-prostatectomy groups, due to untreated PC.
In 1941, Huggins et al demonstrated the responsiveness of metastatic 
PC to androgen deprivation therapy (ADT) (193). Initially surgical 
androgen deprivation was achieved by orchidectomy. Medical 
approaches have included anti-androgens, luteinizing hormone-
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releasing hormone (LHRH) agonists, oestrogens and more recently the 
gonadotrophin releasing hormone antagonists (193; 194). All these 
modalities cause a sudden reduction in PSA in hormone responsive 
disease. Hence PSA is used to monitor the response to ADT. The effect 
of ADT on urinary EN2 levels is not known. ADT promotes apoptosis in 
PC cells, thereby inhibiting tumour growth (195). We hypothesized that 
urinary EN2 levels should be significantly reduced following hormone 
therapy as compared to pre-hormone levels in our cohort of patients who 
had received hormones. We found no significant difference in pre- and 
post-hormone urinary EN2 levels at various intervals (Dayl, 5, 30 and 3 
months). This could be the result of a small sample size, or to some 
patients not providing their urinary samples at the required intervals. The 
other explanation may be that it takes longer than 3 months for the 
urinary EN2 to decrease after hormone therapy. A longitudinal study has 
been set up to explore this further in future.
In the pilot study of a small cohort of nine patients with PC recurrence 
based on PSA criteria, the author demonstrated that the urinary EN2 
levels in this group were significantly higher than in patients following 
radical treatment who were deemed cured based on PSA criteria. A 
study with a larger sample size may help us in further evaluating the 
expression of urinary EN2 in patients with PC relapse.
Various imaging techniques including TRUS, contrast-enhanced 
ultrasound, elastography, H is to s c a n n in g ™ , MRI, positron emission 
tomography (PET) and computed tomography (CT) have also been 
evaluated for their role in the detection of PC (196-198).
Previous small and un-blinded studies to assess the detection, 
localisation and characterisation of PC have reported encouraging
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results (142-144). We assessed the role of Prostate H is to s c a n n in g ™  in 
routine clinical practice. Our independent blinded study on consecutive 
patients showed no correlation between PHS and RP pathology results. 
In a previous un-blinded study, when PHS tumour volume estimation by 
manual method and embedded software methods were compared 
against histopathology measurement of total tumour volume, Pearson 
correlation coefficients were reported to be 0.72 and 0.41 respectively 
(144). These two correlation values represent a wide difference between 
these two PHS volume estimation methods. The manual estimation 
method showed better correlation. This may have been the result of 
operator bias in the manual estimation of cancer on PHS. This study 
also demonstrated that there was better correlation between PHS and 
RP pathology using threshold values of > 0.2 ml or > 0.5 ml rather than 
absolute tumour volumes. These threshold values may be useful in the 
assessment of the presence of clinically significant PC. However, the 
absolute tumour volume values are likely to be more useful in the clinical 
management of these patients. Localised PC, with a tumour volume of 
0.5 ml, would be treated differently from a tumour with a volume of 9 ml.
In a study on 61 patients scheduled for repeat TRUS biopsies, PHS had 
a sensitivity and specificity of 29.7% and 73.3%, respectively for 
detecting PC (199). That study concluded that PHS offered no additional 
benefit over TRUS biopsies in detecting PC, which is consistent with our 
conclusion.
Formalin fixation causes shrinkage of prostatectomy specimens. The 
correlation was worse when the total prostate tumour volume was 
corrected to account for specimen shrinkage. Factors that can affect 
PHS image quality and analysis include bowel preparation, bladder 
emptying before 3D acquisition and appropriate placement of the TRUS
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probe. The author also attempted to account for these factors to 
optimise image quality.
The distance from the ultrasound probe to the prostate gland known as 
the compression zone distance (CZD) may influence the quality of image 
and the final PHS analysis. Simmons et a! suggested that scans with 
CZD < 3.5 mm produce superior images and better estimates of tumour 
volume (144). Although the mean CZD in our series was 2.4 mm; there 
was a poor correlation for tumour volume estimation, index lesion 
volume, index lesion location and presence and location of EPE 
between PHS and RP pathology. Thus, PHS is of no clinical utility for 
urologists planning radical surgery, as it lacks the capacity to assist in 
deciding where to have a wide margin to excise, and to plan nerve- 
sparing radical prostatectomy.
PHS predicted a negative intra-operative frozen section of the postero­
lateral aspects of the prostate in 93% of cases in a retrospective series 
of 80 patients undergoing nerve sparing RP (200). PHS lesions > 0.2 ml 
had a 3.7-fold increased risk of a positive intra-operative frozen section. 
That study did not measure CZD.
In our series, all 3D scans were performed by the author, and acquired 
by another dedicated research clinician. Both had extensive experience 
in TRUS scanning, template biopsies and BXT, and had been trained in 
PHS by its manufacturers. Despite this, there was poor correlation 
between PHS and histopathology results. This may have been a result 
of a ‘learning curve effect’, although more than 100 PHS scans had been 
acquired in other prior studies. The limitation of our PHS study is the 
small number of cases but these are comparable to those in previous 
studies on highly selected patients (142-144).
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With widespread use of PSA screening, improved imaging (201) and 
better sampling techniques of the prostate gland (202), there has been 
an increase in the diagnosis of focal low risk, low volume and early stage 
PC (203-205). Such patients may be suitable for focal therapy to provide 
effective cancer control for low-risk focal disease, but at the same time 
sparing the key surrounding structures including the neurovascular 
bundles, urethra and the rectum with reduced genitourinary and rectal 
side effects (206-208). In view of the emergence of focal therapy as a 
treatment option in the management of PC (203;209-212), sextant 
analysis was performed additionally on all patients, to determine disease 
laterality.
PHS had initially appeared promising in that respect, because it is 
instantly accessible to the clinic, with a lower cost burden than MRI. 
However, being ultrasound-based, it has some inherent limitations. 
These include lack of sound-wave penetration to the anterior part of the 
prostate gland, and the presence of acoustic shadows at the bladder 
neck and calcification within the gland, which leads to incomplete 
assessment of the gland (203).
To ensure quality assurance in our study, AMD Ltd carried out an 
independent analysis of our randomly-selected scans. The findings of 
this analysis were consistent with ours. The author also visited another 
centre in London, UK performing PHS studies to observe their 
technique. AMD Ltd team was also present at the time. We found that 
our scanning techniques were similar. Thus, the author is confident that 
the poor correlation between PHS and RP pathology in our study is not a 
result of our technical deficiency. A larger sample size would have been 
desirable, but with these disappointing results for PHS, it would not have
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been justifiable to spend further charitable funds to continue with this 
study.
Studies involving mpMRI have shown promise in the evaluation of 
localised PC (213;214). A study similar to ours demonstrated a positive 
correlation (Pearson coefficient 0.63) between tumour volume 
assessments by mpMRI when compared against RP histopathology 
(215). Another study on mpMRI reported PPVs of 98%, 98% and 100% 
in the whole prostate, peripheral zone and central gland, respectively 
(136). MpMRI has also been shown to significantly improve the selection 
of PC cases being considered for nerve-sparing RP (216). With such 
consistency in the results of mpMRI, this particular imaging modality may 
be the way forward in the diagnosis, assessment and management of 
PC.
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5 Conclusions
Urinary EN2, a potential new biomarker for PC, shows promise in the 
detection of PC, tumour volume estimation, and follow up after radical 
treatment. It is a convenient and inexpensive urine test that does not 
require DRE. It may also be possible to assay EN2 in seminal fluid, thus 
providing a useful adjunct to the urine assay, particularly in patients who 
are potent and who have a low volume of disease. Further larger studies 
are required to validate the assays in urine and semen.
PHS, on the other hand, offers no clinical benefit in the diagnosis and 
staging of PC in routine clinical practice.
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7 Appendix
Consent forms and patient information sheets used in the studies
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UNIVERSITY OF
SURREY
PROJECT CODE 
EN2-SEM-1
PATIENT INFORMATION SHEET 
(VOLUNTEERS)
Is seminal fluid a good medium for detecting Engrailed 2 (EN2) in
patients with prostate cancer?
Introduction
You are being invited to take part in a research study at the Postgraduate Medical School at 
the University o f Surrey, and the Royal Surrey County and Hospital.
Before you decide whether to take part in this study, it  is important for you to understand why 
the research is being done, and what it w ill involve. This information sheet w ill help you to 
decide. Please take time to read the follow ing information carefully.
We are dedicated to the treatment and research o f diseases such as cancer. This involves co­
operation between laboratory and clinical investigations and medical procedures. Research 
undertaken at the University o f Surrey aims to advance the understanding o f the causes o f 
cancer and to develop new methods o f detection and treatment.
Take time to decide i f  you want to take part. Please ask us i f  there is anything that isn’ t clear, 
or i f  you would like more information.
Why are we doing the study?
Prostate cancer is curable i f  i t ’ s found early. Currently, the ways o f detecting prostate cancer 
are very efficient, but there is a lo t o f room for improvement. So, we are looking for new 
ways o f detecting prostate cancer. We have found that a protein called EN2 is made by 
prostate cancer cells, but not by normal prostate cells. Our studies show that EN2 looks very 
promising as a reliable, specific marker o f prostate cancer. EN2 can be detected in urine, 
using a simple test.
So far, we have looked for EN2 in urine and blood only. We now want to find out i f  we can 
measure EN2 in semen. We expect that EN2 w ill be more concentrated in semen than it  is in 
urine, because semen passes through the prostate gland before it ’ s ejaculated. We hope that 
measuring EN2 in  semen, as well as in urine, could help us to detect prostate cancer even 
earlier, especially in  men who have only a small amount o f cancer.
There w ill be 55 participants in this study: 30 patients w ith prostate cancer, and 25 men who 
are unlikely to have prostate cancer.
EN2-SEM-1 Version 4,26 February 2013 Page 1 of 3
(volunteers)
Who is organising and funding the research?
The study is being sponsored and funded by the University o f Surrey. The sample collection 
w ill be organised by the staff at the Royal Surrey County Hospital in Guildford. The EN2 
measurements w ill be made by the staff at the Oncology Department, Postgraduate Medical 
School (POMS), at the University o f Surrey.
Why have I been chosen?
You have been approached because you are unlikely to have prostate cancer, so there should 
not be any EN2 in your urine or semen. Before we take semen samples from  patients w ith 
prostate cancer, we need to make sure that the test fo r EN2 that we do on urine samples also 
works on semen. To do that, we need semen samples that we don’t expect to contain any 
EN2.
Do I have to take part?
Your urine and semen donations fo r our study are entirely voluntary. I f  you do decide to take 
part in  the study, we w ill ask you to sign a consent form. Even i f  you sign the consent form, 
you’re s till free to withdraw at any time, w ithout having to give a reason. I f  you decide to 
withdraw from the study, it  won’t affect the standard o f care that you w ill receive.
What will happen to me if I take part?
I f  you give your consent, we w ill ask you to give a urine sample. We need about ha lf a cup 
o f urine fo r our tests. We w ill also ask you to give a semen sample the day after your urine 
sample. We w ill give you an instruction sheet explaining how and when to take the samples, 
and what to do w ith them. The samples w ill be labelled w ith a number and the lab staff w ill 
not be able to identify you as an individual from the number.
Expenses and payments:
There w ill be no payment to you fo r participating in  the study, but we w ill reimburse your 
travelling expenses for bringing your semen sample to POMS. The urine and semen samples 
w ill be a g ift for scientific research.
What are the side effects of this procedure?
None.
What are the benefits of this procedure?
There is no direct benefit for you as a result o f this procedure. However, the information 
gained from the research may result in  helping to develop EN2 as a new marker fo r prostate 
cancer, which may be helpful to prostate cancer patients in the future.
Will my taking part in the study be kept confidential?
A ll information which is collected about you during the course o f this study w ill be kept 
strictly confidential: your urine and semen samples w ill be anonymised. Any information 
about you that leaves the hospital w ill have your name and address removed, so you cannot 
be recognised from it. We w ill not give your name or address to anyone outside the hospital.
Your medical records may be seen by RSCH Staff and staff at the Oncology Department at 
the University. They w ill respect your confidentiality.
EN2-SEM-1 Version 4,26 February 2013 Page 2 of 3
(volunteers)
After the study the research team w ill write a report on the results and might write an article 
to be published in  a medical journal or presented at a conference. I f  the results are published, 
we w ill make sure that you cannot be recognised from the article or presentation. Under the 
Data Protection Act 1998, you are entitled to see your study records and to request additions 
or corrections.
What if there’s a problem?
I t ’ s very unlikely that you’l l  come to any harm as a result o f taking part in  this study. 
Nevertheless, i f  you are harmed by taking part in  this research project, the sponsor o f the 
study has made compensation arrangements.
I f  we found higher than expected levels o f EN2 in  your urine or semen samples, we would 
repeat the test. We would then discuss the results w ith you, together w ith your Urologist and 
GP, who would decide how to proceed.
What will happen to any samples I give?
Samples w ill be anonymized by the clinical team, and code numbers w ill be given to your 
samples. Participants’ clinical details go onto a database. This database is password- 
protected, and access is restricted to the Principal Investigator and Research Team. Samples 
w ill be kept in  the laboratory o f the Oncology Department, Post Graduate Medical School, 
University o f Surrey. Analysis w ill be undertaken by the Principal Investigator and Research 
Team at the above-mentioned laboratory. Samples w ill be stored for 5 years, and might be 
used in future research projects that have been approved separately by the ethics committee.
Stored Samples
We would like to store the samples fo r 5 years for use in  possible future research. A t this 
point, we do not know the precise nature o f that research, and whether or not the results 
would be o f benefit to you as a donor. As mentioned above, we would seek ethical approval 
separately for each new research project involving stored samples.
What will happen to the results of the research study?
Research may be published in  a scientific/medical journal, and would therefore available to 
all. Your sample w ill not be identifiable in  any study report. A ll publications appear on the 
PubMed website and are accessible to all.
Who has reviewed the study?
The Study has been reviewed by the South East Coast-Surrey Ethics Committee, by the 
ethics committee o f the University o f Surrey, and by the Royal Surrey County Hospital 
Research and Development team.
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UNIVERSITY OF
SURREY
PROJECT CODE 
EN2-SEM-1
PATIENT INFORMATION SHEET 
(PATIENTS WITH PROSTATE CANCER)
Is seminal fluid a good medium for detecting Engrailed 2 (EN2) in
patients with prostate cancer?
Introduction
You are being invited to take part in  a research study at the Postgraduate Medical School at 
the University o f Surrey, and the Royal Surrey County Hospital.
Before you decide whether to take part in  this study, it  is important for you to understand why 
the research is being done, and what it  w ill involve. This information sheet w ill help you to 
decide. Please take time to read the follow ing information carefully.
We are dedicated to the treatment and research o f diseases such as cancer. This involves co­
operation between laboratory and clinical investigations and medical procedures.
Research undertaken at the University o f Surrey aims to advance the understanding o f the 
causes o f cancer and to develop new methods o f detection and treatment.
Take time to decide i f  you want to take part. Please ask us i f  there is anything that isn’t clear, 
or i f  you would like more information.
Why are we doing the study?
Prostate cancer is curable i f  i t ’ s found early. Currently, the ways o f detecting prostate cancer 
are very efficient, but there is a lo t o f room for improvement. So, we are looking for new 
ways o f detecting prostate cancer. We have found that a protein called EN2 is made by 
prostate cancer cells, but not by normal prostate cells. Our studies show that EN2 looks very 
promising as a reliable, specific marker o f prostate cancer. EN2 can be detected in urine, 
using a simple test.
So far, we have looked fo r EN2 in urine and blood only. We now want to find out i f  we can 
measure EN2 in semen. We expect that EN2 w ill be more concentrated in semen than it  is in 
urine, because semen passes through the prostate gland before it ’ s ejaculated. We hope that 
measuring EN2 in semen, as well as in urine, could help us to detect prostate cancer even 
earlier, especially in  men who have only a small amount o f cancer.
There w ill be 55 participants in this study: 30 patients w ith prostate cancer, and 25 men who 
are unlikely to have prostate cancer.
EN2-SEM-1 Version 6,26 February 2013 Page 1 of 3
(Prostate cancer patients)
Who is organising and funding the research?
The study is being sponsored and funded by the University o f Surrey. The sample collection 
w ill be organised by the staff at the Royal Surrey County Hospital in  Guildford. The EN2 
measurements w ill be made by the staff at the Oncology Department, Postgraduate Medical 
School (PGMS), at the University o f Surrey.
Why have I been chosen?
You have recently had a prostate biopsy, and have been diagnosed w ith prostate cancer, so 
we expect to find EN2 in your urine and semen. You haven’ t had any previous treatment for 
prostate cancer. Also, you are potent.
Do I have to take part?
Your urine and semen donations for our study are entirely voluntary. I f  you do decide to take 
part in  the study, we w ill ask you to sign a consent form. Even i f  you sign the consent form, 
you’re s till free to withdraw at any time, without having to give a reason. I f  you decide to 
withdraw from  the study, it  won’t affect the standard o f care that you w ill receive.
What will happen to me if I take part?
I f  you give your consent, we w ill ask you to give a urine sample at least 7 days after your 
biopsy. We need about half a cup o f urine for our tests. We w ill also ask you to give a 
semen sample the day after your urine sample. We w ill give you an instruction sheet 
explaining how and when to take the samples, and what to do w ith them. The samples w ill 
be labelled w ith a number, and the lab staff w ill not be able to identify you as an individual 
from the number.
We might need to contact you again i f  we find any unexpected results.
Expenses and payments
There w ill be no payment to you for participating in  the study, but we w ill reimburse your 
travelling expenses for bringing your semen sample to PGMS. The urine and semen samples 
w ill be a g ift fo r scientific research.
What are the side effects of this procedure?
None.
Will this affect my treatment?
No. I f  you take part in this study, it  won’t affect your treatment in  any way.
What are the benefits of this procedure?
There is no direct benefit for you as a result o f this procedure. However, the information 
gained from  the research may result in helping to develop EN2 as a new marker fo r prostate 
cancer, which may be helpful to other prostate cancer patients in the future.
Will my taking part in the study be kept confidential?
A ll information that is collected about you during the course o f this study w ill be kept strictly 
confidential: your urine and semen samples w ill be anonymised. Any information about you 
that leaves the hospital w ill have your name and address removed, so you cannot be 
recognised from it. We w ill not give your name or address to anyone outside the hospital.
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Your medical records may be seen by RSCH Staff and staff at the Oncology Department at 
the University. They w ill respect your confidentiality.
A fter the study, the research team w ill write a report on the results and might write an article 
to be published in a medical journal or presented at a conference. I f  the results are published, 
we w ill make sure that you cannot be recognised from  the article or presentation. Under the 
Data Protection Act 1998, you are entitled to see your study records and to request additions 
or corrections.
What if there’s a problem?
I t ’ s very unhkely that you’l l  come to any harm as a result o f taking part in  this study. 
Nevertheless, i f  you are harmed by taking part in  this research project, the sponsor o f the 
study has made compensation arrangements.
What will happen to any samples I give?
Samples w ill be anonymized by the clinical team, and code numbers w ill be given to your 
samples. Participants’ clinical details go onto a database. This database is password- 
protected, and access is restricted to the Principal Investigator and Research Team. Samples 
w ill be kept in  the laboratory o f the Oncology Department, Post Graduate Medical School, 
University o f Surrey. Analysis w ill be undertaken by the Principal Investigator and Research 
Team at the above-mentioned laboratory. Samples w ill be stored for 5 years, and might be 
used in future research projects that have been approved separately by the ethics committee.
Stored Samples
We would like to store the samples for 5 years for use in possible future research. A t this 
point, we do not know the precise nature o f that research, and whether or not the results 
would be o f benefit to you as a donor. As mentioned above, we would seek ethical approval 
separately for each new research project involving stored samples.
What will happen to the results of the research study?
Research may be published in a scientific/medical journal, and would therefore available to 
all. Your sample w ill not be identifiable in any study report. A ll publications appear on the 
PubMed website and are accessible to all.
Who has reviewed the study?
The Study has been reviewed by the South East C oast- Surrey Ethics Committee, by the 
ethics committee o f the University o f Surrey, and by the Royal Surrey County Hospital 
Research and Development team.
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UNIVERSITY OF
SURREY
PROJECT CODE 
EN2-SEM-1
CONSENT FORM
Is seminal fluid a good medium for detecting Engraiied 2 (EN2) in
patients with prostate cancer?
Initial
1. I  confirm  that I  have read the information sheet
fo r the above study. I  have had the opportunity to consider the 
information, and ask questions, and have had these answered satisfactorily.
2. I  understand that my participation is voluntary and that I  am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected.
3. I  understand that relevant sections o f my medical notes and data 
collected during the study, may be looked at by individuals from the 
Research team based at the University o f Surrey (Principal Investigator 
and Data Manager), regulatory authorities or from the NHS Trust, where 
it  is relevant to my taking part in this research. I  give permission for 
these individuals to have access to my records.
4. I understand that samples w ill be stored for 5 years, and might be used in  future 
research projects that have been approved separately by the ethics committee.
5. I  agree to take part in  the above study.
Name of patient (BLOCK CAPITALS) ......
Signature.......................................................Date.
Name of researcher/person taking consent (BLOCK CAPITALS)
Signature .......................................................Date
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Study title: Discovering new cancer biomarkers from 
patients' blood, urine and DNA.
Faculty of
Health & Medical Sciences
Postgraduate Medical School
Daphne Jackson Road 
Manor Park
Guildford, Surrey GU2 7WG UK
Hardev Pandha
FRCP FRACP PhD
Professor of Urological Oncology
Consultant in Medical Oncology
T: +44 (0)1483 688602 
F: +44(0)1483 688558
j.o 'connor@surrey.ac.uk
www.surrey.ac.uk/pgms
1. Introduction
You are being inviteid to take part in a research project currently running at the 
Post Graduate Medical School in the University of Surrey, the Royal Surrey County 
Hospital, Frimley Park Hospital, Ashford and St Peters Hospitals and St George's 
Hospital.
Before you decide it is important for you to understand why the research is being 
done and what it will involve. This information sheet will help you decide if you 
wish to participate in this research. Please take time to read the following 
information carefully.
We are dedicated to the treatment and research of diseases such as cancer. This 
involves a co-operation between laboratory and clinical investigations and 
procedures. Research undertaken at the University of Surrey aims to advance the 
understanding of the causes of cancer and develop new methods of detection and 
treatment.
2. What is the purpose of the study?
Many cancers could be cured if found early. Some cancers produce so called 
tumour markers or biomarkers which are helpful in diagnosis of cancer and in 
detecting cancer recurrence. Some of the known cancer markers are also helpful in 
deciding the best treatment for cancer. Unfortunately very few cancers have 
specific markers. Even the ones we know such as PSA are not ideal. Some of the 
tumour markers can be raised in conditions other that cancer and cause great 
distress and unnecessary investigations and tests. Discovering new cancer markers 
is extremely important for future treatment and diagnosis of all types of cancer. 
Cancer markers are usually made of miniscule proteins that can be detected in 
blood, urine and other bodily fluids. It is possible to analyse very small amounts of 
fluid and tissue and detect various proteins and potential cancer markers. We
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would like to analyse blood, urine, DNA and if the cancer is being removed during 
surgery -a small piece of the tumour-of many patients with suspected diagnosis of 
cancer and confirmed cancer and attempt to discover new cancer markers that 
would help in cancer diagnosis and treatment in the future. We may also ask you 
for some nails clippings as certain heavy metals can have an effect on different 
types of proteins in your body and we will test the nails for presence of metals.
3. Who is organizing and funding the research?
The study is being funded by the University of Surrey. The blood collection is 
conducted by the staff at the Royal Surrey County Hospital, Ashford and St Peter's 
and Frimley Park Hospitals. The samples will be stored in a tissue bank at the 
Postgraduate Medical School, University of Surrey and analysed by scientists who 
specialise in research on cancer markers.
4. Why have I been chosen?
You have been referred for investigations of possible cancer or you may have been 
diagnosed with cancer. We would like to analyse your blood to try and identify 
cancer markers. If you are going to have an operation to remove suspected cancer 
we may ask you to offer a small piece of the tissue removed during surgery.
5. Do I have to take part?
Your participation in the study is entirely voluntary. It is up to you to decide 
whether or not to take part. If you do, you will be given this information sheet to 
keep and be asked to sign a consent form. You are still free to withdraw at any 
time and without giving a reason. A decision to withdraw or not take part will not 
affect the standard of care you will receive.
6. What will happen to me if I take part?
If you give your consent, we will simply obtain a blood and urine sample, make it 
anonymous and store it in a tissue bank. If you are going to have surgery as part of 
your treatment we may obtain a small piece of the tumour removed during 
surgery. This will not compromise your treatment in any way. We may also ask 
you for your toenails clippings. Blood, urine and tissue samples will be used later 
for research to discover new cancer markers. Nail clippings will be analysed for 
heavy metal content. We may also ask you to donate a blood sample in the future 
as it is important to look at the changes in cancer markers as time goes on and 
you undergo treatment. We would not ask for your blood more often than at 6- 
monthly intervals, it would not require a separate visit to the hospital as it would 
be done during your routine appointment. We would also like to collect 
information about your diagnosis and treatment. This information will be strictly 
confidential and only the study researchers will have access to this information.
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7. Expenses and payments:
There will be no paynnent to you. The blood and tissue samples will be considered 
a donation for scientific research.
8. What are the side effects of this procedure?
There are no side effects of a blood test, you may feel a minimal discomfort during 
blood taking but it we will aim to minimise it. The tissue would only be taken as 
part of a routine procedure planned as part of your treatment therefore it would 
not cause any side effects other than the ones described to you by your surgeon.
9. What are the benefits of this procedure?
There is no direct benefit for you as a result of this procedure. However, the 
information gained from the research may result in discovery of new cancer 
markers, which may be helpful to other cancer patients in the future.
10. Will my taking part in the study be kept confidential?
All information which is collected about you during the course of this study will be 
kept strictly confidential: blood , urine and tissue sample will be anonymised. Any 
information about you which leaves the hospital will have your name and address 
removed, so you cannot be recognised from it. We will not give your name or 
address to anyone outside the hospital.
Your medical records may be seen by hospital staff involved in your care. Staff at 
the Oncology Department at the University, Ethics Committee, and the Regulatory 
Authorities that control research. They will respect your confidentiality.
The research team may write a report on the results and might write an article to 
be published in a medical journal or presented at a conference. If the results are 
published, we will make sure that you cannot be recognised from the article or 
presentation. Under the Data Protection Act 1998, you are entitled to see your 
study records and to request additions or corrections.
11. What if there is a problem?
The University of Surrey, the sponsor of the study, has indemnity arrangements in 
place, which allows it to provide compensation without your needing to prove 
negligence. This could apply if you suffered a significant and enduring injury 
(including illness or disease) which is directly attributable to any clinical 
intervention or procedure for which the University is responsible.
If you have any complaint about the way you have been dealt with during the 
study or any other concerns you can speak to Dr Agnieszka Michael on 01483 
688602.
If you have concerns about the NHS involvement in the study the normal NHS 
complaints mechanisms are available to you, and if you are harmed by taking part
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in this research project and you believe this is due to the negligence of the NHS 
then you may have grounds for legal action against the NHS but you may have to 
pay for it.
12. What will happen to any samples I give?
Samples will be anonymized and code numbers will be given. Participants' age and 
sex go onto a database. This database is password protected and access is 
restricted to Principal Investigator and Research Team.
Samples will be kept frozen in the laboratory of the Oncology Department, Post 
Graduate Medical School, University of Surrey. The DNA will be isolated form the 
blood and kept separately in a secure place. Only the research team will have 
access to the samples. The samples will then be used for cancer research by 
scientists with interest and expertise to conduct such research.
13. What will happen to the results of the research study?
Research will be published in a scientific/medical journal and therefore available to 
all. Your sample will not be identifiable in any study report. All publications appear 
on the PubMed website and will be accessible to all.
14. Who has reviewed the study?
The Study has been reviewed by the Leeds (East) Research Ethics Committee
Thank you very much for considering taking part and taking time to read 
this sheet
n
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UNIVERSITY OF
SURREY
C o n s e n t  F o r m  
study Title
Discovering new cancer biomarkers from patients' 
blood, urine and DNA.
•  I the undersigned voluntarily agree to take part in the above study.
•  I have read and understood the Information Sheet provided. I have been
given a full explanation by the investigators of the nature, purpose and 
likely duration of the study, and of what I will be expected to do. I have 
been advised about any discomfort and possible ill-effects on my health 
and well-being which may result. I have been given the opportunity to 
ask questions on all aspects of the study and have understood the advice 
and information given as a result.
•  I understand that all personal data relating to volunteers is held and
processed in the strictest confidence, and in accordance with the Data
Protection Act (1998). I agree that I will not seek to restrict the use of the 
results of the study on the understanding that my anonymity is preserved.
Faculty of
Health & Medical Sciences
Postgraduate Medical School
Daphne Jackson Road 
Manor Park
Guildford, Surrey GU2 7WG UK
Agnieszka Michael 
MRCP PhD
Senior Lecturer
Consultant in Medical Oncology
Initial
I understand and agree that NHS staff. Ethics Committee, authorised 
representatives of the University of Surrey (the sponsor of this study), and 
the Regulatory Authorities that control clinical research may review my 
records to check on details about my health relevant to the study
I understand that I am free to withdraw from the study at any time 
without needing to justify my decision and without my medical care being 
affected.
I confirm that I have read and understood the above and freely consent to 
participating in this study. I have been given adequate time to consider 
my participation and agree to comply with the instructions and restrictions 
of the study.
Name of patient (BLOCK CAPITALS) Name of the researcher
Signed
Date
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SURREY
Hardev Pandha 
FRCP FRACP PhD 
Professor of Urological Oncology 
Consultant in Medical Oncology 
Department of Oncology 
Post Graduate Medical School 
Daphne Jackson Road,
Manor Park
Guildford, Surrey. GU2 7WG
T: +44 (0)1483 68 8602 
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^atient Information Sheet 
Study Title: EN2 urinary biomarker for prostate cancer phase II: the effect of treatment 
)n biomarker level. 
^ECRefNo. 09/H1109/96 
1. Introduction
<ou are being invited to take part in a research project currently running at the Post Graduate 
VIedical School in the University of Surrey and the Royal Surrey County Hospital.
Before you decide it is important for you to understand why the research is being done and what 
t will involve. This information sheet will help you decide if you wish to participate in this 
esearch. Please take time to read the following information carefully.
Ne are dedicated to the treatment and research of diseases such as cancer. This involves a co­
operation between laboratory and clinical investigations and procedures. Research undertaken 
at the University of Surrey aims to advance the understanding of the causes of cancer and 
fevelop new methods of detection and treatment.
2. What Is the purpose of the study?
^restate cancer can be curable if found early. Currently the ways of detecting prostate cancer 
are very efficient but there is room for improvement. Our laboratory has discovered a protein 
hat appears to be present in the urine of patients with prostate cancer and maybe therefore 
jseful as a simple marker of prostate cancer in the future. The work so far indicates that about 
wo thirds of prostate cancer patients secrete this protein into their urine. This study will look at 
a further group of patients to see if this finding is consistent and in addition, we also wish to look 
at the effect of treatment on the amount of EN2 secreted into the urine. Patients who are 
jndergoing radiotherapy, hormonal treatment with tablets or surgical treatment (prostatectomy) 
vill all be included in this study. We are asking patients to donate about 1 tablespoon of urine 
arior to any treatment and then on three occasions after treatment one month apart.
Participation in the study therefore is completed in approximately three months.
PIS
Ne know that the PSA blood test does fall as a result of treatment and we will compare the 
evels of this urine marker in a similar way.
3. Who is organizing and funding the research?
The study is being funded by the University of Surrey. The sample collection is conducted by 
he staff at the Royal Surrey County Hospital in Guildford and the analyses are conducted by 
he staff at the Oncology Department, Post Graduate Medical School, at the University of 
Surrey.
4. Why have I been chosen?
i^ ou have been seen by your urologist and a diagnosis of prostate cancer has been made. Only 
)atients with prostate cancer secrete EN2 into their urine.
5. Do I have to take part?
four urine donation for our study is entirely voluntary. It is up to you to decide whether or not to 
ake part. If you do, you will be given this information sheet to keep and be asked to sign a 
consent form. You are still free to withdraw at any time and without giving a reason. A decision
0 withdraw or not take part will not affect the standard of care you will receive.
6. What will happen to me if I take part?
f you give your consent, we will simply obtain a urine sample before your treatment and ask 
'ou to take home 3 sample bottles which are clearly marked with dates and simple instructions. 
'Ve need approximately 1 tablespoon of urine which is passed into a small plastic bottle. The 
)ottle is then placed in a container suitable for transport through the post and you will be 
)rovided with stamped addressed padded envelopes. The sample is put in the post at your 
lext convenience. We wish to look at 3 consecutive samples one month apart so you will be 
liven three packs each containing a bottle in a container clearly labelled with dates and 
nstructions.
7. Expenses and payments:
"here will be no payment to you. The urine samples will be considered a donation for scientific 
esearch.
8. What are the side effects of this procedure?
Jo side effects are anticipated.
9. What are the benefits of this procedure?
'here is no direct benefit for you as a result of this procedure. However, the information gained 
rom the research may result in an improved diagnostic test, which may be helpful to other
1 restate cancer patients in the future.
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10. Will my taking part in the study be kept confidential?
Ml information which is collected about you during the course of this study will be kept strictly 
confidential: your urine samples will be anonymised. Any information about you which leaves 
he hospital will have your name and address removed, so you cannot be recognised from it.
Ne will not give your name or address to anyone outside the hospital.
^our medical records may be seen by RSCH Staff and staff at the Oncology Department at the 
Jniversity. They will respect your confidentiality.
\fter the study the research team will write a report on the results and might write an article to 
)e published in a medical journal or presented at a conference. If the results are published, we 
vill make sure that you cannot be recognised from the article or presentation. Under the Data 
Protection Act 1998, you are entitled to see your study records and to request additions or 
corrections.
11. What if there is a problem?
The University of Surrey, the sponsor of the study, has indemnity arrangements in place which 
îllows it to provide compensation without your needing to prove negligence. This could apply if 
rou suffered a significant and enduring injury (including illness or disease) which is directly 
attributable to any clinical intervention or procedure for which the University is responsible.
f you have any complaint about the way you have been dealt with during the study or any other 
concerns you can speak to Professor Hardev Pandha on 01483 688602.
f you have concerns about the NHS involvement in the study the normal NHS complaints 
nechanisms are available to you, and if you are harmed by taking part in this research project 
3nd you believe this is due to the negligence of the NHS then you may have grounds for legal 
îction against the NHS but you may have to pay for it.
12. What will happen to any samples I give?
Samples will be anonymized by the clinical team and code numbers will be given to your 
camples. Participants’ clinical details go onto a database. This database is password protected 
înd access is restricted to the Principal Investigator and Research Team. Samples will be kept 
n the laboratory of the Oncology Department, Post Graduate Medical School, University of 
Surrey. Analysis will be undertaken by the Principal Investigator and Research Team at the 
above mentioned laboratory. Samples will be stored for a maximum of 5 years and will not be 
jsed for any other research project unless approved separately by the ethics committee.
13. Stored Samples
Ne would like to store the samples for a period up to 5 years for use in future research. At this 
)oint in time we do not know the precise nature of that research and whether or not the results 
vould be of benefit to you as a donor. As mentioned above ethical approval would be sought 
separately for each new research project involving stored samples.
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14. What will happen to the results of the research study?
Research will be published in a scientific/medical journal and therefore available to all. Your 
cample will not be identifiable in any study report. All publications appear on the PubMed 
vebsite and will be accessible to all.
15. Who has reviewed the study?
The Study has been reviewed by the Surrey Research Ethics Committee.
rhank you very much for considering taking part and taking time to read this sh eet
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CONSENT FORM 
Title of Project: 
EN2 urinary biomarker for prostate cancer Phase II: 
the effect of treatment on biomarker level. 
REG Ref No. 09/H 1109/96
UNIVERSITY OF
SURREY
Faculty of
Health & Medical Sciences
Postgraduate Medical School
Daphne Jackson Road 
Manor Park
Guildford, Surrey GU2 7WG UK
Hardev Pandha
FRCP FRACP PhD
Professor of Urological Oncology
Consultant in Medical Oncology
T: +44 (0)1483 688602 
F: +44 (0)1483 688558
j.o’connor@surrey.ac.uk
www.surrey.ac.uk/pgms
Initial
1. I confirm that I have read the information sheet dated 16.12.2009 version 
2 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.
2. 1 understand that my participation is voluntary and that 1 am free to 
withdraw at any time w ithout giving any reason, without my medical 
care or legal rights being affected.
3. 1 understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by individuals from the 
Research team based at the University of Surrey [Principal Investigator 
and data manager), regulatory authorities or from the NHS Trust, where 
it  is relevant to my taking part in this research. 1 give permission for 
these individuals to have access to my records.
4. 1 agree to take part in the above study.
Name of patient [BLOCK CAPITALS) ............................... .
Signature ...........................................Date ...........................
Name of researcher/person taking consent [BLOCK CAPITALS) 
Signature  Date ............................
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The Royal Surrey County Hospital
NHS Trust
PROJECT CODE 
SHS-02 (Part 2)
PATIENT INFORMATION SHEET 
(PATIENTS HAVING RADICAL PROSTATECTOMY)
HistoScanning^'^ and EN2 in diagnosing, assessing and following
up localised prostate cancer
You’re being invited to take part in a research study. Before you decide, it ’s important for 
you to understand why we’re doing the research, and what it w ill involve. Please take time 
to read the following information carefully. Talk to other people about the study, i f  you 
want.
Please ask us i f  there is anything that isn’t clear, or i f  you’d like more information. Take 
time to decide whether or not you wish to take part.
Why are we doing the study?
The tests that are currently used to find out i f  a man has prostate cancer are not always 
reliable. Those tests are: a blood test for Prostate Specific Antigen (PSA), and taking 
samples o f prostate tissue (prostate biopsy), guided by a machine called an ultrasound 
scanner.
The PSA blood test can give high readings that suggest prostate cancer is present when it is 
not actually the case. So the PSA test is not as reliable as doctors would like it to be.
I f  a man has raised PSA, the doctor then takes biopsies to check i f  there are any cancers in 
the prostate, and where they are. When doctors take a prostate biopsy, they use the 
ultrasound scanner to look at the prostate while they’re taking the biopsy. They insert the 
scanner probe into the back passage (rectum), and take small samples from all over the 
prostate, using fine needles. But, the ultrasound picture doesn’t show where the cancers ( if 
there are any) actually are, so the doctors can’t be sure that they’re taking the biopsies from 
the right places. Having biopsies taken is safe, but can sometimes have unpleasant side 
effects like discomfort, bleeding and infection. So, we need a better test that can reliably 
detect prostate cancers, is not harmful, and is free o f side-effects.
The aim o f this research study, in 100 men, is to find out i f  a new test called 
HistoScanning™ can accurately locate prostate cancer. As a non-invasive method, 
HistoScanning™ would be a significant improvement over current methods.
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In our study, weTl find out how well HistoScanning^^ can identify cancers in the prostate, 
compared with looking, under a microscope, at the same parts o f the prostate after it ’s been 
removed by surgery.
We’ll also test your urine for a promising new marker for prostate cancer called EN2. This is 
a protein that’s produced by prostate cancer cells, but not by normal prostate tissue. I t ’s 
released into the mine, so it ’ s very easy to measure in routine urine samples.
What is HistoScanning™?
HistoScanning™ is a new technology based on ultrasound, developed by Advanced Medical 
Diagnostics (AMD), Belgium. It uses a special computer program to look in a different way 
at the information from the ultrasound scanner. HistoScanning™ uses that new information 
to show up any cancers in the prostate.
To begin with, we hope to use HistoScanning™ to guide ultrasound scans, to see exactly 
where the cancers are in the prostate. We would then need to take fewer biopsy samples.
If, as we expect, HistoScanning™ lives up to its promise, it could be one o f the most 
important advances in the diagnosis and follow  up o f prostate cancer for many years.
HistoScanning™ is in a very early stage o f development. So far, only about 60 patients have 
had the scans, in research that’s been published in scientific journals. The very first results o f 
this work were published in the British Journal o f Urology International. Those results have 
been very well received, and are very promising.
Why have I been approached?
You’ve been approached because you have prostate cancer and have agreed to have an 
operation to remove your prostate (radical prostatectomy).
Do I have to take part?
No. It ’s up to you to decide whether or not to take part. I f  you do, we’l l  ask you to sign a 
consent form. Even i f  you do sign the consent form, you’re still free to withdraw at any time. 
I f  you choose to withdraw from the study, you won’t have to give a reason. I f  you decide to 
withdraw from the study, it won’t affect the standard o f care that you receive.
What will happen to me if I do take part?
The flowchart on the next page gives a summary o f what this study involves:
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STUDY FLOWCHART
STEPl: ELIGIBILITY
•  you’re a man who’s at least 40 years old, and has been diagnosed with prostate cancer;
• you’ve already agreed to have a radical prostatectomy; and
• you haven’t had previous treatment for prostate cancer, including any type o f hormone
therapy.
V
STEPl: INVITATION
You’ve fu lfilled  Step 1, so we’ve invited you to take part in this study.
STEPS: SCREENING VISIT V
After reading this Patient Information Sheet, and having your questions answered, you’ve 
agreed to attend the Screening V isit. A t the Screening V isit, we’ll assess you to see i f  there 
are any reasons why you may not be suitable for the study. I f  there are no reasons why you 
shouldn’t take part, and you still wish to proceed, we’ll offer you a place in the study. 
Signing o f the Consent Form is the formal conclusion o f STEPS 1 to 3.
STEP 4: HISTOSCANNING VISIT AND EN2 SAMPLE V
A t this visit, the data are acquired on your prostate by a simple trans-rectal ultrasound o f 
prostate, just like the scan you had when you were first diagnosed with prostate cancer. This 
does NOT involve taking any prostate biopsies and therefore there is no need for either local 
or general anaesthesia. This visit should take no more than half an hour, although the 
scanning itself takes no more than a couple o f minutes. We’l l  also ask you to give a sample 
o f your urine, for the EN2 test.
STEPS: RADICAL PROSTATECTOMY AND EN2 SAMPLE V
The scheduling o f your operation won’t be affected by your decision to take part in the 
HistoScanning™ study. Your care in relation to the radical prostatectomy w ill be le ft totally 
to your consultant. We’ll ask you to give another urine sample, for an EN2 test, when you 
have your first check-up after your operation.
The laboratory w ill send a standard pathology report on your prostate to your consultant, who 
w ill go through it w ith you. In addition to the standard analysis, we’ll do a detailed 
examination o f your prostate, to check whether HistoScanning™ correctly identified the 
areas o f cancer in your prostate. We w ill also look to see i f  there is any correlation between 
the amount o f cancer and the levels o f EN2 in your urine.
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What are the risks and disadvantages of taking part?
There are no risks involved in this test.
The potential disadvantage to you relates to the 2 extra clinic visits (the screening visit and 
the HistoScanningTM visit) that you’l l have to make. But, it might be possible to do the 
screening and HistoScanning™ at the same visit.
A  transrectal ultrasound scan should not be painful. In terms o f comparison, it should feel 
about the same as a rectal examination done with a gloved finger.
Will this affect my treatment?
No. I f  you take part in this study, it won’t affect your treatment in any way.
What are the possibie benefits of taking part?
As HistoScanning™ and EN2 are in the in itia l stage o f development, we won’t be able to 
draw any conclusions from the results at this stage, and therefore there won’t be any direct 
benefit to you. But in the future the HistoScanning™ process and EN2 test might help other 
men in your situation.
What happens to the data coiiected?
A ll the data w ill be kept confidential, and your personal details w ill be anonymised before 
analysis. The direct comparison o f HistoScanning™ against the final pathology w ill show 
just how accurate HistoScanning™ is at both ‘ruling-in’ and ‘ruling-out’ prostate cancer in 
particular areas o f the prostate. The results o f the EN2 tests may help in the future 
development o f a simple and reliable urine test for prostate cancer.
What will happen to the tissue and urine samples?
During the study, the prostatectomy samples w ill be kept securely at the pathology laboratory 
at the Royal Surrey County Hospital. A t the end o f the study, all the tissue samples w ill be 
destroyed according to standard hospital practice. Urine samples w ill be kept in the 
laboratory o f the Oncology Department, Post Graduate Medical School, University o f Surrey. 
Samples w ill be stored for a maximum o f 5 years, and w ill not be used for any other research 
project unless approved separately by the ethics committee.
What if there’s a problem?
I t ’ s very unlikely you’l l  come to have any harm. Nevertheless, i f  you are harmed by taking 
part in this research project, the sponsor o f the study has made compensation arrangements.
Who’s responsible for this study?
The lead investigator is Professor Stephen Langley, Consultant Urologist at the Royal Surrey 
Hospital, Guildford.
Who’s sponsoring the study?
The Royal Surrey County Hospital NHS Trust at Guildford is sponsoring this study.
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Who’s funding the study?
The HistoScanning part o f the study is being funded by a charity called The Prostate Project, 
Purbecks, Grosvenor Road, Godalming, Surrey GU7 IN Z; telephone: 01483 419501; email: 
info@prostate-Droiect.ors.uk; website: www.prostate-proiect.org.uk.
The EN2 part o f the study is funded by the University o f Surrey.
Who’s reviewed the study?
The study has been reviewed by the Royal Surrey County Hospital Research and 
Development team, the University o f Surrey, and the Surrey Research Ethics Committee.
Where else is the study being done?
HistoScanningTM projects are also being done on other organs such as ovary, breast and 
thyroid. Other EN2 projects are in progress at the Oncology Department at the University o f 
Surrey.
What happens when the research study is over?
When the research study is completed, the data w ill be analysed and the results might be 
published in scientific journals and distributed through the scientific community.
Will anyone else know of my participation in this study?
After you’ve signed the consent form, we’l l  send a letter to your GP informing him or her o f 
your participation in this study. Doctors involved in your care in this or another hospital w ill 
also be notified. I f  you aren’t w illing to consent to that, then we can’t enter you into the 
study, as it ’s important that those doctors and your GP are aware o f your participation in this 
study
Who can I contact about the study?
You can contact M r Saqib Javed or D r E liot Chadwick (doctors who work w ith the 
consultant. Professor Stephen Langley), for further information, any queries or issues 
concerning your participation in this study.
Many thanks for taking the time to read this information sheet.
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The Royal Surrey County Hospital
NHS Trust
PROJECT CODE 
SHS-02 (Part 2 -  radical prostatectomy)
REPLY FORM
HistoScanning™ and EN2 in diagnosing, assessing and following 
up localised prostate cancer
Full name.........................................................................................................................
Address............................................................................................................................
Postcode...........................................................................................................................
Date o f B irth.....................................................................................................................
Dear Professor Langley,
I have read the information sheet regarding this HistoScanning™ project.
I I I would like to participate and am happy to be contacted by your co­
investigators by
Telephone.........................................................
Mobile ..............................................................
Email ..............................................................
EZI I would not like to participate in this study 
Yours sincerely
...........................................(Participant’s signature)
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The Royal Surrey County Hospital
NHS Trust
PROJECT CODE 
SHS-02 (Part 2 -  radical prostatectomy)
INFORMED CONSENT FORM
HistoScanning™ and EN2 in diagnosing, assessing and following 
up localised prostate cancer
Full name. 
Address...
Postcode.......
Date o f Birth. 
C linician.......
GP details
Patient’s initials
I  have read and understand the information leaflet
‘HistoScanning™ and EN2 in diagnosing, assessing and following up prostate cancer’ .
I  understand that this involves a HistoScanning™ image o f the prostate 
and that the data obtained during scanning w ill be analyzed to see 
i f  there is any further useful information to be obtained.
I understand and agree that the pathology lab w ill do an additional analysis 
o f my prostatectomy sample
I agree for my medical notes and data to be looked at by regulatory 
authorities or relevant NHS trust i f  needed
I agree for my anonymised data collected during the study to be looked 
at by the researchers
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I  agree for my GP to be informed about my involvement in this study
I  have received sufficient information and have had the opportunity 
to have my questions answered.
I  understand that my participation is voluntary and I  can withdraw at 
any time without giving any reason, and this won’t affect my medical 
care or legal rights.
I  completely understand, and agree to take part in the study
Participant’s signature........................................................................... Date.
Investigator’s signature........................................................................... Date.
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8 Presentations
The work from this thesis resulted in the following national and 
international presentations,
National Presentations 
Papers
1. ‘Does Prostate Histoscanning™ accurately predict tumour volume and position 
in men undergoing radical prostatectomy?’ at British Association of Urological 
Surgeons (BAUS) on 18 June 2013 in Manchester.
2. ‘Urinary Engraiied-2 (EN2) levels and their correlation with tumour volume and 
pathological tumour stage in men undergoing radical prostatectomy for 
prostate cancer’ at British Association of Urological Surgeons (BAUS) on 18 June 
2013 in Manchester.
Posters
3. An update on urinary Engraiied-2 (EN2), a novel biomarker for detection of 
prostate cancer and its correlation with tumour volume and pathological stage’
at UK and Ireland Brachytherapy conference, 14 June 2013, Goodwood, UK.
4. A novel biomarker for prostate cancer follow up post radical treatment: Urinary 
Engraiied-2’, UK and Ireland Brachytherapy conference, 23-24 March 2012, Leeds, 
UK.
international presentations 
Oral
Poster
5. ‘The role of Prostate HistoScanning™ in assessment of prostate tumour volume 
and pathological stage prior to radical prostatectomy’ at Pakistan Association of 
Urological Surgeons Conference on 6**^  April, 2013, Islamabad, Pakistan.
6. Urinary Engraiied-2 (EN2): A novel biomarker which correlates with tumour 
volume and pathological tumour stage in men undergoing radical 
prostatectomy for prostate cancer’ at Pakistan Association of Urological Surgeons 
Conference on 6’^  April, 2013, Islamabad, Pakistan.
7. Prostate Histoscanning™ for assessment of tumour volume and pathological 
stage prior to radical prostatectomy: What is its role in routine clinical 
practice?’ at European Association of Urology (EAU) Conference on 17 March, 
2013, Milan, Italy.
8. Urinary Engraiied-2 levels correlate with prostate tumour volume and 
pathological stage in men undergoing radical prostatectomy for prostate 
cancer’, Prostate Cancer Translational Research in Europe (EUA) Conference, 27- 
28 June, Malmo, Sweden.
9. Urinary Engraiied-2: A novel biomarker for follow up post radical treatment for 
prostate cancer’. World Congress of Brachytherapy, 10-12 May 2012, Barcelona, 
Spain.
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9 Publications
The work from this thesis resulted in the following peer-reviewed 
publications,
1. Saqib Javed, Stephen Langley The importance of HOX genes in normal 
prostate gland formation, prostate cancer development and its 
early detection.’ (Commissioned review article BJUInt. 2013)
2. Hardev Pandha*, Saqib Javed*, , Prasanna Sooriakumaranc, Simon Bott, Bruce 
Montgomery, Anthony Hutton, Christopher Eden, Stephen E. Langley and Richard 
Morgan. *equai contribution ‘Correlation of urinary engrailed-2 levels to 
tumour volume and pathological stage in men undergoing radical 
prostatectomy.’ (May 2013, Journal of Cancer Therapy).
3. Saqib Javed, Eliot Chadwick, Sabeena Beveridge  ^ Simon Bott, Christopher Eden 
and Stephen Langley ‘Does Prostate HistoScanning™ accurately 
identify prostate cancer, measure tumour volume and assess 
pathological stage prior to radical prostatectomy?’ (May 2013, Journal 
of Clinical Urology).
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Saqib Javed and Stephen E.M. Langley
Department o f Urology, Royal Surrey County Hospital, Guildford, UK
The aims o f this paper were to review the published 
literature on the role o f HOX  genes in  the development 
o f the normal prostate gland and in  prostate cancer and 
to discuss the potential role o f the HOX  family member, 
Engrailed-2 {EN2), as a diagnostic test o f PCa.
Hox genes were first described in  the fru it fly  Drosphila 
melanogaster, where they specify the body plan and 
control the formation o f body segments. They belong to 
a family o f homeodomain-containing transcription 
factors that determine cell and tissue identity during 
normal embryonic development. They have been shown 
to be re-expressed by several different types o f cancers. 
Studies have shown that different Hox genes are 
responsible for the development o f the separate lobes o f 
the prostate gland, the seminal vesicles and the 
epididymis. A ll HOX 13 paralogues are expressed in  the 
adult human prostate, suggesting the possibility o f 
similarities between the function and expression o f 
HOX  genes w ithin urological structures at similar 
anterior-posterior positions.
• The oncogenic and tumour suppressor signalling 
pathways associated w ith PCa converge on the HOX  gene 
network, which ultimately controls gene expression, 
affecting tumour formation and metastatic progression.
• The Engrailed genes {EN l and EN2) from  the HOX  gene 
family show a very high degree o f functional 
conservation during embryonic development.
• Urinary EN2 is being investigated as a potential 
diagnostic marker o f early PCa. It is secreted into the 
urine by PCa cells but not by normal prostatic tissue. A  
recent study has shown an association between urinary 
EN2 levels and cancer volume in  radical prostatectomy 
specimens. The ability to predict tumour volume could 
inform  the treatment decision-making process for 
patients w ith localized PCa choosing between active 
surveillance and radical treatment options.
Keywords
HOX  genes, prostate cancer, prostate gland, prostate gland
development
Introduction
Prostate cancer (PCa) is the most commonly diagnosed 
malignancy in  men in the western world [1]. The risk 
factors involved in  PCa include increasing age, a positive 
family history and race (Black men have a greater risk than 
Caucasian men). Genetics are involved in  PCa and, in  this 
review article, we try  to explain the involvement o f HOX  
genes in  the development o f prostate gland and PCa and 
their potential role in  the diagnosis o f PCa.
HOX  genes are known for their role in  determining the 
identity o f cells and tissues during development, especially 
along the anterior-posterior axis, and in  regulating the 
proliferation and differentiation o f embryonic and adult 
stem cells [2]. Hox genes were first characterized in the
fru it fly. Drosophila melanogaster, and have subsequently 
been identified in  many other species, including mammals 
(Fig. 1). They belong to a family o f homeodomain- 
containing transcription factors that are expressed in 
embryonic development and subsequently re-expressed by 
several different types o f cancers. The homeodomain is a 
highly conserved 61-amino-acid motif, which enables HOX 
proteins to bind to specific sites on DNA, from which they 
can activate or repress target genes. HOX  genes have been 
implicated in  a various biological pathways including 
homeostasis, cell differentiation and the maintenance o f 
organ function, especially in adult tissue [3].
Mammals have 39 HOX  genes split into four paralogous 
clusters (A, B, C and D) located on four different 
chromosomes [4]. Each cluster contains nine to 11 genes
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Fig. 1 Various HOX genes In drosophila, 
mouse and human. (Reproduced with 
permission from Pang and Thompson [46]) 
and aberrantly expressed HOX genes during 
prostate gland development and PCa. 
Abbreviation: PCa, prostate cancer.
Aberrantly expressed of H O X  genes
Prostate gland development • H oxa9-ll
• HoxalS
• HoxblS
• HoxdlS
• Hoxcl 1
Prostate cancer . H 0X C 4
.  H 0X C 5
.  H 0X C 6
.  H 0X C 8
• HOXBIS
.  H 0X A 9
arranged in 13 groups based on homeobox sequence and 
the position w ithin the cluster. Similar genes in separate 
clusters are considered paralogues. The expression o f these 
genes, from the 3' to 5' end o f each cluster, is activated and 
they are expressed w ithin specific tissues o f an organism at 
specific times during development. The 3' genes designate 
anterior regions, whereas the 5' genes are expressed in 
the posterior regions, where they are involved in the 
differentiation o f genitourinary structures. Studies have 
shown that there is deregulation o f HOX  gene expression in 
cancers o f the lung, breast, colon, ovary, thyroid, bladder 
and prostate [5,6].
Hox Genes and the Development of 
the Prostate Gland
Most o f the male sex organs develop embryologically from 
the Wolffian ducts, which are mesodermal in origin. By 
contrast, the prostate gland originates from the urogenital 
sinus, an elongated sac formed by division o f the cloaca in 
the early embryo, which is an endodermal structure [7].
In  mouse prostate, Hox genes play an important role in  the 
normal development o f the gland [8]. In adult rats, the 
most posterior Hox genes are involved in prostate 
development. In a study using quantitative real-time PCR, 
it was shown that the posterior (S') Hox genes were 
responsible for the development o f the separate lobes o f the 
prostate, the seminal vesicles and the epididymis [9]. These 
genes include H oxa9-ll, HoxalS, HoxdlS and HoxblS. It 
was also shown that for each o f these tissues there is a 
unique Hox code that contributes to the organ-specific and 
prostate lobe-specific identities in the adult rat. Thus, the 
Hox code participates in determining lobe-specific prostatic 
identity and cellular differentiation [9]. In another study, it 
was shown that the Hoxcl 1 gene also plays an active role in 
the development o f the urogenital sinus, which then gives 
rise to the prostate gland [10].
Abate-Shen et al. [11] suggested, in a review article, that 
NKX3.1 homeobox genes play an important role in normal 
differentiation o f the prostatic epithelium and its loss 
causes the initiation o f events in PCa formation in  mouse
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models and human patients. Other work has suggested that 
ventral prostatic development in  the mouse is controlled by 
HoxblS [12]. Mice w ith a mutation for both HoxblS  and 
HoxdlS exhibit severe hypoplasia o f the prostatic ducts, a 
change in  epithelium from tall columnar cells to simple 
cuboidal cells, and the complete absence o f ventral prostatic 
secretions, indicating an important role in  ventral prostate 
morphogenesis. These results suggest a specific role for 
HoxblS in  a differentiation pathway that gives the ventral 
prostate epithelium a unique identity [12].
The most 5' aspect o f the mammalian HOX  gene clusters is 
occupied by HOXAIS, HOXBIS, and HOXDIS, which are 
expressed in the developing prostate. In  mice, HoxalS is 
expressed in  both the epithelium and mesenchyme o f the 
urogenital sinus [13]. In  adulthood, HOXBIS is expressed 
in the human colorectal tissue and in  all the epithelial 
glands o f the prostate [14]. There are no reports on the 
expression of, or roles for, HOX  genes during human 
prostate development; however, studies on the expression 
o f HOX  genes in  human prostate have been confined to 
adult pro static tissues where cells express all HOXIS 
paralogues in addition to several anterior HOX  genes
[14].
HOX Genes and PCa
Despite significant developments in  the diagnosis and 
treatment o f PCa, the disease remains a major health issue. 
It is the most commonly diagnosed malignancy in  men in  
Europe, accounting for -12% o f all cancers and 9% o f all 
cancer-related deaths in  adult men in  the European Union
[16].
In  humans, the oncogenic and tumour suppressor 
signalling pathways associated w ith urogenital cancers, 
including PCa, converge on the HOX  gene network, which 
ultimately controls gene expression, resulting in  tumour 
formation and metastatic progression [17].
Aberrations in  the expression o f HOXC genes have been 
detected in  human PCa cells, and in  lymph node métastasés
[15]. Reverse transcription-PCR has shown overexpression 
o f H0XC4, H0XC5, H0XC6  and H0XC8 genes in 
malignant cell lines and in  lymph node métastasés in 
PCa [15]. Another study described an association o f 
overexpression o f H0XC8  w ith the loss o f differentiation in 
human PCa cells [18]. Little or no H0XC8 mRNA was 
detected in  normal prostate cells, or in cells from PCa o f 
low Gleason score. By contrast, levels o f H0XC8 mRNA 
were significantly higher in  cells from  tumours o f high 
Gleason score >7 [18].
HOX genes may also have a role in  androgen receptor 
signalling, which has an important role in  regulating the 
growth and differentiation o f both normal and cancerous
prostate cells [19]. HOXBIS was found to be highly 
expressed in  normal prostate cells and androgen 
receptor-positive PCa cell lines, whereas androgen 
receptor-negative cancer cells expressed very low 
levels o f HOXBIS [14,20]. In  a different study, 
deregulation o f HOXDIS was found in  human breast 
cancer, melanoma and cervical cancer, and also in  
the neuroendocrine differentiation o f advanced PCa [21].
Another study found that HOXBIS was highly 
overexpressed in  hormone-refractory tumours after in itia l 
treatment [22]. It was shown that, i f  HOXBIS was 
m inimally induced to the level o f the normal prostate in 
LNCaP PCa cells, it  markedly promoted cell proliferation, 
but its suppression inhibited cell proliferation in  an 
environment which was androgen-free. This cell growth 
promotion appeared to be through the regulation o f 
p21-mediated E2F signalling [22].
Ewing et al. [23]studied the mutation in HOXBIS genes in  
region o f linkage at 17q21-22 and the risk o f familial PCa 
and showed that the HOXBIS G84E variant was associated 
w ith a significantly increased risk o f hereditary PCa. These 
findings were confirmed by Xu et al. [24], who showed that 
the HOXBIS G84E mutation was present in  -5  % o f 
families w ith PCa, predominantly those o f European 
descent, and confirmed its association w ith PCa risk. A  
similar study showed that the mutation G1S5E in  HOXBIS 
gene was associated w ith increased PCa risk in  Chinese 
men [25].
Engrailed Gene and Its Various Roles
The Engrailed (En) genes are also members o f the 
homeodomain-containing transcription factors fam ily and 
also show a very high degree o f functional conservation 
during embryonic development, and in  translational 
regulation [26]. En was first described as a Drosophila 
mutation that resulted in  a failure o f the development the 
border dividing the posterior and anterior wing 
compartments [26]. Homologues o f En are present in 
various animal groups. Vertebrates have two Engrailed 
genes, Enl and En2, which are more or less functionally 
equivalent [27,28]. EN2 protein has been shown to have 
some additional functionally important properties, 
including the ability to be secreted by some cell types, and 
to be internalized by others [29,30].
En is involved in  the determination o f the 
m idbrain/hindbrain border, which acts as an important 
organizing centre during brain development. H igh levels o f 
Enl and En2 are expressed by the alar (dorsal) cells. When 
transplanted to other areas o f the developing brain, which 
do not usually express En, this expression continues. These 
areas then acquire the characteristics o f the transplanted 
tissue [31,32].
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EN  also plays an important role in  axonal guidance, which 
depends upon the secretion o f EN2 protein and its uptake 
by extending axons. In  the developing brain, this is 
important in  guiding both nasal and retinal axons, and EN2 
protein acts as an attractant for the former and a repellent 
for the latter [33].
EN2 may have a role in  the survival o f dopaminergic 
neurons w ithin the nervous system. These neurons express 
high levels o f EN2, not only during embryonic 
development, but also in  the adult [34]. EN2 was recently 
shown to have an oncogenic role in  breast cancer, when 
non-tumorogenic murine mammary cell lines developed 
malignant characteristics when they were forced to express 
EN2 [35].
HOX Genes and EN2 as a Marker 
for PCa
The role o f HOX  genes has been studied as a marker in 
non-prostatic cancers. A  study by Bitu et al. [36] showed 
that HO XAl may contribute to oral cancer formation by 
increasing tumour cell proliferation. Their study showed an 
association o f higher numbers o f HOXAl-positive cells in 
oral squamous cell carcinomas w ith higher T- and N-stage, 
tumour differentiation and proliferative potential, and that 
this was predictive o f poor survival. This suggests that 
HO XAl expression m ight be helpful as a prognostic marker 
o f oral squamous cell carcinoma.
Another study evaluated the role o f even-skipped 
homeoboxl (EVXl)  genes [37] and postulated that EVXl 
méthylation is altered in  PCa progression.
Hypermethylation was observed in  all PCa cell lines and 
57% o f the tumours. High grade tumours exhibited 
increased méthylation compared w ith intermediate grade 
tumours. They also showed that hypermethylation o f EVXl 
genes predicted treatment failure in  patients w ith moderate 
risk disease.
Combinations o f homeobox genes may also be important as 
prognostic markers in  cancer. In  a study involving the 
genomic pathway analysis o f Meisl, Meis2, Pbxl and 
H0XA9  [38], fresh prostate and seminal vesicle cells 
derived from patients undergoing radical prostatectomy 
were obtained. This genomic analysis can detect survival 
differences in  patients on watchful waiting and predict 
biochemical failure after radical prostatectomy. It also 
predicted Gleason score and differentiated between normal 
prostate gland, primary prostate tumour and metastatic 
disease.
Recent studies have shown that EN2 may be clinically 
useful as a specific diagnostic marker o f PCa. The tests, 
which are used in  current clinical practice to diagnose PCa, 
include PSA assessment, DRE and TRUS-guided biopsies o f
the prostate. Each o f these tests has significant limitations 
[39-41]. In  particular, PSA is increased not only in  PCa, 
but also in  various benign conditions o f the prostate gland, 
thus making it  prostate-specific but not PCa-specific. There 
is an urgent need for new biomarkers to overcome the 
limitations o f the PSA test.
In  2011, Morgan et al. [42] assessed the role o f EN2 in  the 
diagnosis o f PCa. It was shown that EN2 is secreted into 
the urine by PCa cells but not by normal prostatic tissue. 
Semi-quantitative real-time PCR confirmed the expression 
o f EN2 in  PCa cell lines PC3, DU145 and LNCaP and in  
PCa tissue from prostate biopsy cores, while none o f the 
non-cancerous prostate biopsy cores expressed EN2. 
Immunohistochemistry also confirmed that EN2 was highly 
expressed by PCa tissues and not by normal prostatic tissue 
or by high grade prostatic intraepithélial neoplasia. EN2 
levels in  first pass early morning urine samples (5-10 mL) 
were measured using ELISA. The presence o f EN2 in  urine 
was highly predictive o f PCa, w ith  a sensitivity o f 66% and 
a specificity o f 88.2%, without the requirement o f DRE. 
W ith such a high predictive value in  urine, EN2 has the 
potential to be used alongside PSA, making this test 
attractive for diagnosis o f PCa and also potentially as a 
simple screening tool in  the community, thereby reducing 
the need for taking prostate biopsies [42].
Previous studies showed no relationship between serum 
PSA level and tumour volume [43,44]. In  patients w ith PCa 
who are choosing between active surveillance and active 
treatment options, a biomarker that could reliably predict 
prostate tumour volume, would be valuable in  the 
treatment decision-making process. In  2012, Pandha et al. 
[45] evaluated the relationship between levels o f EN2 in  
urine and cancer volume in  men who had undergone 
radical prostatectomy for PCa. Archived pretreatment 
mid-stream urine samples w ithout previous DRE were 
assessed using ELISA. A  strong statistical relationship was 
noted between urinary EN2 and PCa volume by linear 
regression (P = 0.006). The level o f urinary EN2 was 
significantly higher in  patients w ith  T2 cancer than in  those 
w ith  T1 cancer (P = 0.027). As DRE is not required and the 
ELISA is a simple, reliable and inexpensive test, EN2 has 
the potential to become a useful diagnostic biomarker for 
PCa, which may also help in  risk stratification and 
management by assessing tumour volume in patients w ith 
PCa [45].
Conclusion
H0XA9-11, HOXAIS, HOXBIS, HOXDIS and H O X C ll 
genes play an important role in  the embryological 
development o f the prostate gland, while H0XC4, H0XC5, 
H0XC6, H0XC8, HOXBIS and H0XA9  are aberrantly 
expressed in  PCa. Urinary EN2 which belongs to the HOX
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gene family is emerging as a promising diagnostic
biomarker for early PCa.
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ABSTRACT
The aim o f this study was to assess the relationship between pre-prostatectomy urinary Engrailed-2 (EN2), a transcrip­
tion factor secreted by prostate cancer cells, w ith tumour volume and pathological characteristics in resected prostate 
specimens. First pass urine samples (10 m l) without prior prostatic massage were collected and stored at -80°C. EN2 
levels were measured using an enzyme-linked immunoabsorbent assay. Tumour volume in the prostatectomy specimens 
was determined histologically. 57 men undergoing RP in one urological cancer network were evaluated. EN2 was de­
tected in 85% o f  RP patients. EN2 correlated w ith tumour volume (but not total prostatic volume) in a linear regression 
analysis, w ith increasing pathological T stage and margin positivity. Using three “ cutoff levels”  o f tumour volume (0.5 
ml, 1.3 ml and 2.5 m l) to define “ significant disease” , men w ith  “ significant disease”  had markedly higher levels o f u ri­
nary EN2 (p < 0.001 for each cut o f f  level). Levels o f urinary EN2 may be useful in predicting tumour volume in men 
w ith prostate cancer by potentially identifying men w ith small volume “ insignificant”  disease. This study justifies a 
larger multicentre evaluation o f urinary EN2 levels as a biomarker o f PC significance using cancer volume, pathological 
and PSA criteria.
Keywords: Biomarker; Prostate Cancer; Urine
1. Introduction
For over 20 years, prostate specific antigen (PSA) testing 
has provided the opportunity for the detection o f prostate 
cancer (PC) at an earlier and, therefore, more likely eura- 
tive stage o f the disease. Although PSA has been (and 
remains) a valuable cancer biomarker, the limited sensi­
tiv ity  and specificity o f PSA for cancer at the age-spe- 
eific cut-offs [1,2] and its elevation in benign prostate 
disorders continues to lim it its u tility. In  addition, there is 
no consistent correlation between PSA and the grade, 
stage or volume o f disease [3]. Attempts to increase the 
predictive value o f PSA using PSA density and velocity, 
the ratio o f free to total PSA and different PSA isoforms 
have made little  impact clinically [4]. There is an urgent
*The authors declare no conflict o f interest.
"Equal contribution.
^Corresponding author.
need for novel biomarkers which aid clinical decision 
making w ith respect to biopsy and primary therapy [5].
We reported the potential diagnostic u tility  o f En- 
grailed-2 (EN2), a transcription factor involved in em­
bryonic brain development that is re-expressed in PC [6]. 
The presence o f EN2 in urine was predictive o f PC, w ith  
a sensitivity o f 66% and a specificity o f 88.2% (AUC o f 
0.81) We further demonstrated a strong positive corre­
lation between pre-surgical levels o f urinary EN2 and 
tumour volume in RP specimens in a retrospective series, 
as well as a correlation between EN2 levels and tumour 
stage (T2 vs. T3) [7].
The objective o f the current study was to prospectively 
examine the relationship o f pre-surgical urinary EN2 
levels w ith  tumour stage and tumour volume in RP spe­
cimens and thereby to provide an indication whether 
EN2 could potentially be used, in conjunction w ith other 
criteria, to designate patients as suitable for immediate
Copyright © 2013 SciRes. JCT
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active treatment versus active surveillance.
2. Materials and Methods
2.1. Patients
The patients were recruited to the study between De­
cember 2010 and February 2012. Patients were identified 
in multidisciplinary uro-oncology clinics from the Surrey, 
West Sussex and Hampshire Cancer Network, UK. A ll 
patients gave written informed consent and the study 
received approval by the local ethics committee (REF: 
09/H l 109/98). Patients were recruited prospectively and 
consecutively and not selected in any way apart form the 
follow ing criteria. The main criterion for inclusion was 
planned RP (laparoscopic or robotic) for clinically local­
ised PC. The diagnosis o f PC was established based on 8 - 
12 core (transrectal sextant and/or template biopsies). 
Patients w ith a urinary tract infection, on any therapy for 
PC or on finasteride, w ith  non-organ confined disease 
and any histologically confirmed second malignancies 
were excluded.
Serum PSA was measured 1 - 2  weeks prior to urine 
procurement. First pass urine samples (10 m l), without 
prostatie massage, were collected a minimum o f 4 weeks 
after any biopsy procedure (sextant or template) and, in 
general, were between 1 day and 2 weeks before RP. We 
previously reported that EN2 protein is stable in urine at 
room temperature for at least 4 days [6], and all urine 
samples were received for processing w ithin 30 hours 
post donation. Upon receipt in  the laboratory, samples 
were divided into 1.5ml aliquots, centrifuged 10,000 g 
for 5 minutes and the supernatant removed and stored at 
-80°C.
A ll RP specimens and biopsies were evaluated by a 
specialist uro-pathologist. Tissue samples were fixed in 
10% formalin, paraffin embedded, and sectioned at 5- 
mm intervals before mounting o f whole sections on 
slides. In conducting a complete sampling procedure, the 
apical portion, the base, and the neck o f the prostate were 
separated and sampled using a cone technique. The 
Gleason grading system (International Society o f Uro­
logical Pathology revised version) was applied and the 
TNM  classification for staging was used. Each focus o f 
PC was outlined on the histology sections and tumour 
volume calculated by multiplying the area by the section 
thickness. The individual volumes o f mutifocal tumours 
were calculated and combined as the total tumour vo l­
ume.
2.2. Enzyme-Linked Immunosorbent Assay
A  modified version o f the previously published ELISA 
method [6] was used for this study. EN2 was bound di­
rectly to the surface o f a plastie assay plate (Nunc Max-
isorb) by incubating urine in each well for 2 hours. The 
wells were subsequently washed w ith  PBS w ith 0.1% 
Tween 20, and the EN2 protein bound to the plastic sur­
face was detected using a mouse anit-EN2 monoclonal 
antibody linked to alkaline phosphatase. Samples were 
tested anonymously to eliminate patient identification. 
100 p i o f the urine supernatant samples or a dilution o f 
the EN2 fragment in buffer was tested in duplicate. A  
standard curve was generated from dilution series to al­
low the concentration o f EN2 in each sample to be 
measured.
2.3. Statistical Analysis
The GraphPad Prism (GraphPad Software Inc, USA) 
package was used in  statistical calculations. To test the 
significance o f differences between mean EN2 concen­
trations in different patient groups (defined by T-stage or 
Gleason grade) an unpaired /-test w ith  Welch’ s correc­
tion was used as the EN2 values were not normally dis­
tributed. Correlations between PSA and tumour volume/ 
prostate volume, and EN2 and tumour volume/prostate 
volume were calculated by linear regression. Receiver 
operator characteristics (ROC) curves were generated for 
the EN2 and PSA values. The area under the curve was 
tested for significance using an unpaired /-test against the 
hypothesis that the real area under the curve was 0.5 {i.e. 
no diagnostic value). The threshold value for significance 
o f EN2 level in urine was set at 42.5 ng/ml based on the 
original study [6].
3. Results
3.1. Patient Characteristics
The patient characteristics o f the 57 men in  the study are 
shown in Table 1. C linical stages T ic , T2a, T2b and T3a 
were reported in 36, 8, 8, 4 and 1 man, respectively. The 
mean number o f positive cores was five (median 5, in­
terquartile range (IQR) 3-7). The median combined 
Gleason score in biopsies and RP specimens was 7, IQR 
6-7). Seventeen patients had their Gleason score up­
graded after RP; two patients were downgraded. The RP 
Gleason scores were as follows: 3 + 3 (n =  15); 3 + 4 (n 
= 33); 4 + 3 (n = 5); 4 + 4 (n = 0); 3 + 5 (n = 3); and 4 + 
5 (n = 1). The pathological grades in the RP specimens 
were: Gleason 6 (26.3%); 7 (66.6%), 8 (5.2%) and 9 
(1.7%).
The mean tumour volume in the RP specimen was 
4.92 ml (median 4.35 ml, IQR 1.81-6.7ml). EN2 levels 
across the cohort were not normally distributed. O f the 
total o f 57 patients in the eohort, 85% were positive for 
EN2 in their urine having levels above 42.5 ng/ml de­
scribed previously) [6]. In these men, the mean EN2 level 
in urine was 347.73 ng/ml (median 265, IQR 184-524).
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The demographic and pathological features o f patients 
who were positive or negative for EN2 secretion are 
shown in Table 2. The groups differed only on the basis 
o f tumour volume, where EN2 secretion was associated 
w ith  larger tumour volume at prostatectomy. The differ­
ence between the mean EN2 levels between the two 
groups was statistically significant (p < 0.0001). The 
difference between the mean tumour volume between the 
two groups was also statistically significant (p < 0.0001).
In  eight o f the nine men who were not secreting EN2, 
one or more o f their original diagnostic prostatic biopsies 
were positive for EN2 staining (data not shown).
3.2. Correlation between Serum PSA, Urinary 
EN2 and Pathological Findings
No correlation was found between serum PSA level and 
levels o f urinary EN2 in pre-RP samples {p = 0.075; 
Figure 1). Higher levels o f EN2 were detected in more 
advanced clinical T  stage but this did not reach signifi­
cance (p =  0.1936). However, digital rectal examination 
prediction is notoriously variable between individuals 
and is o f limited value in staging. Regarding pathological 
stage, significant differences were noted in the median 
levels o f EN2 in pT2 (n = 39) and pT3a (n =  19), which 
were 210 ng/ml (IQR 52 ng/ml - 347 ng/ml) and 420 
ng/ml (IQR 282 ng/ml - 662 ng/ml) respectively {p = 
0.0063) (Figure 2). Men w ith  positive margin(s) had 
significantly higher median levels o f EN2 in margin pos­
itive patients (n = 14) o f 554.5 ng/ml (IQR 354.2 ng/ml - 
733.7 ng/ml) versus 227 ng/ml (IQR 90.25 ng/ml - 375 
ng/ml) in margin negative patients (n =  43) {p = 0.0078) 
(Figure 3). Although men w ith  perineural invasion 
showed the same trend, this did not achieve statistical 
significance (data not shown).
The relationship between urinary EN2 and serum PSA 
and Gleason grading o f biopsies and RP specimens was 
examined. In  the biopsies, higher levels o f EN2 were 
associated w ith  Gleason 7 disease compared w ith Glea­
son 8, although there were far fewer cases o f Gleason 8. 
In the RP specimens, there were equally high levels in 
Gleason 6 and 7 and again lower levels in Gleason 8.
Table 1. Patient characteristics of 57 men included in 
Radical Prostatectomy group.
Table 2. Demographic and pathological features of patients who 
were positive or negative for EN2 secretion. The difference between 
the mean EN2 levels between the two groups was statistically sig­
nificant ip < 0.0001). The difference between the mean tumour 
volume between the two groups was also statistically significant [p 
<  0.0001).
Mean Median Range
Age(years) 64.8 66 48 - 77
PSA (mg/L) 9.1 8 2.4 - 27
EN2 (ng/ml) 347.73 265 0-1129
Tumour volume (ml) 4.92 4.35 0.15-14.8
Total prostatie volume (ml) 46.2 40 13.7-160
Non EN2 Producer 
Le. <  42.5 ng/ml n = 9 
(16%)
EN2 Producers 
Le. > 42.5 ng/ml n = 48 
(84%)
Age (years)
Mean 64.3 64.9
Median 67 66
Range Min. 49 48
Max. 73 77
PSA ng/ml
Mean 8.08 9.81
Median 6.4 9.1
Min. 4.47 2.4
Max. 23 29
EN2 ng/ml
Mean 7.5 411.52
Median 0 331.5
Min. 0 68
Max. 36 1129
Tumour Volume on RP cc
Mean 1.06 5.65
Median 0.82 5.2
Min. 0.15 0.3
Max. 2.75 14.8
Prostate Volume cc
Mean 47 46
Median 49 40
Min. 21 13.7
Max. 90 160
Sum Gleason on Biopsy
Mean 6 7
Median 6 7
Min. 6 6
Max. 7 7
Sum Gleason on RP
Mean 7 7
Median 7 7
Min. 6 6
Max. 7 9
Differences did not reach statistical significance in either 
the biopsy or RP sampling group. PSA levels varied to a 
lesser extent than EN2 levels in relation to Gleason lesser 
extent than EN2 levels in relation to Gleason grading in 
biopsy and RP specimens; in both cases this did not 
reach statistical significance.
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Figure 1. Correlation between levels of serum prostate- 
specifîc antigen (PSA) and pre-prostatectomy urinary En­
grailed-2 (EN2) levels.
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Figure 2. Comparison of pre-prostatectomy urinary En­
grailed-2 (EN2) levels in PT2 versus pT3 prostate cancers.
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Figure 3. Comparison of pre-prostatectomy urinary En­
grailed-2 (EN2) levels in patients with positive and negative 
resection margins in the RP specimen.
3.3. Correlation of Pre-Prostatectomy Urinary 
EN2 Levels and Serum PSA with Total 
Prostate and PC Volume
There was no significant correlation between PSA level 
and total prostate gland volume (p =  0.2846; Figure 4(a)) 
or PC volume (p =  0.0909; F igure 4(b)). Similarly no 
correlation was found between EN2 levels and prostate 
gland volume (p =  0.2846; F igure 5(a)). In  contrast, a 
very strong correlation was identified between tumour 
volume and EN2 levels (p =  0.0001; F igure 5(b)).
Several studies have shown small prostate cancers are 
unlikely to progress locally and and/or metastasise, and 
therefore may represent “ insignificant”  disease not re­
quiring immediate treatment [8,9]. Based on these previ­
ous studies, 3 volume cut offs o f 0.5 ml, 1.3 m l and 2.5 
m l were selected and the potential o f PSA and EN2 lev­
els to indicate significant disease was tested. PSA was 
unable to distinguish between significant and insignifi­
cant disease using cut offs o f 0.5 m l and 1.3 m l (Figures 
6 (a) and (b)). In  contrast, a highly significant difference 
between cancers using all three cutoff levels was ob­
served w ith EN2 (p <  0.0001 at all cutoffs; F igure 7).
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Figure 4. Relationship between pre-prostatectomy prostate- 
specific antigen (PSA) levels and (a) prostate volume and (b) 
total tumour volume.
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Figure. 5. Relationship between pre-prostatectomy urinary 
Engrailed-2 (EN2) levels and (a) prostate volume and (b) 
tumour volume.
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Figure 6. Relationship between prostate-specific antigen 
(PSA) level and prostate tumour volume (TV) using cutoff 
points of (a) < 0.5 ml and > 0.5 ml; (b) < 1.3 ml and > 1.3 ml; 
and (c) < 2.5 ml and > 2.5 ml.
4. Discussion
The unmet need for biomarkers for prostate cancer now 
includes not only improved diagnostic sensitivity and 
specificity, but also whether any tumour detected re­
quires immediate treatment or can be safely monitored. 
Small prostate cancers have a low propensity to progress 
locally and metastasize [10,11]. Non-invasive methods o f 
reliably identifying these small cancers would have high 
clinical u tility. Our retrospective study showed a signifi­
cant correlation between pre-surgical urinaiy EN2 and 
tumour volume, but included what would currently be 
regarded as a high-risk population and evaluated samples 
from a biobank collected during non-contemporary clinical
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Figure 7. Relationship between pre-prostatectomy urinary 
Engrailed-2 (EN2) levels and prostate tumour volume 
using cutoff points of (a) < 0.5 ml and > 0.5 ml; (b) < 1.3 ml 
and > 1.3 ml; and (c) < 2.5 ml and > 2.5 ml.
practice in terms o f patient imaging, biopsy techniques 
and surgical prostatectomy techniques [7]. I t  was thus felt 
important to evaluate EN2 in a prospective study reflect­
ing current practice, diagnostic and surgical techniques. 
Compared to the previous retrospective study, we evalu­
ated the relationship between pre-surgical levels o f EN2 
in urine and pathological features in a lower risk RP 
group.
The relationship between PSA and tumour volume has 
been extensively investigated as both PSA and tumour 
volume are independent predictors o f outcome [12]. In 
this study, the RP population was representative o f con­
temporary practice w ith 63% o f men presenting w ith T ic  
disease. Most men (85%) in this study had significant 
levels o f EN2 in their urine. There was a strong correla­
tion between EN2 and tumour volume {p <  0.001) and 
pathological T stage (pT2 versus pT3a p  <  0.0063). 
There was no correlation between PSA levels w ith  either 
tumour volume or total prostatie volume. There was also 
a significant correlation w ith  margin positivity. No statis­
tical differences in EN2 and PSA levels and Gleason 
grade were evident: this is understandable in terms o f 
patient selection for RP in this study, and w ill be evalu­
ated again in an ongoing prospective study involving a 
number o f PC diagnostic biomarkers in addition to EN2.
Low volume PC (< 0.5ml) is considered to have a low 
potential to metastasize and this cutoff has been used to 
designate cancers as being insignificant [9]. A  recent 
analysis o f prostatectomy patients w ith in  the ESPRC 
(The European Randomized study o f Screening for Pros­
tate Cancer) study proposed that the threshold volume for 
significance may be higher: 1.3 m l and 2.5 m l for index 
lesion and total volume respectively [9]. There may be 
considerable clinical value in  a pre-treatment tumour 
marker that provides an accurate assessment o f cancer 
volume in terms o f assessing PC progression risk i.e. to 
identify patients suitable for active surveillance (AS). We 
found that when using any o f the three tumour volumes 
cited above, there was a highly significant difference in 
EN2 levels above and below these cut offs.
Patients on AS, by definition, should have small vo l­
ume and low risk disease. One o f the key objectives o f 
the AS concept is that after identifying suitable patients 
there is continual evaluation during fo llow  up to see i f  
they should remain in AS or be treated. There are cur­
rently no good markers o f progression in  these patients, 
including PSA, necessitating repeated biopsy. There are 
indications that Gleason 7 disease may be significant 
whereas Gleason 6 may not. In  our study we did not de­
tect a difference in EN2 levels between Gleason 6 and 7 
patients, although such a correlation may be better ex­
plored w ith a larger cohort. Our results to date and the 
simplicity and low cost o f EN2 testing justifies a pro-
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spective study o f 6 monthly urinary EN2 testing in con­
junction w ith  other AS criteria, and this study is currently 
being designed.
There are currently large numbers o f potential PC 
biomarkers in blood, urine and tissue under evaluation 
(reviewed in [13]). A  significant association between low 
PCA3 scores and low tumour stage and grade has been 
reported [14,15]. In  contrast, other studies have identified 
a correlation between high PCA3 scores and extra cap­
sular extension [16], or have indicated no correlation 
w ith tumour volume or tumour grade [17,18]. Low levels 
o f PCA3 were shown to correlate w ith low volume pros­
tate cancer but not w ith higher volume and stage disease 
in the largest prospective study to date [19]. A  logical 
future study would be to evaluate potential synergy o f 
EN2 (predicting cancer volume) and PCA3 (predicting 
extracapsular extension) biomarkers in predicting sig­
nificant disease. Furthermore, the potential u tility  o f EN2 
to aid in the active surveillance versus immediate treat­
ment decision process may also be realised through its 
inclusion in continuous multivariable prediction models, 
such as nomograms [20]. There are a number o f lim ita­
tions w ith our study in terms o f the cohort size and single 
network. However, confirmatory studies are currently 
ongoing in centers in Europe and the USA and EN2 w ill 
be evaluated concurrently w ith  other urine and serum 
biomarkers concurrently w ith  M R I imaging in the PRO­
MIS study in the United Kingdom 
(http://www.controlled-trials.com/ISRCTN16G82556).
This study confirms a strong correlation between u ri­
nary EN2 levels and both tumour volume and tumour 
stage in a prospective cohort as determined at RP. EN2 
levels were significantly higher in men w ith disease vo­
lumes previously used to delineate significant versus 
non-significant disease. This study justifies a larger mul­
ticenter evaluation o f urinary EN2 levels as a biomarker 
o f PC significance using cancer volume, pathological and 
PSA criteria.
5. Acknowledgements
We would like to thank Sarah Stone our sample co-or­
dinator, Angie Boxall for assistance w ith the EN2 assay 
and D r Ben Haagsma for reviewing all histology. This 
work was funded by the University o f Surrey and the 
Prostate Project Charity, United Kingdom. We would 
like to thank the follow ing for assistance w ith sample 
procurement and review o f data: Agnieszka Michael, 
Richard Hindley, Philip Dundee, and Francesca Laun- 
chbury.
REFERENCES
[1] R. W. Veltri, M. C. Miller, G. J. O’dowd and A. W.
Partin, “ Impact of Age on Total and Complexed Prostate- 
Specific Antigen Cut offs in a Contemporary Referral Se­
ries o f Men with Prostate Cancer,”  Urology, Vol. 60, No. 
4, 2002, pp. 47-52. doi: 10.1016/S0090-4295('02t01695-3
[2] H. Lilja, D. Ulmert and A. J. Vickers, “Prostate-Specific 
Antigen and Prostate Cancer: Prediction, Detection and 
Monitoring,”  Nature Reviews'. Cancer, Vol. 8, No. 4, 
2008, pp. 268-278. doi:10.1038/nrc2351
[3] S. M. Falzarano and C. Magi-Galluzzi, “Prostate Cancer 
Staging and Grading at Radical Prostatectomy over Time,”  
Advances in Anatomic Pathology, Vol. 18, No. 2, 2011, 
pp. 159-164. doi: 10.1097/PAP.0b013e31820cb506
[4] J. E. Oesterling, S. J. Jacobsen, G. G. Klee, et a l, “Free, 
Complexed and Total Serum Prostate Specific Antigen: 
The Establishment of Appropriate Reference Ranges for 
Their Concentrations and Ratios,”  The Journal o f Urol­
ogy, Vol. 154, No. 3, 1995, pp. 1090-1095.
doi: 10.1016/S0022-5347f01166984-2
[5] S. F. Shariat, A. Semjonow, H. Lilja, et a l, “ Tumour 
Markers in Prostate Cancer 1: Blood-Based Markers,” 
Acta Oncologica, Vol. 50, No. SI, 2011, pp. 61-75.
doi: 10.3109/0284186X.2010.542174
[6] R. Morgan, A. Boxall, A. Bhatt, et a l, “Engrailed-2 
(EN2): A Tumor Specific Urinary Biomarker for the 
Early Diagnosis o f Prostate Cancer,”  Clinical Cancer 
Research, Vol. 17, No. 5, 2011, pp. 1090-1098.
doi: 10.1158/1078-0432.CCR-10-2410
[7] H. Pandha, K. D. Sorensen, T. F. Orntoft, et a l, “Urinary 
Engrailed-2 (EN2) Levels Predict Tumour Volume in 
Men Undergoing Radical Prostatectomy for Prostate Can­
cer,”  BJU International, Vol. 110, No. 6, 2012, pp. E287- 
E292. doi : 10.1111 / i. 1464-4 IOX.2012.11208.x
[8] J. 1. Epstein, P. C. Walsh and H. B. Carter, “Dedifferen­
tiation o f Prostate Cancer Grade with Time in Men Fol­
lowed Expectantly for Stage T ic  Disease,”  The Journal 
o f Urology, No\. 166, No. 5,2011, pp. 1688-1691.
[9] T. Wolters, M. J. Roobol, P. J. van Leeuwen, et a l, “A  
Critical Analysis o f the Tumour Volume Threshold for 
Clinically Insignificant Prostate Cancer Using a Data Set 
of a Randomized Screening Trial,”  The Journal o f Urol­
ogy, Vol. 185, No. 1,2011, pp. 121-125. 
doi:10.1016/i.iuro.2010.08.082
[10] H. U. Ahmed, M. Arya, A. Freeman, et a l, “Do Low- 
Grade and Low-Volume Prostate Cancers Bear the Hall­
marks o f Malignancy?”  The Lancet Oncology, Vol. 13, 
No. 11,2012, pp. c509-e517.
[11] L. Klotz, “Active Surveillance for Prostate Cancer: A 
Review,”  Current Urology Reports, Vol. 11, No. 3, 2010, 
pp. 165-171. doi : 10.1007/s 11934-010-0110-z
[12] L. Salomon, O. Levrel, A. G. Anastasiadis, et a l, “Prog­
nostic Significance of Tumour Volume after Radical 
Prostatectomy: A Multivariate Analysis of Pathological 
Prognostic Factors,”  European Urology, Vol. 43, No. 1, 
2003, pp. 39-44. doi:10.1016/S0302-2838r02100493-l
[13] J. R. Prensner, M. A. Rubin, J. T. Wei, et a l, “Beyond 
PSA: The Next Generation o f Prostate Cancer Biomar­
kers,”  Science Translational Medicine, Vol. 4, No. 127, 
2012, Article ID: 127rv3.
Copyright © 2013 SciRes. JCT
Correlation of Urinary Engrailed-2 Levels to Tumour Volume and Pathological Stage
in Men Undergoing Radical Prostatectomy
733
[14] G. Ploussard, X. Durand, E. Xylinas, et a l, “Prostate 
Cancer Antigen 3 Score Accurately Predicts Tumour Vol­
ume and Might Help in Selecting Prostate Cancer Patients 
for Active Surveillance,”  European Urology, Vol. 59, No. 
3, 2011, pp. 422-429. doi: 10.1016/i.eururo.2010.11.044
[15] H. Nakanishi, J. Groskopf, H. A. Fritsche, et a l, “PCA3 
Molecular Urine Assay Correlates with Prostate Cancer 
Tumor Volume: Implication in Selecting Candidates for 
Active Surveillance,”  The Journal o f Urology, Vol. 179 
No. 5,2008, pp. 1804-1809. 
doi:10.1016/i.iuro.2008.01.013
[16] E. J. Whitman, J. Groskopf, A. Ali, et a l, “PCA3 Score 
before Radical Prostatectomy Predicts Extracapsular Ex­
tension and Tumor Volume,”  The Journal o f Urology, 
Vol. 180, No. 5, 2008, pp. 1975-1979. 
doi:10.1016/i.iuro.2008.07.060
[17] M. P. van Gils, D. Hessels, C. A. Hulsbergen-van de Kaa, 
et al, “Detailed Analysis of Histopathological Parameters
in Radical Prostatectomy Specimens and PCA3 Urine 
Test Results,”  The Prostate, Vol. 68, No. 11, 2008, pp. 
1215-1222. doi:10.1002/pros.20781
[18] D. Hessels, M. P. van Gils, O. van Hooij, et al, “Predic­
tive Value of PCA3 in Urinary Sediments in Determining 
Clinico-Pathological Characteristics of Prostate Cancer,”  
The Prostate, Vol. 70, No. 1, 2010, pp. 10-16.
doi: 10.1002/pros.21032
[19] M. Auprich, F. K. Chun, J. F. Ward, et a l, “ Critical As­
sessment o f Preoperative Urinary Prostate Cancer Anti­
gen 3 on the Accuracy o f Prostate Cancer Staging,”  Eu­
ropean Urology, Vol. 59, No. 1, 2011, pp. 96-105.
doi: 10.1016/i.eururo.2010.10.024
[20] M. W. Rattan, “Do We Need More Nomograms for Pre­
dicting Outcomes in Patients with Prostate Cancer?”  Na­
ture Reviews Urology, Vol. 5, No. 7, 2008, pp. 366-367. 
doi: 10.103 8/ncpuro 1128
Copyright © 2013 SciRes. JCT
Journal of Clinical Urology
http://uro.sagepub.com/
!S Prostate HistoScanningTM accurately identify prostate cancer, measure tumour volume and 
assess pathological stage prior to radical prostatectomy?
Saqib Javed, Eliot Chadwick, Sabeena Beveridge, Simon Bott, Christopher Eden and Stephen Langley
Journal of Clinical Urology published online 22 May 2013 
DOI: 10.1177/2051415813489682
The online version of this article can be found at: 
http://uro.sagepub.eom/content/early/2013/05/22/2051415813489682
Published by: 
®SAGE
http://www.sagepublications.com
On behalf of:
P<P
The B rîtish .4.ssocimox 
ÛE' U hologicai. Surghons
British Association of Urological Surgeons
Additional services and information for Journal of Clinical Urology can be found at: 
Published online 22 May 2013 in advance of the print journal.
Email Alerts: http://uro.sagepub.com/cgi/alerts 
Subscriptions: http://uro.sagepub.com/subscrlptions 
Reprints: http://www.sagepub.com/journaIsReprints.nav 
Permissions: http://www.sagepub.com/journalsPermissions.nav
»  OnlineFirst Version of Record - May 22, 2013 
What is This?
Downloaded from uro.sagepub.com at UNIV OF SURREY on May 29,2013
